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Polyketide synthases (PKS) are the enzyme complexes that synthesise a wide range of natu-
ral products of medicinal interest, notably a large number of antibiotics. The present work
investigated the mupirocin biosynthesis system, in comparison with similar pathways such as
thiomarinol and kalimantacin, with the focus on the structural modelling of the protein com-
plexes involved in antibiotic synthesis via the tools of structural bioinformatics. β- methylation
in the mupirocin pathway is catalysed via enzymes encoded by the “HMG-CoA synthase (HCS)
cassette”and replaces a β-carbonyl with a methyl group. To understand better, what might al-
low the HCS cassette to recognise β-branch associated ACPs, molecular modelling was used to
explore the interaction of the ACPs with MupH (the HMG-CoA synthase homologue). Hidden
Markov models (HMM) were used to classify ACPs as branching and non-branching. HMM
analysis highlighted essential features for an ACP to behave like a branching ACP. A homology
model of MupH was docked with the NMR structure of each of ACPs mupA3a and mupA3b.
The docking results were also supported by the biological context based on analysis of phylo-
genetic variations in amino acid conservation and physical properties of the interface residues.
Modelling and mutagenesis identified helix III of the ACP as a probable anchor point of the
ACP:HCS complex. The position of this helix is determined by the core of the ACP and substi-
tuting the interface residues modulates the interaction specificity.
Although docking and mutagenesis studies performed on ACP:MupH complex laid down
the general specificity rule of ACP:MupH recognition in the β-branching. BatC from closely re-
lated kalimantacin cluster cannot substitute for the function of MupH. However, Prof. Thomas’
group have shown upon mutating BatC it is possible to successfully complement a ∆mupH mu-
II
tant. β-branching ACPs from the thiomarinol cluster complements the β-branching ACPs in the
mupirocin cluster however, the β-branching ACP from the kalimantacin cluster does not. These
observations suggests a pair wise specificity between the ACP:HCS proteins in the β-branching.
Molecular dynamics simulation of the ACP:MupH complex revealed large movements of
the surface loops at the opening of the active site in MupH. These movements were found to be
greater in a MupH monomer as compared to the MupH dimer structure and may assist in the
accommodation of the ligand inside the MupH active site.
Molecular dynamics simulations of apo, holo and acyl forms of ACPs in the mupirocin clus-
ter revealed that the PKS ACPs form a cavity upon the attachment of the phosphopantetheine
and acyl chains similar to what is seen in the fatty acid synthase (FAS) ACPs. The cavity formed
does not form a deep tunnel as in the FAS ACPs but, is rather solvent exposed cleft, enabling
the polar groups on the acyl chain to hydrogen bond with the solvent. It was also observed that
a bulky residue (I61 in ACP-mupA3a) in the PKS ACPs is likely to prohibit the formation of a
deep tunnel as opposed to the case of smaller residue (alanine) at the equivalent position in the
FAS ACPs, where a deep tunnel is seen.
Molecular docking of the cognate substrate with the ketosynthase (KS) homo dimer of mod-
ule 5 of the MmpA in the mupirocin pathway revealed a loop at the dimer interface that appears
to be responsible for the recognition specificity of α-hydroxylated substrate. Mutagenesis ex-
periments showed that, upon swapping this recognition loop from a KS which does not bind an
α-hydroxylated substrate, the pathway produces a full length product in the absence of MupA,
the enzyme thought to be responsible for α-hydroxylation, whereas the wild type KS ∆mupA
mutant does not. Furthermore the loop swap experiment produces a product that is slightly
more hydrophobic than pseudomonic acid A, the most abundant product from the mupirocin
synthesis pathway, the enhanced hydrophobicity consistent with a product lacking a hydroxyl.
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Polyketide synthases (PKSs) are large mega-Dalton multi-domain enzyme complexes that syn-
thesize a wide range of natural products of medicinal interest. The structure, dynamics and orga-
nization that governs these multi-domain proteins during polyketide biosynthesis is still poorly
understood. Developing insight into these systems with the aim of routinely re-engineering
them for the biosynthesis of novel compounds, such as anti-cancer drugs and antibiotics, is a
long standing goal of many of the PKS research community.
Ever since the inception of the first antimicrobial agent penicillin, observed by Alexander
Fleming in the late 1930s, the scientific community has endeavoured to discover new types of
antibiotics. From the 1960s to the 1980s the world has seen a boom in the antibiotic industry
with the introduction of a diversity of drug variants and classes. However, the introduction
of new antibiotics from the late 1980s till the present date remained stagnant, with very few
antibiotics approved by the regulating agencies and also with very few new classes of antibiotics
discovered by the scientific community.
The increasing number of bacterial species acquiring drug resistance and the lack of de-
velopment in antibiotic discovery has become a threat to humanity. Resistance is now found
against almost all classes of antibiotics, even the last line of drugs such as vancomycin (Alanis
2005; Saga and Yamaguchi 2009). Drug resistance ranges from single drug resistance to mul-
tiple drug resistance (MDR). Recently bacterial species have been found with extensive drug
resistance (XDR) i.e. resistance to all the available antibiotics except colistin, which is a highly
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toxic agent and not in regular use. Even worse, the world is facing upcoming issues with pan
drug resistant (PDR) organisms, which are resistant to all existing antibiotics including colistin
(Powers 2004; Conly and Johnston 2005; Alanis 2005; Saga and Yamaguchi 2009).
Although resistant organisms have reached the community and can be found in outpatients
the real threat is still to hospitalized patients. Patients in intensive care units, on steroids or
with a compromised immune system are readily susceptible to nosocomial infections. Surgical
wound infections commonly caused by methicillin-resistant Staphylococcus aureus can only
be treated with very few antibiotics, e.g. mupirocin. Thus it has become imperative for the
scientific community to discover new antibiotics with better efficacy against resistant species.
Polyketide compounds have shown a variety of medicinal uses, which includes antibiotics.
In recent years PKS researchers have shown the capability to re-engineering these pathways in
order to produce novel compounds (Kapur et al. 2012; Sugimoto et al. 2014). In the present
study I have worked on the biosynthesis pathway of the antibiotic mupirocin. In spite of being
potent against skin infections, mupirocin can only be used as a topical drug as it gets systemi-
cally metabolised (Parenti et al. 1987). Furthermore, bacteria such as MRSA, which mupirocin
was effective against, are developing resistance. Therefore, remodeling the mupirocin biosyn-
thetic pathway to produce variants is a possible way to increase its usability. Similar methods
could also be applied to other PKS systems to enhance features such as the binding affinity, and
the metabolic profile of the compounds produced. For example, type I polyketide synthases can
introduce β-carbon branches into a growing polyketide chain, through tailoring enzyme, allow-
ing introduction of for example a methyl group, halogens or cyclopropane, however it is still
not understood what regulates the interaction between the tailoring enzymes and PKSs. Un-
derstanding of the underlying mechanism of β-branching can be used to instil the β-branching
capability into non-β-branching systems. The dynamic behaviour of the proteins in the path-
way, such as acyl carrier proteins (ACPs) that interact with several domains along the pathway,
is clearly an important part of these process.
The present thesis mainly focusses on the β-branching mechanism in the mupirocin path-
way and on the dynamic behaviour of ACPs. This chapter consists of a general introduction
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about polyketides, polyketide synthases, challenges and success in polyketide synthase re-
engineering, mupirocin biosynthesis and bioinformatics methods available for PKS research.
Chapters 3 and 4 presents the results on the computational prediction of the protein-protein in-
teraction involved in the β-branching mechanism and the experimental validation respectively.
Chapter 5 presents the results on the dynamics of ACPs, and how these might affect recognition
process in β-branching. Chapter 6 presents the results of two independent projects, first on the
ketosynthase specificity towards α-OH substrates in the mupirocin system and the second on
molecular dynamics of the loops in ACP-mupA3a + MupH complex assisting the ligand in the
MupH active site. Chapter 7 gives the general discussion of the whole thesis.
1.1 Polyketide
Polyketides are natural products produced by bacteria, fungi, plants, molluscs, sponges, insects
and dinoflagellates; many of these products have medicinal properties, including antibiotics,
antifungal, immunosuppressants, antitumor, antituberculosis and anticholestrol agents (Figure
1.1). As the name suggests polyketides are polymers of simple ketone units synthesized by
polyketide synthases (PKSs), which may or may not be further modified by the tailoring en-
zymes. Due to the diverse nature of modification during the synthesis process, polyketides
exist in the form of macrolides, ansamycins, polyenes, polyethers, tetracyclines, acetogenins,
and aromatic compounds. Polyketides are produced as secondary metabolites which are non
essential for the growth of an organism but may play a crucial role in defence mechanisms, ag-
gression or communication (Bender et al. 1999; Staunton and Weissman 2001; Weissman and
Leadlay 2005).
Polyketide and other natural product based drugs also have a huge market share, which
drives pharmaceutical companies to continuously invest in research and manufacturing. Around
10,000 natural products had been identified by the year 1998 and many of these are being used
as drugs. Between 1998-2004, 21 natural product based drugs were launched worldwide and
around 19 were approved by the FDA between 2005-2010 (Mishra and Tiwari 2011b; Mishra




       O       
                     
O       
       
       
O       
              
       
       
O       
              
       
O              
N       
       
O       
              
       
       
       
       
       
O       
              
       
O       
       
       
O       
       
O       
       O       
       O       
              
       
N       
       
       
              
       
       
       N       
       
       
O       
              
       
O       
       
O       
rifamycin B
(antituberculosis)
O       
O       
O       O       
O       
O       
O       
O       
O       
O       
O       
O       
O       
N       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
N       
       
       
       
O       
O       
       
       O       
       
       
O              
O       
       
       
       
       
              
       
       
       
O       
       
       
       
       
       
       
       
O       
       
       
              
H       
              
              
       
              
       
O       
O       
       
H       
       
       
       
       
       
O       
       
              
       
       
H       
O       
O       
       
H       
O       
rapamycin
(immunosuppressant)
O       O       
O       
O       
O       
O       
O       
O       
O       
O       
O       
N       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
doxorubicin
(antitumor)
       
       
O       
       
       
       
       
       
       
O       
O       
O       
       O       
O       
       
       
       
       
       
O       
       
O       
       
       
       
O       
       
       
       
O       
       
N       
       
       
       
O       
O       
       
       
       
       
       
       
O       
       
       
       
       
O       
       
       
       
O       
O       
       
       
       
       
       
       
              
       
O       
H       
amphotericin
(antifungal)
O       
O       
O       
O       
O       
       
              
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
              
       
H       
lovastatin
(anticholesterol)
Figure 1.1: Example polyketide compounds (http://www.drugbank.ca)
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billion a year according to a news report in Science magazine published on 1 March, 2001
(http://news.sciencemag.org/2001/03/bugs-making-drugs).
Polyketide research dates back to 1907 with the John Collie’s work at London University
on deducing the structure of orcinol (Collie 1907). However, the main impetus to the field
came from Arthur Birch’s work on 6-methyl-salicylic acid (6-MSA) produced by Penicilium
patulum in the 1950s. Arthur Birch explained the mechanism of 6-MSA production based on
data from experiments feeding radioactively labelled acetate to the producing strain (Birch et
al. 1955). The labelled product was shown to have the same pattern as was to be expected
from Birch’s proposed mechanism. These observations of Collie and Birch later on came to be
known as the Collie-Birch polyketide hypothesis, which explains that not only these complex
natural products were a result of the condensation of simple acetate units, but also that they can
be further transformed through enzymatic reactions to produce aromatic or cyclic compounds.
The detection of these compounds until the 1960s was based on deductive chemistry, where
chemists break down the complex molecules into smaller recognizable moieties which were
then intuitively assembled on paper (Powers 2004). Later on the advancement in spectrometric
techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) completely
transformed the research into easier and more accurate measurements. However, the detailed
mechanistic view in the biosynthesis of these compounds and the genes/proteins involved was
only possible after 1980s owing to the development of genetic manipulation methods. Genetic
methods also enabled the scientific community to realize the potential for de novo production
of these compounds with altered functional groups. In the present era, with the new concept of
synthetic biology, researchers are aiming to design synthetic machineries for the production of
novel compounds that can be used for beneficial purposes.
1.2 Polyketide synthases
Polyketides are produced by multi enzyme complexes called polyketide synthases (PKSs). Not
surprisingly PKS are equally as complex as polyketide compounds. It was only after the 1980s
that researchers were able to characterize the genes and proteins involved in the PKS. The very
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first genes for a PKS were characterized by David Hopwood’s group in 1984, for actinorhodin,
an aromatic polyketide compound (Malpartida and Hopwood 1984). Later on Peter Leadlay
and Leonard Katz independently identified the gene cluster responsible for the antibiotic ery-
thromycin produced by Saccharopolyspora erythraea (Cortes et al. 1990; Tuan et al. 1990).
1.2.1 FAS and PKS analogous reaction mechanism
PKS share sequence and mechanistic similarity with the very well studied fatty acid synthases
(FAS) . FAS synthesizes a relatively small group of saturated compounds as compared to the
myriad of polyketides. Fatty acids are produced by a monotonous process of decarboxylative
condensation of two ketone units followed by a series of reductive steps till a fully saturated
molecule is achieved. The acyl transferase (AT) domain loads the starter (acetyl) and the ex-
tender units (malonyl) to the acyl carrier protein (ACP), which covalently tethers the ligand via
a thioester bond to the long phosphopantetheine arm. The ACP transfers the starter or the ex-
tender units to the ketosynthase (KS) for the decarboxylative condensation and also carries the
newly synthesized product to be passed on to the other domains for further processing. Acting
successively, keto reductase (KR) reduces the β-keto group to a hydroxyl which is further re-
duced by a dehydratase (DH) to produce an alkene, this double bond is then reduced to a fully
saturated chain by an enoyl reductrase (ER). The process of decarboxylative condensation and
successive reductions continue till the fatty acid chain reaches to a required length, where upon
it is then released by the thioesterase (TE) domain.
Both PKS and FAS enzyme systems can be classified into type I, II, with an additional type
III for PKS (more detail on PKS types in Section 1.2.3). Type I FASs as found in mammals
and fungi, are large multi domain complexes where the catalytic domains are covalently linked
together in a long polypeptide chain. A single set of seven catalytic domains, as mentioned
above, are utilized to produce a single molecule of fatty acid of the required length. Whereas,
the type II FASs are free standing discrete mono functional catalytic units, used iteratively. Type
II FASs are commonly found in bacteria, chloroplasts and mitochondria.
In comparison to FAS machinery, PKS machinery is more complex and dynamic. PKSs vary
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the reductive steps on the β-keto acyl moiety after the condensation has happened, thus produc-
ing products with combinations of non modified β-keto groups, hydroxyl and enoyl groups.
Several type I modular PKS were also found with modules lacking any condensation activity,
for example the module 5 in the mmpA subunit of the mupirocin system. PKSs also have a
choice of various starter and extender units (Khosla et al. 1999; Staunton and Weissman 2001),
in contrast to FASs which always start with acetyl and malonyl as the starter and extender unit
respectively. Among many possible examples, of polyketide antibiotic pathways which utilize
non conventional starter and extender units, as compared to the FAS, two examples are aureothin
synthesis, which incorporates p-nitrobenzoate as the starter unit, and the erythromycin system
which utilizes (2S)-methylmalonyl-CoA as the extender units. PKS products are usually mod-
ified by various types of tailoring enzymes working in trans for purposes such as cyclization,
beta branching, epoxidation, pyran ring formation etc. Figure 1.2 shows the generic reaction
mechanism carried out by the FAS and PKS.
1.2.2 FAS and PKS models
Over the years many research groups have proposed the likely domain organization and struc-
tural models for the FAS and PKS systems. The very first model proposed and widely accepted
was the head to tail model in the 1970s which was later on overtaken by a newer head to head
model for the FAS system and subsequently for the PKS as well. These simple models based
on the domain organisation of the gene cluster and a few crosslinking experiments, helped
researchers to understand FAS and PKS assembly until augmented by more accurate atomic
resolution structures for full length FAS that were determined through X-ray crystallography.
Although, researchers managed to successfully determine the structures for the FAS from var-
ious organisms we still lack a complete structure of a PKS. Some recent efforts have indeed
produced structures of individual or binary domains from different PKS systems but a complete
















































































































































































































































































































































































































































































































































































































1.2.2.1 Head to tail/head models for FAS
Evidence in the 1970s and 1980s seemed to support the existence of a head to tail model for
FAS structure and function (Figure 1.3 A), but this was eventually superseded by a head to head
model (Figure 1.3 B) In the 1970s many researchers observed that FAS mono functional units
fail to catalyse chain elongation. FASs can be reversibly dissociated into functional units on
exposure to low ionic strength buffers at cold temperature; the function restores in high ionic
media at room temperature (Kumar et al. 1970; Smith and Abraham 1971). The loss of elonga-
tion implied that for condensation to happen the active cite cysteine of the ketosynthase needs
to be in close proximity of the phosphopantetheine arm of the ACP. Later on it was discovered
that the active site cysteine of one subunit can be cross linked to the phosphopantetheine of
the ACP on the other subunit by 1,3-dibromopropanone. This cross linking experiment was
interpreted as meaning that the condensation required the interaction of KS and ACP from the
opposite subunits (Wakil and Stoops 1983). Another experiment on the FAS dimer with blocked
thioesterase, showed two hanging fatty acids (Singh et al. 1984). Additionally sequence analy-
sis revealed that the ACP is located far away from the KS on the FAS cluster. Thus the above
observations seemed to support the fully extended head to tail model where there were two
reaction sites which were coordinated by the ACPs from the opposite subunit.
Thus, the head to tail model gained a wide acceptance till it was challenged on the basis
of the mutant complementation experiments. The complementation experiments showed that
in the animal FAS the KS and ACPs can function together on either subunit (Witkowski et al.
1996). Joshi and co-workers from the Smith group created several mutant knockouts in which
different domains were inactivated. These mutant subunits were made to re-associate to create a
mixed population of hetero and homo dimers. There findings revealed that homodimers formed
by the KS, ACP, DH or TE mutant knockouts (at least one point mutation) and the hetero dimers
formed by the ACP and TE mutant, ACP and DH mutant and DH and TE mutants were unable to
carry out synthesis. However, heterodimers formed by KS and either DH, ACP, or TE mutants
were able to carry out the synthesis at a reduced rate. These observations showed that the ACP
and DH which are located far on the same subunit were able to interact which suggest that it
9
















Figure 1.3: Head to tail/head models for FAS. (A) The fully extended head to tail model (B) The coiled
head to head model. Figure adapted from Smith and Tsai (2007).
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was not necessary for the FAS to be in fully extended head to tail conformation. On the other
hand a coiled state would explain the ability of the far placed ACP and DH to interact (Joshi
et al. 1997; Joshi et al. 1998).
These observations lead to questioning the interpretation of previously conducted crosslink-
ing experiments, which had showed that 1,3-dibromopropanone can be used to cross link the ac-
tive cite cysteine of ketosynthase to the phosphopantetheine arm of the ACP. The re-examination
of the original cross linking experiment data revealed three bands, which would correspond to
the double cross linked inter subunit species, single cross linked inter subunit species and single
cross linked intra subunit species. If the interaction of the head to tail model, as in Figure 1.3
(A), held true then there would have been only two bands for the single and double inter cross
linked species. The presence of the third band indicates the possibility of the intra subunit KS -
ACP interaction.
To put the last nail in the coffin of the head to tail model, Joshi and co workers created an
engineered mammalian FAS with only one functional subunit, all the domains from the other
subunit were inactivated. This engineered FAS was able to catalyse all the biosynthetic steps
in the fatty acid synthesis (Joshi et al. 2003). These observations were enough to refute the
requirement of the fully extended state of the head to tail model but would rather support the
requirement of a scaffold which allows the domains on the two subunits to be accessible to their
companion domain (Figure 1.3 (B)).
This scaffold would support the newer head to head model in which the KS forms a dimer
at the centre and the flanking domains coil around it, instead of KS being at the polar ends
as in the head to tail model as shown in Figure 1.3 (A). This model also agrees with the KS
in the FAS type II in which the KSs are known to exist as homo dimers and the active site is
formed by the contribution of both the subunits (Moche et al. 1999; Olsen et al. 2001; Price
et al. 2003). Experiments carried out by Witkowski and co-worker showed that a truncated N
terminal FAS (i.e. with incomplete KS) fails to dimerise. They also showed that the two KS
subunits can be cross linked via an engineered cysteine at the N terminal of the KS at a close
proximity of 6 Å. This crosslinking failed if one of the subunits lacks an engineered cysteine.
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They concluded their observation by performing mass spectrometry on the digested cross linked
product (Witkowski et al. 2004b).
1.2.2.2 Models for modular PKS
In the 1990s groups from the USA and UK lead by Khosla and Cane, and Staunton and Leadlay
respectively, proposed the likely models for modular PKSs. The independent studies carried
out by both the groups on the DEBS system using different methods agreed on the presence of
two catalytic chambers for the condensation reaction in the modular PKSs. The studies also
confirmed the dimeric nature of the PKSs similar to FASs. However, the proposed models by
the two groups were strikingly different, details of which are discussed below.
The UK group in a series of experiments carried out limited proteolysis of the DEBS sub-
units using four proteases. The different sized fragments produced due to proteolysis were
identified using N-terminal sequencing. They also determined the oligomeric state of the frag-
ments using gel filtration and analytic ultracentrifugation. All the large fragments carrying the
complete module were found to be homodimeric. The loading domain and the AT-ACP domains
of the module 1 were found to be monomeric along with all the KR and ER domains in module
1,3,5 and 6 and module 4 respectively. On the basis of the cross linking experiment carried on
the FAS (as mentioned in the previous section), the UK group used 1,3-dibromopropanone to
cross link the 4’-phosphopantetheine moiety to the cysteine in the KS active site. The cross link-
ing experiment confirmed an interaction between the KS and ACP from the opposite subunits
(Aparicio et al. 1994; Staunton et al. 1996).
These observations laid the basis for two models for the modular PKS, which were proposed
to be parallel dimers. In the first model they proposed parallel dimers formed by the interaction
of the KS and ACP at the interface and the other reductive domains protruding outwards from
the axis, keeping all the domains at the reachable distance of the 4’-phosphopantetheine arm.
In the second model (which alter came to be known as Cambridge model) the parallel dimers
form a helical core utilizing KS, AT and ACP and the reductive domains again protrude away
from the axis. Both the models showed the possibility of stacking multiple subunit on top of
each other without affecting the functioning of the biosynthesis pathway. However, on the basis
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of the ultra-centrifugation results, that the protein dimer does not dissociate even at very low
concentrations, the helical model was predicted and favoured to be more stable structure. These
observations also proposed the inherent ability of the PKS to accommodate additional PKS
which can be stacked with the rest of multi enzymes. Since the reductive domains protrude
outside the dimeric core there is also a possibility of adding diversity to the reductive steps
(Aparicio et al. 1994; Staunton et al. 1996), as represented in Figure 3 A and B of Staunton
et al. (1996).
At the same time Khosla and Cane worked on finding the evidence for the domains partic-
ipating in polyketide biosynthesis by generating several active site mutant PKSs. The experi-
ments were performed in vitro using DEBS 1 + TE, which consist of two modules along with an
engineered TE domain. DEBS 1 + TE produces a cyclic triketide by utilizing propionyl-CoA
and (2RS)-methylmalonly Co-A as starter and extender units respectively, and NADPH as the
hydride donor. These experiments were carried out with the assumption that the modular PKS
forms head to tail homodimers similar to the then prevalent idea for mammalian FASs. In one
study they produced three different active site DEBS 1 + TE mutants in which either the KS
from module 1 or 2 or the ACP from module 2 was inactivated, refered to as KS10, KS20 and
ACP20. These three parental mutant homodimers were utilized to produce three mutant het-
erodimers in which heterodimer a) consist of KS10 and KS20 , b) consist of KS20 and ACP20
and c) consist of KS10 and ACP20. The first two heterodimers were found to be active and
were able to produce the triketide moiety however, the heterodimer c was unable to produce the
triketide product. These observations gave substantial evidence that polyketide biosynthesis is
based on the participation of two sets of active sites from opposite subunits and the cognate pair
of KS and ACP can only be involved in the chain transfer (Kao et al. 1996). These results were
in contrast to FAS biosynthesis which allows chain elongation through either the KS-ACP pair
from the opposite subunit or from the same.
In another study, following a similar mutant complementation strategy, Khosla and cowork-
ers created an AT null mutant. This AT mutation was carried out in the module 2 and was paired
with either the KS10 or KS20 mutants, thus generating two pairs of heterodimers. The aim of
13
the experiment was to test whether the AT2 domain would be able to load the methylmalonyl
extender unit to ACP2 from the same or the opposite subunit. If the loading of the extender
unit is similar to the KS-ACP interaction from the opposite subunit then only the heterodimer
carrying KS10 and AT20 should be active and not the heterodimer carrying KS20 and AT20. The
complementation experiment showed that both the heterodimers were active and the AT domain
were able to load the extender unit both inter and intra subunit. Kinetic studies showed no dif-
ference in the rate of extender unit loading between the intra or inter subunit transfer (Gokhale
et al. 1998).
1.2.3 Types of polyketide synthases
As mentioned in the previous sections, PKSs can be classified into three types, I, II and III
where type I and II PKS are similar to FAS type I and II. Apart from the three canonical PKS
types various PKS systems exist as hybrid with one or more other types. Hybrids also exists
between one of the PKS types and a closely related non PKS system called non ribosomal
peptide synthases (NRPS). The following sections describe the different PKS types in detail
with relevant examples.
1.2.3.1 Type I PKS
Type I PKS are large single polypeptide multi domain protein complexes which can be further
sub classified into modular and iterative types. As the name suggests, modular type I PKSs
are composed of multiple modules where each module consists of all the necessary domains
required for a single round of polyketide chain elongation and associated β-carbon processing.
Whereas type I iterative PKSs utilize a single set of covalently bound catalytic domains iter-
atively until the required length of the polyketide product with correct β-carbon processing is
reached (Hertweck 2009). Type I modular PKSs are usually found in bacteria, for example the
DEBS system in Saccharopolyspora erythraea (Figure 1.4), whereas type I iterative PKSs are
found in fungi for example the lovastatin system in Aspergillus terreus (Figure 1.5). Type I
modular PKSs can also be further classified as cis and trans-AT systems. Cis-AT systems (e.g.
DEBS) consist of a covalently fused AT domain within each module, which is responsible for
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loading the extender unit specific for the cognate module. Where as in trans-AT systems (e.g.
mupirocin) the AT domain is not covalently fused within each module but it exists as a separate
discrete domain. Trans-ATs are responsible for loading the starter unit at the beginning of the
pathway as well as the extender units at each module throughout the pathway.
In type I modular PKSs since each module is responsible for a single step of chain extension
and subsequent β-carbon processing, it is possible to deduce the product being produced just
by studying the sequence in which the modules are arranged in the biosynthetic cluster. This
collinearity rule has enabled the development of various computational methods to predict the
probable metabolite being produced directly from the DNA or protein sequence. Section 1.5
gives a more detailed account of the computational methods developed till now to predict the
polyketide as well as other secondary metabolites from their biosynthetic gene/protein cluster.
Although this collinearity rule in type I modular PKSs is effective in predicting metabolite
production straight from the sequence, it does not hold true in trans AT systems and in systems
where a certain module is used iteratively or skipped altogether.
For many years DEBS served as the model system for studying type I modular PKS. DEBS
is responsible for the production of 6-deoxyerythronolide B which acts as a precursor in the
production of the antibiotic erythromycin. The DEBS system consists of 28 domains spread
across 3 polypeptides (DEBS 1, 2 and 3) of 350 kDa each, with each polypeptide containing
two modules (Figure 1.4). DEBS 1 contains an extra module which consists of an AT and
ACP domain prior to the condensing module 1. This extra module is responsible for priming
the KS in module 1 with a propionate unit. DEBS 3 contains a TE domain after module 6,
for polyketide release. Each module in the DEBS system is responsible for a single round
of Claisen condensation utilizing methyl malonate as the extender unit. Every module in the
DEBS system also performs β-keto reduction of the condensed product and only module 4
further reduces the β-carbon with a dehydratase and an enoyl reductase (Figure 1.4) (Khosla
et al. 2007). Due to the modular nature of the DEBS system and ease of cloning the DEBS
genes into an appropriate host like S. coelicolor and E. coli, many research groups exploited the






















































































































































































































































































































































































































































































































































































































PKSs. Section 1.2.6 explains an example of successes and challenges in re-engineering PKSs.
KS MAT DH MT ER KR ACP CON
SH
KS MAT DH MT ER KR ACP CON
SO
KS MAT DH MT ER KR ACP CON
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KS MAT DH MT ER KR ACP CON
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Figure 1.5: A Type I polyketide synthase (iterative), the lovastatin system. The figure here only shows the
PKS LovB out of the two PKSs LovB and LovF utilized in the production of lovastatin. LovB is respon-
sible for the production of dihydromonacolin L moiety which is produced by the iterative condensation
of 9 malonyl-CoA extender unit. LovB carries a non functioning ER domain for which the function is
substituted by LovC. The other domains in LovB consist of a ketosynthase, a malonyl transferase (MAT),
a methyl transferase (MT), a dehydratases (DH), an enoyl reductases (ER), a ketoreductases (KR), an
acyl carrier protein (ACP) and a condensation domain (CON).
Another popular and well studied example is the type I iterative PKS that produces lovas-
tatin, which is produced by the fungi Aspergillus terreus. Lovastatin is a cholesterol lowering
agent which acts as a precursor for the popular drug simvastatin. The lovastatin biosynthesis
pathway consist of two PKSs LovB and LovF. LovB, which is responsible for the nonaketide
moiety dihydromonacolin L, consists of a ketosynthase, a malonyl transferase (MAT), a methyl
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transferase (MT), a dehydratases (DH), an enoyl reductases (ER), a ketoreductases (KR), an acyl
carrier protein (ACP) and a condensation domain (CON) (Figure 1.5). The ER domain in LovB
is non functional therefore LovB utilizes a free standing ER LovC. LovB utilizes 9 malonyl-
CoA extender units, a methyl donated from a S-adenosyl-L-methionine (SAM) molecule and an
NADPH to produce dihydromonacolin L. LovF consists of all the above mentioned domains but
it has a functional ER. LovF catalyses the formation of the 2-methylbutyrate moiety by the con-
densation of two acetyl units. Other enzymes encoded within the same gene cluster includes
LovA and LovD. LovA encodes a cytochrome P450 oxygenase which oxidises the dihydor-
monacolin L produced by the LovB, which is covalently joined to the 2-methylbutyrate moiety
by the trans esterase activity of the LovD. Figure 1.5 shows the production of dihydromonacolin
L by LovB and LovC in the lovastatin biosynthesis pathway, and includes the proposed stage of
a Diels-Alder reaction for ring formation in the growing polyketide (Kennedy et al. 1999; Ma
and Tang 2007; Campbell and Vederas 2010; Ames et al. 2012).
Apart from the minimal PKS domains and one or more required β-keto processing domains,
several type I PKS gene clusters contain a number of tailoring enzymes which perform further
different functions at different stages of polyketide synthases. These tailoring enzymes may act
on the ACP bound polyketide intermediate or on the released product post production. One
such tailoring enzyme is 3-hydroxy-3-methyl glutryl-CoA synthase cassette (HCS) which is
responsible for the β-branching in many type I PKS systems for example mupirocin, thiomarinol
and kalimantacin (Haines et al. 2013). The HCS cassette adds a methyl branch at the β-position
of the growing polyketide chain by the coordinated action of five enzymes which include an
ACP, an HMG-CoA synthase, two enzymes from the crotonase family and a decarboxylase.
This β-methylation step is considered to be rate limiting and more complex as compared to the
methylation of an α carbon by a methyl transferase. At the onset of β-methylation an ACP
delivers a polyketide intermediate to the HMG-CoA domain in the HCS cassette. This delivery
requires the ACP and the HMG-CoA from the HCS to interact and recognize each other at the
appropriate stage of polyketide synthesis. At the time of starting my thesis, it was not very well
understood what enables the HCS cassette to recognize the correct ACP for the β-branching.
18
One of the projects in the present study was to explore the specificity mechanism of ACP-HCS
interaction in the mupriocin pathway, which is described in Chapter 3.
Another recently discovered tailoring enzyme of interest is halogenase. In the curacin sys-
tem this halogenase domain works in conjunction with the HCS proteins and is responsible for
the addition of a chloride on the γ carbon in the growing polyketide chain. In a study published
by Busche et al. (2012), they found the recognition specificity between this halogenase domain
and the ACP. Advances in PKS research are slowly unfolding the details of several different
pathways, with a diversity of enzymes functioning in conjunction core PKS function. It is be-
coming increasingly interesting to understand structure function relationship of these auxiliary
enzymes and to exploit them for synthetic biology purposes.
1.2.3.2 Type II PKS
Type II polyketide synthases produce aromatic compounds (polyphenols) in Gram-positive bac-
teria of the class actinomycetes, found in soil and marine environments. Some of the famous
examples of type II polyketides are tetracyclines, which is a class of broad spectrum antibiotics,
and doxorubicin, which is an anti cancer agent. In contrast to the type I PKSs, where all the
catalytic domains are covalently bonded in a single polypeptide chain, the domains forming
the type II PKS are encoded on separate genes. However, the genes encoding the type II do-
mains are usually found to be clustered together. Type II PKSs utilize an acyl starter unit and a
malonyl extender unit for Claisen condensation, using a single set of mono functional enzymes
iteratively. A minimal set of a type II PKS domains comprises of two KSs, a KSα and a KSβ
domain, and an ACP domain. Other catalytic domains such as ketoreductases and aromatases
amongst others perform β-keto processing. It is much more difficult to study type II PKS as
compared to type I PKS due to the very short span of stability of the intermediates produced.
With type II PKS it is also not possible to predict the metabolites produced straight from the
sequence of the biosynthetic domains involved, which is much simpler in type I modular PKS
(Hertweck et al. 2007).
The KSα and KSβ domains form heterodimers, where KSα is responsible for Claisen con-






















































































































































































































































































































































































































































































































































































































































































factor’(CLF). KSβ lacks a catalytic cysteine and therefore it can not perform Claisen condensa-
tion but upon mutating the position where a catalytic cysteine would be expected to a glutamine
(KSQ) it is capable of decarboxylating the malonyl unit into an acetate (Keatinge-Clay et al.
2004). This KSQ functionality is similar to the KSQs found in the modular type I PKS where
they are utilized to convert a malonyl unit into an acetate starter unit (Bisang et al. 1999). Swap-
ping CLF from different type II PKS can result in the production of metabolites of different
chain lengths.
It is still not very well understood what catalyses the loading of a malonyl unit to the ACP
of a type II PKS. Two alternative hypothesis were proposed both with similar possibility and
experimental evidence. One hypothesis favours the self malonylation of the ACP, which was
experimentally verified in vitro in a purified sample of type II PKS (Arthur et al. 2005). The
other hypothesis argues a potential involvement of a malonyl-CoA:ACP transacylase (MAT)
but most of the type II PKS cluster lacks an MAT therefore it was hypothesized that this MAT
is borrowed from a FAS in the cell (Dreier et al. 1999; Keatinge-Clay et al. 2003). Type II
PKS are also found to utilize domains such as KR, DH and ER from the host FAS (Tang et al.
2006a).
Figure 1.6 summarizes the biosynthetic pathway of the type II antibiotic actinorhodin pro-
duced by Streptomyces coelicolor as an example of a type II PKS. Actinorhodin biosynthesis
initiates by the priming of the malonate unit onto an ACP by the malonyl-CoA transacylase.
The malonyl-CoA unit is decarboxylated and transferred to the cysteine thiol of the KSα which
acts as the starter unit. This step is followed by seven iterative Claisen condensation cycles. At
the end of the condensation cycles the intermediate product undergoes keto reduction and suc-
cessive aromatization and cyclization to produce the polycyclic end product actinorhodin. Acti-
norhodin biosynthesis is carried out purely by a minimal set of type II PKS followed by down-
stream processing with tailoring enzymes however, other secondary metabolites like R1128 and
doxurubicin require an initiation module to produce a diketide starter unit prior to the minimal
type II PKS activity. This initiation module consists of a KS homodimer and an ACP, the ab-
sence of the CLF suggests the non requirement of chain length control in this module. Further
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details, including a cartoon representation of an initiation module, are given elsewhere (Das and
Khosla 2009).
1.2.3.3 Type III PKS
Type III PKS commonly found in plants, but with recent discoveries in bacterial systems as
well, belong to the superfamily of chalcone synthases (CHS) / stilbene synthases (STS) . CHS
is the first step in the plant flavanoid biosynthesis and is responsible for a variety of plant
metabolites, with functions including defence, pigmentation and fertility. CHSs utilizes a single
homodimeric ketosynthase iteratively, catalyses Claisen condensation of a p-coumaroyl-CoA,
as a starter unit, to the three acetate units derived from malonyl-CoA. The same catalytic centre
is also further utilized for successive aromatization and cyclization to produce chalcone. Figure
1.7 explains the chalcone biosynthetic pathway proposed by Ferrer et al. (1999). PKS type
III represents a divergent class of this CHS functionality with the diversity in the choice of
starter units, extender units, number of chain extensions and subsequent cyclization. There
were differences found in the bacterial and plant type III PKSs, for example bacterial type III
PKS can utilize an acyl-ACP starter unit by involving an ACP from an FAS, whereas plants
use acyl-CoA as the starter unit. Based on structural analysis of the type III PKS ketosynthase
Qiu et al. (2001) have suggested the emergence of these enzymes from the fatty acid KAS
III. FAS KAS III are responsible for the initiation of type II FAS biosynthesis. The type III
PKS utilizes CoA thioesters instead of a phosphopantetheinylated ACP to tether the growing
polyketide product (Austin and Noel 2003).
1.2.4 PKS domains
1.2.4.1 Acyl carrier protein (ACP)
Acyl carrier proteins (ACP) belong to a class of carrier proteins which are involved in chan-
nelling the substrates via a phosphopantetheine prosthetic group. These carrier proteins are
known to be involved in fatty acid synthesis (FAS), polyketide synthesis (PKS) and non-ribosomal
peptide synthesis (NRPS) . The carrier proteins involved in FAS and PKSs are called ACPs, but










































































































































































































































































































































































































































































































































































































































































































































































































































































































































to pass the substrate to the different domains of the module multiple times whereas in PKSs,
especially in type I modular PKS, each module has its cognate ACP to perform the substrate
channelling for that module. Although the carrier proteins share a wide range of sequence iden-
tity among various organisms, they still share a common structural fold. A sequence identity
of >80% is reported between ACPs from E. coli and V. harveyi, whereas 21%-27% sequence
identity between E. coli and rat ACPs (Byers and Gong 2007). A common carrier protein fold
consists of a 4 helical bundle which ranges from 70 to 100 amino acids long. Among the three
major α helices, helix I runs antiparallel to helix II and IV with a small helix III which runs
almost perpendicular to the axis of the three major helices. Inspite of their small structure car-
rier proteins are found to exhibit great degree of plasticity in their backbone movement. FAS
ACPs are found to sequester the growing fatty acid chain within the hydrophobic pocket in the
centre of ACP (Chan et al. 2008). On the other hand NRPS PCPs have been shown to be in-
volved in backbone rearrangement and helical movement during substrate chanelling (Koglin
et al. 2006). However, no such intrinsic conformational motion has yet been reported in PKS
ACPs, which is discussed in more detail in Chapter 5. These carrier proteins are translated
as inactive apo proteins that are activated by addition of the 4’-phosphopantetheine moiety of
a coenzyme A, through the action of 4’-phosphopanthetheine transferase (Mootz et al. 2001).
This 4’-phosphopantetheine moiety is attached to a conserved serine at the end of the helix II via
a phosphodiester bond (see Figure 1.8). Carrier proteins have also been found to be abundant
in various organisms, with 80 reported in Streptomyces avermitillis.
In a typical PKS pathway an ACP has to interact with a large number of proteins which
include 1) an AT domain, either cis or trans 2) an upstream KS domain 3) a downstream KS
domain 4) other catalytic domains for example KR, DH, ER, and 5) several other tailoring en-
zymes. Until recently it was not known how the relatively small structure of the carrier proteins
interact with such a diverse set of interacting partners. There were several unanswered questions
such as, how much of the carrier protein’s surface interacts with the partner protein? Does each
interaction occur at a different face of the protein? What drives the phosphopantetheine arm to
the different catalytic domains? Some of these questions have been answered lately however,
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Figure 1.8: Cartoon representation of an acyl carrier protein (ACP-A3a) from the mupirocin biosyn-
thesis pathway (PDB ID 2L22). A phosphopantetheine arm is modelled attached to the catalytic serine,
represented as sticks (Haines et al. 2013).
there is still a lot to be discovered.
In a study of FAS ACPs by Zhang et al. (2003) helix II was shown to interact with various
interacting partners as the “recognition helix”. Helix II being conserved and negatively charged
interacts with the positively charged channels of various ACP dependent proteins (Zhang et al.
2001). However, studies by Khosla’s group of PKSs have shown by structural modelling and
mutagenesis work that loop I and helix I are the interacting interface for the chain elongation and
translocation steps respectively. In another study on curacin biosynthesis helix III on the ACP
was found to be interacting with and the halogenase enzyme (Busche et al. 2012). In the present
work as well, helix III is shown to be one of the anchors that interacts with MupH, as described
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in Chapter 3. Thus, it can be said that helix II, which was considered to be the “recognition
helix”, is not the only surface with which ACPs interact with other proteins. Further exploration
may lead to finding some other novel features not yet discovered.
Till now there are only 6 entries in the PDB representing 4 different structures solved for
the ACPs from PKS systems, 2 for each cis and trans AT systems. The first set of structures
for the cis AT PKS were published in 2007 from module 2 of the DEBS system (PDB ID 2JU1,
2JU2) (Alekseyev et al. 2007), followed by the structure of ACP1 from the CurA module of
curacin system (PDB ID 2LIU, 2LIQ) in 2012 (Busche et al. 2012). Structures from the trans
AT systems came out very recently in 2013 for the didomain ACP in the MmpA subunit of
the mupriocin system which are involved in β-branching mechanism (PDB ID 2L22) (Haines
et al. 2013) followed by the solution structure of ACP 5 from the virginiamycin cluster (PDB
ID 4CA3) in early 2014 (Davison et al. 2014).
1.2.4.2 Acyl transferases (AT)
In PKS and FAS systems acyl transferase domains are responsible for loading the starter and
extender units onto the ACPs. In the type I modular PKS systems the AT domains can either be
covalently bound in the same polypeptide chain, which are called cis AT e.g. as in erythromycin
synthesis, or can exist in trans as discrete domains e.g as in mupirocin synthesis. In FAS sys-
tems, the acetyl starter and malonyl extender moiety are transferred on to the same AT domain,
at different times, via acetyl/malonyl transferase from an acetyl-CoA/malonyl-CoA molecule.
Thus, an FAS AT domain has dual specificity for the starter and extender units and there is a
competition between the two substrates for the AT active site. This phenomenon also holds
in many trans AT PKS systems, for example mupirocin, where a single set of AT domains is
responsible for loading both the starter and the extender units. On the other hand, cis AT PKS
systems have a separate module for loading the starter unit and the AT domain that is covalently
bound to a particular module allows loading its cognate extender unit. Thus in principle AT
domains can have specificity towards their own extender units allowing different extender units
to be utilized at each elongation step (Khosla et al. 1999).
The AT domain catalyses the starter and extender unit’s transfer from a CoA on to the phos-
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phopantetheine of an ACP. This transfer is achieved by a ping-pong bi-bi reaction mechanism
utilizing a conserved SER-HIS diad (e.g. S642 and H745 in DEBS AT5). The malonyl or
methyl malonyl moiety was found to interact with the conserved active site ARG (e.g. R667 in
DEBS AT5) at the beginning of the reaction (Tang et al. 2006b). The catalytic SER resides in a
highly conserved motif, GHSXG, and is responsible for the nucleophilic attack on the carbonyl
of the acyl moiety offered by the CoA. This nucleophilic attack leads to the formation of a SER-
acyl tetrahedral geometry, which is hypothesized to be stabilized by an oxyanion hole formed
by the backbone amides (e.g. Q9 and V98 in S. coelicolor MAT structure), and to the release
of CoA (Keatinge-Clay et al. 2003). HIS in the diad helps to enhance the nucleophilicity of
the SER. In the second step of the reaction the thiol of the incoming phosphopantetheine initi-
ates a nucliophilic attack on the SER bound acyl carbonyl forming SER-acyl-ACP tetrahedral
intermediate which is released by the protonation of the active site SER by the active site HIS
(Figure 1.10) (Tsai and Ames 2009; Dunn et al. 2013).
Figure 1.9 shows the cartoon structure of an AT domain from the module 5 of the DEBS
system and the proposed reaction mechanism is shown in Figure 1.10. AT domains follow an
α/β-hydrolase fold as the core catalytic domain of approx 240 residues attached to a smaller
ferredoxin like domain of approx 60 residues. The N-terminus of the AT domains in the cis-
AT systems are found to contribute to the KS-AT linker (approx 140 residues) which is termed
equivalent to the docking domain in the trans-AT systems (Tang et al. 2006b; Gay et al. 2014).
However, the docking domain in the trans-AT systems does not carry any portion of the AT
domain but is formed by the linker sequence in between the KS and the subsequence domain
(Gay et al. 2014). This linker region in the cis system (DEBS) is found to be important for the
interaction of the ACP during chain transfer and elongation (Kapur et al. 2010; Kapur et al.
2012). Although the crystal structure of a docking domain attached to the KS in the trans AT
system was recently published the role of the docking domains are still not understood (Gay
et al. 2014).
Although the ATs from type I and II PKS and FAS share the same catalytic reaction mech-
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Figure 1.10: Proposed reaction mechanism of AT domain. Figure adapted from (Smith and Tsai 2007).
extender units they transfer on the ACP. In silico and mutagenesis experiments have identified
conserved motifs within the vicinity of active site serine which determines the specificity to-
wards the different substrates. The loading domains in the cis-AT systems were found to have
more tolerance for a greater variety of starter units such as acetyl, propionyl, isopropionyl than
the AT domains responsible for loading the extender units such as malonyl and methyl manlonyl
(Lau et al. 1999; Liou et al. 2003).
The X in the GHSXG motif, which is usually a branched amino acid such as valine or
isoleucine in the malonyl specific ATs, is either a glutamine or methionine in the methyl malonyl
specific ATs (Haydock et al. 1995). On comparing AT structures from DEBS AT5 with a
mammalian FAS AT, DEBS AT5 has a glutamine at the X position which makes it specific for
methyl malonyl extender unit, whereas mammalian FAS AT has a valine or leucine at the X
position which makes it specific for malonyl extender unit (Tang et al. 2006b).
In another study, Yadav et al. (2003a) studied 187 AT sequences from 19 type I modular PKS
clusters and predicted motif QQGHS[QMI]GRSHT[NS]V was responsible to confer speci-
ficity towards methyl malonyl substrate and QQGHS[LVIFAM]GR[FP]H[ANTGEDS][NHQ]V
motif was associated with malonyl specificity. They have also identified a position R117 in E.
coli malonyl-CoA:acyl carrier protein transacylase crystal structure (PDB ID 1MLA) which
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was conserved in all the malonyl and methyl malonyl specific ATs but changes to a non polar
amino acid for the ATs specific for monocarboxylic substrates such as propionate. These motifs
are embedded in their PKS domain detection program SEARCHPKS (Yadav et al. 2003b). An-
other motif is the YASH motif which contains the catalytic histidine 100 residues downstream
of the catalytic serine. YASH motif was found to be specific in the methyl malonyl specific ATs
whereas HAFH at the same position was specific for the malonyl substrates (Haydock et al.
1995).
1.2.4.3 Ketosynthases (KS)
Ketosynthases are responsible for catalysing Claisen condensation in PKS, FAS and NRPS sys-
tems. KSs belong to the thiolase family of proteins and in type I FAS and type I and III PKS
they form homodimers (Austin and Noel 2003; Tang et al. 2006b). KSs in type II PKS also
forms the dimer but only one subunit performs the Claisen condensation and the second subunit
which is also known as chain length factor is a non functional KS considered to be responsi-
ble for keeping a check on the growing polyketide chain length (Tang et al. 2003; Szu et al.
2011). The homodimeric state in type I PKS and FAS is considered to be the primary fac-
tor for the dimerization of the two subunits. Although ER and DH domains are also found to
form dimers, experiments have shown that upon KS deletion the FAS subunits fails to dimer-
ize (Smith and Tsai 2007). The thiolase fold of the two dimer forming KSs follow the same
alternating α/β/α/β/α architecture. The active site is formed at the dimer interface by the con-
tribution of the residues from both the subunits. The active site can be viewed as two segments,
one at the most buried segment is next to the dimer interface and bind the acyl intermediate,
and an outer tunnel starts from the enzyme surface and binds the phosphopantetheine arm. Se-
quence analysis has shown diversity and lesser sequence similarity in the residues lining the
acyl intermediate binding pocket as compared to the phosphopantetheine binding tunnel (Olsen
et al. 2001). This is due to the ability of the KS across different systems to accept a variety of
substrates which are however, attached to the same phosphopantetheine arm.
There are two main classes of Claisen condensations for carbon-carbon bond formation;
the decarboxylating and the non-decarboxylating. The structures of the KSs used for both the
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classes are low in sequence similarity but still have the same three dimensional thiolase fold
(Heath and Rock 2002). The decarboxylating condensing enzymes can be further divided into
two sub classes based on the primary sequence analysis 1) Initiation ketosynthase such as type
I FAS, FabH and 2) Elongation ketosynthases such as type I FAS, FabB and FabF (Davies et
al. 2000). The initiation enzymes utilize CoA substrate as the primer whereas the elongation
enzymes utilize ACP thioesters however, the reaction mechanism followed by both the enzymes
is same. The initiation ketosynthases as the name suggests are found at the beginning of the type
I FAS and PKS usually in the loading module for example the niddamycin pathway (Kakavas
et al. 1997).
After years of disagreement and research and with the availability of the high resolution
crystal structures of KSs from both FAS and PKS systems researchers have come to the con-
sensus that the Claisen condensation is a three step process involving a CYS-HIS-HIS catalytic
triad (Figure 1.11). In the E. coli FAS (FabB/FabF) KS (PDB ID 1DD8) C163, H298 and, H333
forms the catalytic triad (Figure 1.12). The Claisen condensation initiates with the acyl chain
transfer from an ACP on to the catalytic cysteine forming an ACP-acyl-KS thioester tetrahe-
dral intermediate. In FAS (FabB/FabF) this tetrahedral geometry is stabilized by the backbone
amides contributed by the catalytic cysteine and a glycine (G391). The pKa of a free cysteine
(8.0 to 8.8) is not sufficient for the deprotonation and the nucleophilic attack on the acyl car-
bonyl. A pKa of about 7.0 or lower is required for the cysteine to act as a nucleophile under
physiological conditions. Qiu et al. (1999) suggested H244 may be involved in assisting the
deprotonation of the cysteine thiol. However the distance between the N ε ans S γ of the H244
and catalytic cysteine respectively were too far for this to happen. Furthermore replacement of
H244 with an alanine resulted in a protein that was unable to catalyse the complete condensa-
tion reaction, but was 6 times faster in transacylation than the wild type. However, mutagenesis
studies on H244 do show that it assists in the deprotonation of the thiol at low pH (Davies et
al. 2000). The probable explanation for the deprotonation of the catalytic cysteine thiol under
physiological conditions was given on the basis that the cysteine is present at the N-terminus of
the alpha helix, the positive end of the dipole moment of the helix could stabilize the negative
31
charge, allowing transfer to the acyl chain to the cysteine (Davies et al. 2000).
The second step involves the decarboxylation of the malonyl extender unit attached to the
ACP. The two histidines are considered to be involved in the decarboxylation of the malonyl
unit. A water molecule in the active site is thought to be activated by one of the histidines
which in turn attacks the C3 carbonyl of the malonyl resulting in the formation of an enol
intermediate, stabilized by the histidines. This decarboxylation step also happens in the absence
of the acyl-cysteine thio ester and that is why the above mentioned initiation keosynthases that
lacks catalytic cysteine are able to decarboxylate a malonyl or methylmalonyl units into an
acetyl or propionyl units respectively. Such initiation ketosynthases carry a glutamine in place
of a cysteine (also known as KS Q). In the final step the enol intermediate forms a carbanion
which in turn attacks the acyl-cysteine thio ester resulting in a tetrahedral intermediate which is
again stabilized by the oxyanion hole followed by the release of the acyl-ACP (Heath and Rock
2002).
In modular cis-AT PKS, Ketosynthases have shown to be tolerant in terms of substrate speci-
ficity and can readily accept non native substrates. Studying the structure of the type I and type
II KS, type I KSs have a loop at the interface in the homodimers which is replaced by a helix
in the type II KSs. This loop region is hypothesized to be responsible for providing additional
space to accommodate non native substrate which otherwise is restricted by the helix in the
type II KSs (Pan et al. 2002). KSs were able to catalyse chain elongation with inactivated KR5
or ER4 domain in the DEBS system. KS2 in the DEBS system was also found to be tolerant
towards several substrates (Khosla et al. 1999). Using a KS1 knockout strain Khosla et al.
(1999) showed that (2S,3R)-diketide and analogous substrates attached to a NAC molecule tol-
erated and processed by the KS2 domain. Not only different variants of diketide moeities they
also tested an anhydro-triketide moiety which was able to be processed by the KS2, these sub-
strate variants produced analogues of 6-DEB molecule. As well as KS2 being tolerant towards
(2S,3R)-diketide moiety KS3, KS5 and KS6 were also able to accept and produce triketide
products (Khosla et al. 1999).
Recent phylogenetic studies have shown that the cis and trans PKS evolved independently
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through different routes. The KS from the trans-AT systems were likely to be incorporated via
horizontal gene transfer as opposed to gene duplication events in the cis-AT systems. This dif-
ference may explain how trans AT systems came to be more specific towards their substrates as
compared to their cis-AT counterparts (Nguyen et al. 2008). These hypothesis were also exper-
imentally supported by the two recent collaborative papers by Piel and Oldham group. In the
first paper by Jenner et al. (2013) utilizing a newly developed mass spectrometry (MS) based
method to study ketosynthases specificity analysed substrate specificity of KS5 from bacillaene
and KS1, KS2 and KS30 from psymberin biosynthesis pathways. KS5 in the BaeL subunit re-
sides right before the key β-branching step which naturally makes it tolerant for non branched
substrates. Similarly KS1 and KS2 from PsyA processes non branched substrate and KS30 from
PsyD is a non condensing keto synthase but is capable of acyl transfer. Jenner et al. (2013) incu-
bated these ketosynthases with different SNAC analogues containing branched and unbranched
substrates and tested their ability to produce product with MS. They found that the KS5 from
BaeL and KS30 from PsyD do not tolerate branched substrate however were able to successfully
process unbranched substrates. On the other hand KS1 and KS2 from PsyA were able to pro-
cess branched substrate with lowered specificity. Upon sequence analysis, homology modelling
and substrate docking of KS5 of BaeL, they found that the residue right before the catalytic
cysteine (X-cys) seems to interact with the β-carbon. This position X is usually a bulky residue
like methionine in the non branch accepting ketosynthases and a smaller residue like glycine or
alanine in the branched chain accepting ketosynthases. KS5 from BaeL and KS30 from PsyD
have methionine on that position whereas KS1 and KS2 form PsyA have an alanine, which
explains the more tolerant behaviour of the branched substrate by KS1 and KS2. To test this
prediction from the computational analysis Jenner et al. (2013) created a KS5 M237A mutant
and incubated it with branched and unbranched SNAC analogues. The unbranched analogues
were successfully transferred onto the catalytic cysteine of the KS5 mutant as the more space
created inside the active site would have not affected the binding of the unbranched substrate.
However, the KS3 mutant also showed increased levels of branched substrate specificity which
suggests the necessity of the space created by replacing a bulky residue with a small residue
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immediately preceding the catalytic cysteine. These experiments laid down the new rules for
predicting the specificity of KS domains towards branched and unbranched substrates. Al-
though this rule is only restricted to the β- position in the substrates authors do not deny the
possibility of discrimination based on the interactions at other parts of the substrate.
In the second paper, Kohlhaas et al. (2013) tested the specificity of the bacillaene system
KS1 domain from BaeJ for amino acid derived intermediates using the same protocols as men-
tioned above. KS1 in BaeJ accepts a glycine derived substrate from an upstream NPRS module,
to test the tolerance of KS1 for different amino acid based substrates Kohlhaas et al. (2013) cre-
ated several different full length acyl-SNAC analogues utilizing glycine, alanine and valine to
generate 2-amido variants. Upon incubating KS1 with the three 2-amido variants, the glycine
derived substrate was able to readily transfer to the KS1 whereas the alanine based substrate
did so with lower efficiency. The substrate based on valine failed to acylate KS1. In order to
accommodate the bulkier valine derived substrate Kohlhaas et al. (2013) identified M268 and
L450 as the likely residues that offer steric hindrance in the entry of the substrate. They created
two mutants M268A and L450A and tested all the three amino acid derived substrates. Glycine
and alanine variants were still able to acylate however, the valine variant couldn’t. These dif-
ferences in the acylation efficiency suggested the intrinsic incompatibility of the groups at the
α position. They also created SNAC analogues to test any long range interaction beyond the
β-position in the intermediates and the affect of not incorporating amide from an α amino acid.
There were no acylation observed in the substrate created to test the long range interaction as
well as for the amide from the non α amino acid. Two other acyl-SNAC analogues featuring
2-amino and 4-keto groups were also incubated to test for acylation efficiency. 2-amino SNAC
was able to acylate efficiently however, no observable acylation occurred with a 4-keto SNAC
substrate. These observations suggested the need for an NH at the 2nd position, which would
act as an efficient hydrogen bond donor, and that there is no requirement of the 4th carbonyl for
the successful acylation.
Kohlhaas et al. (2013) also tested KS1 for the effect of different residue type N-terminal to
the catalytic cysteine on KS1’s ability to accept different substrates. Through sequence analy-
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sis they found that most of the amino acid accepting KSs posses an asparagine residue at the
position before the catalytic cysteine along with a few occurrence of alanine. On comparing
with other ketosynthases in either cis or trans-AT systems they could never find an asparagine
at that position. The dominating presence of an asparagine residue suggested its likely involve-
ment in the acylation of the 2-amidoacetly substrate to KS1. To test this hypothesis they created
an N206A mutant and incubated with 2-amidoacetly-SNAC. The mutant strain showed much
lowered acylation efficiency.
1.2.4.4 Ketoreductases (KR)
Ketoreductases are enzymes responsible for reducing the β-keto group to hydroxyl in FAS and
PKS systems with the involvement of NADPH as the reducing agent. Unlike KSs which need
to exist as a homodimers to function, KRs exist as functional monomers in the PKS dimer.
KRs are thought to be responsible for the formation of most of the chiral centres in Polyketide
products.
The stereo specificity of the products of KR domains was verified through domain swapping
experiments with the KR2 from the DEBS system and the KR2 from the rapamycin system. The
KR2 in the DEBS system produces an L-β-hydroxyl group whereas the KR2 from the rapamycin
system is responsible for a D-β-hydroxyl group. In a model system using DEBS1 (Figure 1.4)
and the DEBS thioesterase, domain swaps from rapamycin KR2 to DEBS KR2 produced a
triketide with a D-β-hydroxyl group, confirming the stereo specificity of the KS product (Cortes
et al. 1995). It should also be noted that the mammalian FAS are known to produce D-β-
hydroxyl groups whereas DEBS KRs produce an L-β-hydroxyl group, this observation also
suggests that the KRs are not only responsible for the β-keto reduction but also for assigning the
correct stereo chemistry to the resultant hydroxyl group (Kao et al. 1998). KRs from the DEBS
systems were also found to be tolerant of different substrates. In a domain swap experiment,
a system with KR5 from the DEBS system replacing KR2 successfully produced the DEBS1
triketide product, suggesting a wide tolerance for KR substrate specificity (Khosla et al. 1999).
Ketoreductases can be classified into three types, type A which is responsible for L-β-
























































































































































































reduction. Type A and B can be further sub classified as 0, and 1 and 2 depending upon whether
they reduce an un-α-substituted substrate or an α-substituted substrate. A0 and B0 will be type
A and B which cater an un-α-substituted substrate whereas A1, B1 accepts D-α-substituted sub-
strates and A2, B2 accepts L-α-substituted substrates (i.e. [LD]-α-alkyl-[LD]-β-hydroxyl). The
type C KRs can also be sub classified as C1, which are non functional, and C2, which do not
perform β-keto reduction but are capable of epimerase activity for the α-substituted substrates
(Keatinge-Clay 2007). These classifications were made on the basis of the conserved motifs
found through sequence analysis and subsequent mutagenesis and domain swap experiments
(Caffrey 2003; Zheng and Keatinge-Clay 2011).
Ketoreductases belong to the superfamily of short chain dehydrogenases/reductases (SDR)
and their structures is made up of two Rossmann like fold domains for ≈480 residues. The N-
terminal structural domain (KRs) does not catalyse the reduction but is thought to be important
for providing correct orientation to the C-terminal catalytic domain (KRc). The junction of the
(KRs) and (KRc) is marked by the N-terminal β (β1) strand of (KRs) which is also thought to
mark the boundary of the KR, forms a continuous β sheet with the C-terminal β (β7) strand
leading to the (KRc) domain. Similar to the SDRs, KRs in modular polyketide synthases were
hypothesized to involve the conserved catalytic triad of tyrosine, serine and lysine to carry out
β-keto reduction (Keatinge-Clay and Stroud 2006; Zheng and Keatinge-Clay 2011). Homology
modelling of KR6 from the DEBS3 and subsequent mutagenesis study on the catalytic residues
proved the importance of these residues in the β-keto processing. Reid et al. (2003) found
that in the complete DEBS system a KR6 Y2699F mutation completely abolishes the pathway
whereas KR6 K2664Q and KR6 S2686A significantly reduce polyketide production. However,
in a truncated DEBS Module6+TE system all the three KR6 mutations completely abolish the
triketide production. Figure 1.13 shows the equivalent positions of the catalytic residues in the
KR crystal structure from the first module of the DEBS biosynthesis pathway. In the proposed
reaction mechanism for the PKS KR, similar to SDRs the catalytic tyrosine was responsible for
donating the proton to the carbonyl oxygen of the substrate. Serine provided stability to the
ligand through hydrogen bonds and lysine was hypothesized to lower the Pka of the catalytic
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Figure 1.14: Proposed reaction mechanism for β-keto reduction. Figure adapted from (Reid et al. 2003).
tyrosine to assist proton transfer. All the KRs from the DEBS system were also shown to utilize
pro-S hydride of NADPH. For the L and D configuration of the resultant β-hydroxyl group it was
proposed that keeping the position of the catalytic residues and the bound cofactor (NADPH)
fixed there could be two ways in which the substrate presents the β-carbonyl to the active sites
(Figure 1.14).
1.2.4.5 Dehydratases (DH)
DH domains catalyse the reversible dehydration of β-hydroxy acyl-ACP to α, β-unsaturated
acyl-ACPs in cis or trans configuration. The dehydratase domains in the bacterial FAS forms
a dimer in a structural fold called a “hot dog”(Figure 1.15). This hot dog fold comprises a
central helix enveloped by the seven β-strands. In this hot dog dimeric structure there were two
active sites formed at the interface in which an active site dyad histidine is contributed from one
subunit and an aspartate from the other subunit. On the contrary the DHs in both the mammalian
FAS and dimeric PKS (for example curacin DHs) are formed of dimers of double hotdog folds
in which the histidine and aspartate are provided by the N and C-terminal hotdog respectively
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Figure 1.15: Cartoon representation of the dehydratases monomer domain (CurF PDB ID 3KG6 chain
A) from curacin biosynthesis pathway. The double hot dog structure is coloured in rainbow colours with
blue at the N-terminal and red at the C-terminal. The catalytic diad H1720 and D1893 are drawn in
sticks and labelled (Akey et al. 2010).
(Figure 1.15). The orientation of the dimers in the mammalian FAS and dimeric PKS were
different with respect to each other (Akey et al. 2010). In the proposed reaction mechanism the
catalytic histidine which acts as a general base helps in the removal of the proton from the α
position and aspartate helps in the removal of β-hydroxyl (Figure 1.16). The stereochemistry of
the dehydrated product is thought to be dependent on the configuration of the β-hydroxyl group
(Keatinge-Clay and Stroud 2006; Maier et al. 2008; Akey et al. 2010).
1.2.4.6 Enoyl reductases (ER)
The enoyl reductases (ER) in the PKS systems belong to the superfamily of MDR (medium
chain dehydrogenase reductases) proteins and are responsible for the reduction of the enoyl-
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Figure 1.16: Proposed reaction mechanism for β-hydroxy dehydration.
ACP to a fully saturated acyl-ACP on the growing polyketide molecule. These domains usually
serve as the last domain in fatty acid and polyketide chain extension and modification cycle
before the next round of extension begins. Most of the members of MDR superfamily including
ERs exist as homo dimers or tetrameters in FASs and PKSs with the exception of the type I
iterative PKS, lovastatin, which contains a free standing monomeric ER (Figure 1.17).
The lovastatin ER lovC is composed of two domains the catalytic domain and the cofac-
tor binding domain (Rossmann fold), these structural domains were also found in the other
members of the MDR superfamily. The crystal structure solved by Ames et al. (2012) and sub-
sequent mutagenesis studies have shown key residues which are responsible for LovC catalysis.
Figure 1.17 highlights the active site residues S51, K54, T68, N263 and G282 in the LovC
crystal structure responsible for the oxyanion hole formation and catalysis. In the proposed re-
action mechanism (Figure 1.18 ) K54 and G282 (backbone amide) participate in the oxyanion
hole formation to stabilize the enolate oxide formed due to the pro-R hydride transfer from an
NADPH. In the next step the enolate oxide accepts a proton most likely from a water molecule
and produces a fully saturated α, β-acyl-ACP. However, the ER in the type I fungal FAS is an
exception to this commonly followed reaction mechanism in which the proton is not transferred
by an NADPH but instead it utilizes flavin mononucleotide (Ha et al. 2006).
The co-factor (NADPH) binding domain can be characterised by the presence of GXGXXG
/ AXXXG / A motif and in the DEBS ER4, mutating the NADPH binding motif HAAAG-
GVGMA to HAAASPVGMA completely abolishes the ER activity. Experiments have shown
that ERs have broad substrate specificity and can easily be swapped across different pathways
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Figure 1.17: Cartoon representation of the enoyl reductase domain from the lovastatin biosynthesis
pathway (LovC PDB ID 3B6Z). The catalytic domain (fire brick red) and the NADPH binding domain
(purple blue) are separately highlighted. The key active site resides S51, K54, T68, N263 and G282 and
NADPH are drawn as sticks and labelled (Ames et al. 2012).
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Figure 1.18: Proposed reaction mechanism for enoyl reduction in lovastatin biosynthesis pathway
(LovC). Figure adapted from (Ames et al. 2012).
in both FAS and PKS systems (Khosla et al. 1999; Witkowski et al. 2004a; Khosla et al. 2007).
1.2.4.7 Thioesterases (TE)
Thioesterases (TE) are the domains responsible for the hydrolytic release and sometimes macro-
cyclization of the polyketide chain attached to an ACP. In modular PKSs, TEs are usually the
terminal domains however, experiments from Khosla’s group have shown that TE domains are
also capable of performing well when attached to a bi modular DEBS1 subunit (Gokhale et
al. 1999). Thus, TE domains are capable of exhibiting a broad range of substrate tolerance.
TE domains have a typical α/β hydrolase fold and a S, H and A catalytic triad, both in the
type I modular PKSs and type II fungal iterative PKSs. In the DEBS system the hydrolytic
release of the polyketide chain has been proposed as a two step process, in the first step the
catalytic S142 initiates a nucleophilic attack on the incoming polyketide intermediate resulting
in the transacylation of the acyl chain to the catalytic S142 forming an acyl-enzyme complex.
In the second step H259 helps to deprotonate the C-13 hydroxyl on the TE bound polyketide
intermediate which results in the release and macro cyclization of the 6-deoxyerythronolide B.
In the DEBS TE the 14 membered ring is also supported by seven hydrogen bonds inside the
active site, which ensures the correct orientation of the C-13 hydroxyl group close to the Ser-
O-acyl linkage (Gokhale et al. 1999; Sharma and Boddy 2007; Khosla et al. 2007). Figure
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Figure 1.19: Cartoon representation of the thioesterases domain monomer from DEBS biosynthesis
pathway (PDB ID 1KEZ). The catalytic triad S142, H259 and D169 are drawn as sticks and labelled
(Tsai et al. 2001).
1.19 and 1.20 show the crystal structure of the TE monomer from the DEBS system with the
highlighted active site triad and the proposed reaction mechanism respectively (Tsai et al. 2001).
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Figure 1.20: Proposed reaction mechanism for thioesterase in DEBS biosynthesis pathway. Hydrogen
bonds are drawn as dotted lines. Figure adapted from (Tsai et al. 2001).
1.2.5 Complete modular structures of FAS/PKS
The earliest attempts made to experimentally determine the complete modular structure of an
FAS were carried out in the late 1980s using small angle neutron scattering and electron mi-
croscopy using samples from chicken, pig and human FAS (Stoops et al. 1987; Kitamoto et al.
1988; Brink et al. 2002). Owing to the poor quality of the electron density measured those mod-
els were only used to support the feasibility of the previously proposed head-to-head model over
the fully extended head-to-tail model. Those models were also not good enough to correctly
determine whether the two chains of the FAS were arranged in a back to back manner or were
crossed over.
In the mid 2000s Nenad Ban and his colleagues were able to successfully determine the
structure of a complete FAS module from mammalian and fungal species through X-ray crys-
tallography at various resolutions (Maier et al. 2006; Jenni et al. 2007; Maier et al. 2008). And
later on in 2013 they produced a cryo-EM structure of the Mycobacterial FAS (Boehringer et al.
2013). Similar to the previous attempts Ban’s group also struggled in correctly determining the
structure of the highly flexible regions such as the terminal ACP and the TE domains and it
was only the yeast FAS in which they could successfully locate the position of the ACP. All the
other structures were determined without the ACP and the TE domain.
1.2.5.1 Mammalian FAS
The first crystal structure determined by the Ban group was the 4.5 Å resolution mammalian
FAS an α2-homodimeric protein with all the seven FAS domains on each of the two subunits.
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In spite of being successful in obtaining crystals of the porcine FAS the resolution was not
good enough to correctly determine the position of the side chains in the molecule however,
the secondary structural elements were clearly detectable. Therefore, they utilized the electron
density map to fit the previously determined crystal structures of individual domains from type
II FAS to obtain a domain architecture of the mammalian FAS (PDB ID 2CF2) (Maier et al.
2006).
The overall shape of the mammalian FAS was like an X, imagining this as a person, the KS
homodimers form the lower and DH domain pseudo dimers form the upper portion of the torso
of the body, the MAT domains forming the legs attached to the KS, the ER domain homo dimer
the head and the KR domains forming the arms (Figure 1.21). This arrangement of the domains
in the quaternary structure was in contrast to the linear arrangement of the domains in the
primary structure and has dimensions of 210 Å x 180 Å x 90 Å. The architecture also revealed
two main dimerization interfaces, one at the KS and the other at the ER domains covering an
area of ≈5000 Å2. The KS dimer was found to be similar to bacterial KS I from FabB and was
in agreement with cross linking experiments conducted in the mammalian FAS to cross link the
N-terminus of a KS domain with the engineered active site cysteine of the other (Witkowski
et al. 2004b). The ER domain homodimers form a continuous 12 stranded beta sheet at the
interface joining the two nucleotide binding domains, six strands coming from each monomer.
Apart from the dimer interfaces between the KS and the ER domains a small portion of the
lower end of the DH domains also contribute to the overall dimer formation. The DH domains
sit on top of the KS domains with the lower portion of the DH domains making a contact with
the upper portion of the KS, domains which forms the waist like region. Linker regions were
found in between the KS and the MAT domain and also between the MAT and DH domain. The
KR domains are separate single domains hanging out as arms with no contacts between the two
which was contrary to observation of tetrameric bacterial KRs (Maier et al. 2006; Boehringer
et al. 2013).
Maier et al. (2006) made an interesting observation that the X shape of the mammalian FAS
is asymmetrical. The conformation in which the X-ray structure was obtained had different
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sized reaction centres in the KS domain. The distance between the KRs and the MAT domains
on the same sides were not similar and they were measured to be 72 Å on one side and 87
Å on the other. It was speculated that this difference in the size of the reaction centres may be
caused by the mechanism of substrate binding to the KS and the product release after elongation,
mediated by a hinge in the “waist” region. In support of this hypothesis, the bacterial KSs
in FabB have shown non symmetrical mode of substrate binding. They also proposed that
the KS/MAT linker region might also allow the MAT domains to move in the “up and down”
direction. The proposed cumulative effect of these motions were to accommodate the ACPs
close to the enzymatic domains. As the observed length of the phosphopantetheine arm was
only long enough for the bound substrate to reach to the centre of the active sites, implies if the
ACPs were in close contact with the individual catalytic domains then there should be enough
space in the quaternary arrangement of the FAS domains to accommodate the ACP next to the
active site entrance of each domain. This hypothesis also strengthened by work by Zhang et
al. (2003), which identified the key residues responsible for the interaction between the ACPs
and the KR domains in the bacterial type II FAS, thus proving the existence of domain-domain
interaction between the ACPs and the FAS catalytic domains.
Following the determination of the mammalian FAS domain architecture based on the 4.5
Å resolution X-ray crystallographic map, Ban’s group successfully determined the 3.2 Å reso-
lution crystal structure of FAS in its NADP+ free and bound states (PDB ID 2VZ8). The res-
olution for this crystal structure was good enough to correctly determine the side chains along
with the secondary structure (Figure 1.21). However, even in this attempt they couldn’t deter-
mine the structure for the ACP and the TE domains. The 3.2 Å resolution structure also agreed
with the previously observed X shaped domain organization of the mammalian FAS. However,
they identified two additional structural domains. One of the additional domains resembled a
methyl transferase but is apparently catalytically inactive, and thus referred to as pseudo methyl
transferase, and the other domain was similar to a ketoreductase which was thought to provide
structural scaffold for the correct orientation of the catalytically active KR. This structure had
similar dimerisation interfaces between the KS and the ER domains to those observed in the 4.5
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Figure 1.21: X-ray structure of the mammalian FAS (PDB ID 2VZ8) rendered as cartoon. The catalytic
(KS and MAT) and the modifying domains (KR, DH and ER) are coloured and labelled as indicated. The
linker domains (LD) are coloured as grey and the pseudo domains (ME and KR) are labelled with the
symbol ψ.
49
Å resolution model. However, the size measured was according to the electron density observed
for the mammalian FAS side chains rather than the fit from the type II FAS discrete domains.
The overall contact area in the dimerisation interface of the 3.2 Å was measured to be 5400 Å2
which included 150 amino acids with the contributions of ≈2600 and 1600 Å2 from KS and
ER domains respectively. The two DH domains also contributed 800 Å2 to the dimerization
interface along with the linker region between MAT, DH and the KS domains. This crystal
structure also revealed the linker regions between the KS and the MAT domains, consisting of
two helices and three β-strands forming an anti parallel β-sheet. This linker, which was thought
to prevent any direct linkage between the KS and MAT domains, was also observed in the KS-
AT crystal structure in the type I modular DEBS PKS determined at the same time by Khosla’s
group (Tang et al. 2006b; Tang et al. 2007). On the basis of the sequence context this region
was also speculated to be present in the trans AT systems and a very recent crystal structure
of the KS homodimers from a trans AT system showed the presence of a similar linker region
attached to the C-terminal of the KS domains (Gay et al. 2014). The precise role of this linker
region is still unknown however experiments from Khosla’s group have shown that they might
be necessary for the ACP docking during the elongation and acyl-transfer stages (Kapur et al.
2010).
1.2.5.2 Fungal FAS
In 2007 Ban group solved the crystal structure of 2.6 mDa α6β6 -dodecameric fungal FAS
from Thermomyces lanuginosus (PDB ID 4V58) and that of Saccharomyces cerevisiae (PDB
ID 2UV8), both at 3.1 Å resolution (Jenni et al. 2007). The structure determined from S. cere-
visiae also revealed the position of the ACP attached to the KS active site. Although both the
mammalian and fungal FAS are type I FAS where the domains are covalently attached in a sin-
gle polypeptide their quaternary structures are very different from each other. The fungal FAS
structure comprised of a central wheel sandwiched between two dome like structures (Figure
1.22) providing two distinct reaction centres with five entrances through the walls and top of
the domes. The two reaction centres were connected by six passages through the central wheel.
The central wheel was composed of 6 α subunits whereas the domes were composed of 3 β
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subunits each. One α and one β subunit join to form a single non-redundant FAS unit. Thus in
a fungal FAS complex there are six functional units of FAS formed by 12 polypeptide chains.
The α chains consists of KS and the KR domains and the β chains consist of AT, MPT (mal-
onyl/palmitoyl transferase) , DH and ER domains with numerous inter-chain contacts between
the domains. All the active sites were found to point towards the inner side of the catalytic
centres in the two domes. The fungal FAS also had phosphopantetheinyl transferase (PPT) do-
mains attached to the C-terminal hanging outside the reaction centres. PPT are responsible for
attaching the phosphopantetheine arm to the ACP.
The all helical acyl carrier proteins in the fungal FAS were twice the size of their bacte-
rial counterpart with the first four helices overlapping very well with their homologues. The
catalytic Serine was found to be on a loop between helices 7 and 8 whereas helix 8 was con-
sidered to be the recognition helix when making a contact with the KS. There were three ACPs
each in both the reaction centres and these are doubly tethered, to the reaction centre wall at
the N-terminus and to the central wheel at the C-terminus. The AT and the MPT domains had
similar folds and were thought to be involved in charging ACPs with the acetyl or malonyl, and
palmitoyl moieties respectively. The fungal FAS KS domains exhibit broad substrate specificity
as compared to their bacterial homologues. A single FAS KS is capable of iteratively catalyse
fatty acid chain elongation from C2 to C16 whereas three different KS domains are required
in the bacterial FAS. All the KS domains were found to be tightly embedded in the central
wheel of the fungal FAS with the active sites pointing towards opposite reaction centres. The
ketoreductases found in fungal FAS followed the classical Rossmann fold however they were
dimeric as compared to the monomeric mammalian and tetrameteric bacterial KRs. The DH
domains in the fungal FAS formed a triple hot dog fold as compared to the mammalian double
hot dog fold. The ER domains in the fungal FAS were also different from their mammalian and
bacterial counterparts since the fungal ER utilizes flavin mononucleotide (FMN) instead of an
NADPH and forms a TIM barrel as opposed to Rossmann fold (Jenni et al. 2007; Leibundgut
et al. 2007).
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Figure 1.22: X-ray structure of the fungal FAS (PDB ID 4V58) rendered as cartoon. Helices in the
domes and the middle wheel are coloured in green and red respectively. Beta sheets are coloured in blue.
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1.2.5.3 Bacterial type I FAS
In the year 2013 Ban’s group published the cryo-EM reconstruction of a Mycobacterial FAS
structure at 7.5 Å resolution from the Mycobacterium smegmatis species (PDB ID 4V8L, Boehringer
et al. (2013)). The Mycobacterial FAS showed a barrel shaped domain architecture similar to
the fungal FAS (Figure 1.23). However, the structure was more compact with wider openings
for the external entrance into the structures. Boehringer et al. (2013) used the yeast FAS crys-
tal structure to fit the Mycobacterial EM density map. The 7.5 Å resolution was good enough
to detect the individual helices however, the β strands were not clearly visible. Although the
flattened shape of the β sheets were detectable.
The Mycobacteium smegmatis FAS is a 2.0 mDa α6 homohexameric structure coded as
a single polypeptide containing all the catalytic domains as compared to the domains spread
across two polypeptides in the fungal FAS. However, it lacked the phosphopantetheinyl trans-
ferase domain attached to the C-terminus. PPTs, called ACP synthases in Mycobacteria, are
standalone homotrimers encoded by a separate gene.This explains the presence of wider open-
ings in the dome walls to let the ACP synthases reach the ACPs inside the reaction centres
within the domes.
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Figure 1.23: X-ray structure of the mycobacterial FAS (PDB ID 4V8L) rendered as cartoon. Helices in
the domes and the middle wheel are coloured in red and blue respectively. Beta sheets are coloured in
yellow.
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Figure 1.24: X-ray structure of the KS-AT homodimer from the DEBS (PDB ID 2HG4) system rendered
as cartoon. Ketosynthase (KS) dimers are coloured in two different shades of purple, linker domains
(LD) are coloured in grey and acyltransferase (AT) domains are coloured in lemon yellow.
1.2.5.4 Cis and trans AT PKS
Soon after the FAS structural elucidation by Ban’s group the PKS community also released
atomic resolution structural models for PKS systems. Khosla and colleagues were only able
to crystallize the KS-AT homodimeric structures from DEBS 3rd and 5th modules (Tang et al.
2006b; Tang et al. 2007), and until very recently those were the only structures available for
the PKS systems, which only represent part of the module. The first structure which came out
was the 2.7 Å resolution crystal structure of the 194 kD KS-AT homodimer from the module 5
of DEBS system (PDB ID 2HG4). This structure agreed very well with the then resolved 4.5
Å resolution domain architecture structure of the mammalian FAS and was similar to the leg
region of the mammalian FAS structure (Figure 1.24).
Apart from the two full length domain structures of the KS and AT domain the solved struc-
ture also had three linker regions. The N-terminal helical linker region, the linker region/domain
between the KS and AT domains and the C-terminal linker which was thought to connect the
AT and the KR domains. The KS domains form the dimer at the two fold axis and cover an
area of 2,828 Å2 at the interface. The KS domain fold was similar to their bacterial type II FAS
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counterpart and superimposed well with the E. coli KS I domain. The N-terminal linker forms
a helical dimer which protrudes outwards towards the solvent and does not make any contact
with the rest of the protein complex. These linkers were thought to be involved in the inter mod-
ular interaction between the N-terminal linker of the KS domains with the C-terminal linker of
the ACP from the previous module. The two helices make hydrophobic contacts and a salt
bridge between them. The well defined KS to AT linker region was formed by three β-strands
sandwiched between three α-helices from one side and two alpha helices from the other side
contributed by the AT domains and the AT-KR linker forming an αβα fold. The C-terminus of
the AT domain folds back towards the KS-AT linker and extends a further 30 aa extend across
the surface of the KS, which presumably forms the linker between the AT and the KR, making
8 hydrogen bonds with the KS domain and 5 hydrogen bonds with KS-AT linker. Such a fold
was not previously reported in the PDB.
Similar to the KS domains, AT domains also had the similar fold to that of the bacterial
type II AT domains and superimposed well with the E. coli AT domain, with the RMS deviation
of 1.59 Å. This structure also revealed an ≈80 Å distance between the active site C199 and
the S642 in the KS and AT domains respectively which suggested an extensive movement of
the ACP domains in substrate channelling that would otherwise not be possible just by the
phosphopantetheine arm of ≈20 Å.
The active site of the KS domains also matched well with their bacterial type II homologues
where it centres around the active site Cysteine reaching towards the dimer interface. The active
site cleft was formed by the contribution of the residues from both the subunits and was con-
nected via a tunnel to the outer opening at the surface of the KS domain. The residues lining the
tunnel were highly conserved among the KS’s homologue with the primary role of supporting
the phosphopantetheine arm. Another interesting observation made through the KS-AT homod-
imer structure was the flexible loop region (residue 153-161) at the dimer interface which forms
the part of the active site. This loop region is a helix in the type II KSs. It was hypothesized that
this loop might be responsible for the KS specificity and helps in accommodating substrates of
different size. This observation agreed well with the previous observations that the KS 5 can
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accommodate substrates of larger size than the native ligand (Tang et al. 2006b).
The second structure solved by Khosla and colleagues was the 190kD KS-AT homodimer
from the DEBS module 3 (PDB ID 2QO3, Tang et al. (2007)). The overall fold of this strcutre
was similar to the previously determined KS 5 structure however, it lacked the N-terminal linker
region. The KS3 domain overlapped with the KS5 domain with an RMS deviation of 0.85 Å
for 386 backbone Cα atoms. One obvious difference was observed between the two KSs in the
region from residue 71 to 91 (number according to KS3). This loop region on the surface in
KS3 was longer as compared to the equivalent region in KS5. Sequence alignment with the
other KSs from the DEBS system revealed that all the other KSs in the DEBS system were
longer than KS5 by 12 residues in this region.
The KS-AT linker/domain in the KS3-AT3 structure also superimposed well with the KS5-
AT5 linker region with an RMSD of 1.54 Å. Tang et al. (2007) also observed the difference in
the active site lining residues in the KS3 and KS5 active sites. KS5 active site had fewer bulkier
residues than KS3 active site, presumably to accommodate a larger substrate. They also found a
conformational difference between a loop at the dimer interface from the residue 153 to 158 in
the KS3 structure and residue 149 to 154 in the KS5 structure, the region that is a helix in type II
KSs as explained above. Thus this loop region shows the importance not only in differentiating
between the KS type I and type II but also exhibit differences between the same type from one
KS to another.
In 2014, for the first time, a complete modular structure for a PKS module was determined
by Dutta et al. (2014) for module 5 (PikAIII) in the pikromycin cluster from Streptomyces
venezuelae. The PikAIII consists of KS, AT, KR and ACP domains, the structure was deter-
mined by single particle electron microscopy (cryo-EM) at 7.5 to 9.5 Å resolution. The cryo-
EM maps were able to identify the secondary structures, which were used for the rigid body
fitting of X-ray structures of the KS, AT, KR, and ACP domains from the DEBS system (Figure
1.25).
The EM structure revealed a striking difference between the PikAIII PKS module and the
mammalian FAS structure which was till now considered to be the scaffold for the PKS modules
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Figure 1.25: EM structure of module 5 (PikAIII) from pikromycin cluster. Ketosynthase (KS) dimers are
coloured in cyan, acyl transferase (AT) domains are coloured in green, ketoreductase (KR) domains are
coloured in magenta and acyl carrier protein (ACP) domains are coloured in yellow (Dutta et al. 2014).
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as well. The PikAIII structure revealed a single reaction chamber utilized by that module’s
ACP to reach all the catalytic domains within the module, whereas the ACP from the previous
module delivers the polyketide intermediated through a separate entrance outside the reaction
chamber. The PikAIII symmetrical dimer folds into an arch shaped structure with KSs forming
the dimer interface at the dome with the ATs hanging on either side of the KS dimer rotated at
≈120°from their relative positions in mammalian FAS and also DEBS KS-AT dimer structures.
The AT domains were also found to form an extensive interface with the KSs as compared to
their counterparts in the mammalian FAS and DEBS KS-AT structures. The KR domains are
lowered towards the base of the arch attached to the AT domains with the active sites of the AT
and KR domains facing towards the reaction chamber. The ACPs were found either at the top,
just below the KSs in between the two ATs, or at the base of the arch sandwiched between the
two KRs. No evidence was detected for the two ACPs to be in different positions at the same
time for example one near the ATs and the other near the KRs.
The cryo-EM maps also revealed that the linkers between the KRs and ACPs are long
enough to reach both the KSs in the dimer. In another work from the same group, Whicher
et al. (2014) have shown a structural rearrangement of the KS-AT domains upon substrate bind-
ing in the PikAIII. In the parent paper, Dutta et al. (2014) have also shown that dimer formation
of the PikAIII is not completely dependent on KS dimerization but is partly contributed by the
post ACP dimerization helices. The presence or absence of the ACP domains was also found to
influence the orientation of the KR domains. In a PikAIII ∆ ACP5 strain, the KR domains were
found to be rotated at ≈165°about the axis of the arch legs. Upon expressing ACP4 from the
previous module into the PikAIII ∆ ACP5 strain the ACP4 was found to be interacting at the
N-terminal docking domain of the module 5 KSs, completely away from the reaction chamber
where ACP5 would be found. This evidence established the involvement of a separate entrance
for the acyl chain transfer on the KSs from an upstream module than utilizing the same reac-
tion chamber involved in the chain elongation and β-carbon processing. In another unexpected
observation KSs were found to have a second entrance to the active site for the entry of the
extender units during elongation reaction. This second entrance was previously not reported
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either in the FAS or PKS structures.
1.2.6 An example of re-engineering PKSs
A number of groups have made contributions to our current understanding of PKS pathways
and how to re-engineer them (Weissman and Leadlay 2005; Challis 2008; Piel 2010; Kwon et
al. 2012), with the macrolide systems being particularly popular systems for study (Park et al.
2010). Much work has been focused on the type I PKSs. For example, Khosla’s group have
extensively manipulated and modelled the DEBS system (Khosla et al. 2007). In their work
using a number of chimeric constructs of ACPs, crystal structure determination and computa-
tional protein-protein docking revealed how an ACP has specificity for the chain elongation in
the DEBS pathway (Kapur et al. 2010). How the same ACP specifically passes the processed
substrate onto the next module (Kapur et al. 2010; Kapur et al. 2012), and why a PKS dimer
might be required for function.
Chimeras of ACP3 and ACP6 from deoxyerythronolide B synthase, the ACPs from modules
3 and 6 of the synthetic pathway, indicate that the loop between helix I and helix II were criti-
cal during the elongation process of synthesis. Computer docking of the ACP onto the crystal
structure of the KS5-AT5 homodimer indicated two residues in the loop that appeared critical
for electrostatic complementarity (D44 and R45). Further modelling showed electrostatic com-
plementarity between the KS-AT didomain in each module and the equivalent residues in their
cognate ACP, ACP3 (R44, R45), ACP4 (R44, K45), ACP5 (D44, R45) and ACP6 (D44, Q45).
Mutations R44A/R45A in ACP3 confirmed the importance of the residues at these positions.
The authors noted that these key residues of the ACP interact with the linker (docking domain)
between the KS and AT modules, as well as the AT module, and thus this mechanism cannot be
the same for PKSs that have the AT acting in trans unless it docks in a similar orientation to the
cis AT.
In contrast to the elongation mechanism, for the transfer of the substrate from an ACP to the
KS on the next module they found a different mechanism, one that relied on the 1st ten residues
in helix I of the ACP. They also concluded that the PKS domains are made up of subdomains and
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they have a distinct role in mediating interdomain interaction. These experiments also support
the idea of homodimeric architecture of multimodular PKSs. This work emphasizes the benefit
of computational modelling working together with well-designed experiments to elucidate the
engineering principles underlying the PKS.
From understanding the principle behind the ACP-KS recognition in the polyketide chain
elongation and translocation steps, an obvious question arises. Is there a way that this uni-
directional ratchet flow of the pathway can be modified? Khosla’s group identified a charge
complementarity mechanism during chain elongation at the position 23 on the ACP at the KS-
AT interaction interface. They found that the opposite charge on KS-AT linker of the following
module attracts the preceding ACP, whereas the similar charge on the KS-AT linker of the parent
module repels it, thus allowing the reaction to always move forward. Exploiting this mecha-
nism they re-programmed module 3 of the DEBs system to carry out an iterative step of chain
elongation. In an experiment they swapped the helix I of ACP3 with the helix I of ACP2, as the
helix I is responsible for the chain elongation step. This swapping did not allow the ACP3 to
transfer the chain to the module 4 instead it falls back to the KS3 in the module 3 for one more
round of chain elongation. The reaction stopped after one round of iterative chain elongation
for reasons unknown. However, it could be a limitation of the KS active site to accommodate
the larger substrate.
1.3 NRPS
Nonribosomal peptide syntetases (NRPSs) are also highly prevalent in secondary metabolite
biosynthesis and often synthesize compounds in conjunction with PKSs. The NRPS and PKS
systems have similar modular structures and thus NRPSs warrant some discussion here. Nonri-
bosomal peptides are the product of the sequential addition of amino acid monomers catalyzed
by NRPSs, involving the domains similar in function to that of PKS system. The amino acid
monomers are selected and activated by an adenylation (A) domain which transfers to a thio-
lation domain or a peptide carrier protein (T or PCP), peptide bond formation is catalyzed by
a condensation (C) domain. The PCP has a phosphopantetheine prosthetic group that facili-
61
Figure 1.26: Mupirocin structure
tates the transfer of growing peptide chain/monomers to the various active sites and function
analogously to an ACP with a similar four helix bundle structure. The adenylation (A) domain,
condensation (C) domain and thiolation or peptide carrier protein (PCP) form the minimal set
of domains required to carry out the NRP biosynthesis. In both, the modular PKS and NRPS
system the individual domains are linked together by a polypeptide linker region which has also
been found to be responsible for functional communication within the domains.
1.4 Mupirocin
Mupirocin is a polyketide antibiotic used as a topical drug against MRSA and various other
Gram positive bacteria, to treat bacterial skin and hospital acquired infections (Fuller et al.
1971). Mupirocin is produced by Pseudomonas fluorescens NCIMB 10586 and consists of
four different pseudomonic acids (PAs) A,B,C and D. PA A, B, C, D contributes 90%, 8%,
<2% and <2% respectively to the mixture. PAs are made up of monic acid esterified to 9-
hydroxynonanoic acid (Figure 1.26). Mupirocin acts by inhibiting bacterial isoleucine tRNA
synthetase thus inhibiting protein production resulting in the cell death (Hughes and Mellows
1978).
1.4.1 Mupirocin Drawbacks
Mupirocin has proved to be more potent on bacterial IleRS than on the corresponding eukary-
otic enzyme, which is highly desirable for any pharmaceutical product. Weak affinity for the
eukaryotic IleRS minimises the chances of eukaryotic toxicity and side effects of the drug.
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Thus, the pseudomonic acids have excellent structures and biological activity as pharmaceuti-
cal compounds. However, mupirocin can only be used as a tropical drug as it gets disintegrated
inside the body by the hydrolysis of the ester bond between monic and 9-hydoxynonanoic acid
(Figure 1.26). It also loses its activity at higher pH, thus preventing it from being used as a
systemic drug.
Recent studies (Patel et al. 2009; Thomas et al. 2010) have also shown increasing oc-
currences of mupirocin resistance in S. aureus. This resistance can be of low level as well
as high level. In low level Mupirocin resistance a single amino acid mutation has been ob-
served in the Rossmann fold region of IleRS, which normally binds to the ATP or else to the
9-hydroxynonanoic acid of Mupirocin. Hence the single amino acid change prevents Mupirocin
from inhibiting its target. High level resistance usually results from the presence of eukaryotic
like IleRS. This can be acquired either through horizontal gene transfer or through a plasmid
containing the mupA gene. The P. fluorescens strain, which produces mupirocin, has two differ-
ent IleRS producing genes of which one is similar to eukaryotic IleRS. This eukaryotic similar
IleRS enables P. fluorescens to keep on synthesising proteins even at high concentration of
Mupirocin. Low-level resistance is not of present concern but the high-level resistance in clin-
ical strains of S. aureus acquired through the expression of the mupA gene is alarming. Many
of the plasmids containing these genes can conjugate which may cause clonal expansion of the
resistant strains.
Therefore with increasing levels of Mupirocin resistance and its limitation for systemic use,
there is a need to develop new analogues which may overcome the limitations of Mupirocin.
However, before we reach up to the level of producing new analogues we need to understand
better the underlying pathway.
1.4.2 Mupirocin Biosynthesis
The mupirocin biosynthetic cluster (mup) consists of a 75kb region encoding 35 ORFs. Figure
1.5 explains the mup cluster and the probable pathway as proposed by Thomas and co- workers
(Thomas et al. 2010; Gurney and Thomas 2011). The mup cluster encodes six designated MMPs
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(Mupirocin multifunctional proteins; mmpA to mmpF) out of which five encode for polyketide
synthases. The non-PKS domain is MmpC, encoding two acyltransferase domains, which is a
characteristic of a trans AT system. The proposed biosynthesic pathway initiates in a typical
Type I PKS manner where MmpD holds the first starter unit and produces a C12 unit, with
MmpA extending this to C17, with further tailoring enzymes producing monic acid. MmpD and
MmpA consist of four and three modules respectively each containing a KS and ACP domain.
MmpD also consists of KR, DH and MT domains while MmpA only has one KR domain. The
first module in MmpD has a non-functional DH and the first module in MmpA is proposed to be
involved with the transfer of the growing polyketide chain from MmpD to MmpA. Mupirocin
biosynthesis starts with an activated acetyl as a starter unit and uses malonyl-CoA as an extender
unit. C16 and C17 carbons in the monic acid unit are derived from S-adenosyl methionine (SAM).
The C15 carbon is hypothesised to be incorporated by the HMG-CoA synthases activity of
MupH in the HCS cassette (MupG, MupH, MupJ and MupK). Knocking out any of the HCS
genes stalls the pathway at the end of MmpA and results in the accumulation of intermediate
mupirocin H. (Wu et al. 2007). The HCS cassette has at least four enzymatic functions: an ACP,
a hydroxymethyl glutaryl-CoA synthase, a decarboxylase and one or more dehydratases from
the crotonase superfamily, in some cases supplemented with other functions. HCS cassettes
variously introduce e.g. β-methyl, cyclopropane and vinyl chloride moieties, depending on the
system they are found in and the exact nature of the cassette. HCS cassettes are found to act
on the type I modules, which lack KR, DH or ER domains but which tend to have tandemly
repeated ACPs. Given the variety of functions that the HCS cassette can perform, artificially
including them in a PKS cluster provides a powerful tool for the synthesis of novel compounds.
To achieve this we need to understand what allows the enzymes of the cassette to know at what
point in the pathway they are supposed to work, in particular how a system such as myxovirescin
uses two HCS cassettes to produce two specific β modifications in the same system.
MupC, mupF, mupO, mupU, mupV and macpE provides the correct oxidation state around
the pyran ring and mutating any of these genes would result in the accumulation of pseudomonic
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































group C8 in order to create the pyran ring.
Finally, MmpB is proposed to synthesise 9-hydroxynonanoic acid starting from 3-hydroxy-
propionate via three condensations with malonate iterated three times in the same PKS. 3-
hydroxypropionate starter unit is hypothesized to be produced jointly by mAcpD, MupS and
MupQ. It is also not understood whether 3-hydroxy-propionate is first attached to mAcpD and
then elongated to produce 9-hydroxynonanoic acid or is first esterified to monic acid and then
elongated further.
The mupirocin biosynthesis pathway has an ACP doublet (ACPmupA3a/b in MmpA) and
an ACP triplet (ACP5, 6 and 7 in MmpB) which is thought to hold multiple substrates for high
throughput in rate limiting steps. Apart from the six orfs, which code for the Mmps, the rest of
the orfs encode for discrete polypeptides.
1.5 Bioinformatics approaches in PKS research
Research into PKS pathways has been carried out in two major areas. Firstly to identify and ex-
perimentally characterize new polyketide natural products and secondly, to develop a synthetic
biology tool box for the design and synthesis of novel natural products by the re-engineering of
naturally occurring polyketide biosynthetic machinery, both of which might provide the basis
for novel drugs. Bioinformatics analysis of PKS clusters has played a major role in guiding
recent experiments via a variety of tools, examples are PKSDB (Yadav et al. 2003a) a database
of PKS domains developed a decade ago, which was one of the first tools available, SBSPKS
(Anand et al. 2010) and antiSMASH (Medema et al. 2011), which are recent advanced sequence
analysis tools guided by protein structure analysis.
Most work in the field has focused on the core PKS functions, particularly type I PKSs, thus
there is still little known about the mechanisms of the tailoring enzymes acting in trans. Such
tailoring enzymes are an essential part of any PKS system since they provide additional chem-
ical diversity to the polyketide chain. An ability to predict the function of tailoring enzymes
and their compatibility with other PKS modules would provide much additional functionality
to the synthetic biology tool box. Trans-AT systems are less well studied and since software
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tools are primarily targeted at cis-AT systems they tend to completely fail or have limited capa-
bilities in predicting trans-AT systems. PKSDB/SEARCHPKS and NRPS-PKS were the first
available webservers for identifying PKS/NRPS domains in an unknown sequence as well as
relating PKS/NRPS sequences to their corresponding secondary metabolites; recent reviews
(Jenke-Kodama and Dittmann 2009; Bachmann and Ravel 2009) give a detailed discussion on
the utility of the PKSDB and the NRPS-PKS databases. Following similar lines, resources like
ASMPKS (Tae et al. 2007), ClustScan (Starcevic et al. 2008), CLUSEAN (Weber et al. 2009),
NP.searcher (Li et al. 2009), NRPSpredictor (Röttig et al. 2011), NRPSsp (Prieto et al. 2012)
and antiSMASH (Medema et al. 2011) have been developed for the discovery of secondary
metabolites through genome analysis. All these servers primarily utilize sequence information
either for domain identification or to correlate the various PKS domains to their corresponding
metabolic products. However, many of them also utilize structural information for predicting
the most likely starter and extender units picked by the acyl transferase domains, and SBSPKS
models the 3D structure of PKS modules. Table 1.1 gives a summary of the resources available
for PKS/NRPS pathway analysis with a detailed description in Section D.1 of Appendix IV.
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1.6 Research objectives and thesis outline
The mupirocin biosynthesis pathway provides a model system for understanding trans-AT
PKSs, and contributing to our understanding of the way proteins and substrate recognition
events are regulated. In the present work the analysis was mainly focused on the structural
modelling of the protein complexes involved in the mupirocin synthesis via the tools of struc-
tural bioinformatics supplemented with information from experiments. The findings in this
thesis will be a prototype for the modelling of large macromolecular complexes in prokaryotic
systems and the structural models produced will enhance our understanding of the synthetic
pathways allowing us to re-engineer them with greater success.
The overall thesis is divided into four results chapters Chapter 3 to 6, which discuss the
results of three major projects in their respective chapters and two minor projects compiled in
one chapter. Chapter 2 describes the methods used in the different projects in detail. The last
chapter of the thesis summarizes and discusses the entire thesis.
The project discussed in Chapter 3, aimed to elucidate the mode of interaction between
ACP-mupA3ab:MupH complex, which are involved in beta branching, proposing key inter-
acting residues for mutagenesis experiments. Structural models and properties of MupH the
HMG-CoA synthase homologue in HCS cassette were predicted using various bioinformatics
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tools. ACP sequences from characterised PKS pathways were also classified into beta and non-
beta branching type using hidden Markov model analysis. Mutagenesis experiments carried out
by Prof. Thomas’ group on the predicted ACP:MupH interface supports the predicted com-
plex and residues responsible for the specificity of the interaction. Some of the findings of this
project are already published in Haines et al. (2013).
Based on the hypothesis generated in the first project, further lab experiments were car-
ried out as described in Chapter 4. The aim was to complement the β-branching-ACPs in the
mupirocin cluster with the β-branching-ACP(s) from the kalimantacin cluster. It was hypoth-
esized that the β-branching ACP(s) from the kalimantacin cluster would not work with MupH
but will work with BatC (MupH equivalent form kalimantacin cluster). The aim was also to
identify the key residues at the interface of the β-branching ACPs from the mup cluster and
BatC which can be modified to work efficiently with BatC.
As the experiments and molecular dynamics (MD) simulations carried out on FAS ACPs
(Chan et al. 2008) have shown the formation of a hydrophobic tunnel which sequesters the fatty
acid chain, the third project was to see if a similar mechanism might exist in the PKS ACPs.
Molecular dynamics simulations of the ACPs from module 2 and 3 of MmpA in the mupirocin
cluster were carried out in explicit solvent with a time scale of 50 ns to 1 µs. Several macro-
scopic properties were calculated by analysing the MD simulation trajectories, a sequestering
of the substrate to the ACP surface was seen but the atomic details are different from what was
seen in the FAS system.
Chapter 6 presents the results of two independent projects, the first project aimed to find out
the means of recognition specificity of the KS-mupA2 towards the predicted α-OH substituted
substrate and the results suggest a specific recognition motif that may stall substrate progression
until it has been hydroxylated. The second project aimed to investigate the significance of
movements of loops on the MupH surface that were seen in the simulations presented in Chapter






In the present study various databases have been used to retrieve sequence (DNA and Protein)
and protein structure information. For the sequence analysis in Section 3.2.1 RefSeq microbial
and UniProtKB/TrEMBL (with 6408654 seq and 20127441 seq respectively, as on 9th March,
2012) were used to search for ACP homologues using the hidden Markov models. RefSeq
is a non-redundant database of DNA, RNA and protein sequences curated by the sequences
from International Nucleotide Sequence Database Collaboration (INSDC) hosted at the Na-
tional Centre for Biotechnology Information (NCBI) . RefSeq (http://www.ncbi.nlm.nih.
gov/refseq/) provides the reference sequence for a species, each entry being annotated and
cross-linked to other databases by collaborating groups and NCBI staff. RefSeq can be accessed
via the Entrez search engine, through a sequence similarity search using BLAST or by the Ref-
Seq FTP server. The RefSeq microbial dataset was used, which consists of sequences from
microbial genomes/proteomes.
UniProtKB/TrEMBL (http://www.uniprot.org) is a collection of computationally an-
notated protein sequences. The sequences in UniProtKB/TrEMBL are derived from the compu-
tational translation of the coding sequences (CDS) submitted in INSDC databases. UniProtK-
B/TrEMBL can be accessed through keyword or uniprot identifier searches on the UniProtKB
website or through a sequence similarity search using BLAST. The purpose of selecting two
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databases was not only to retrieve the highest quality sequence information from a curated
database but also to have maximum coverage of sequences available through an automated
database. The sequence data from both the databases were obtained from their FTP websites in
the FASTA format.
For molecular modelling, as explained in Section 2.3.1, protein structure coordinate infor-
mation was taken from the Protein Data Bank (PDB) (http://www.rcsb.org). The PDB is
the single archive for macromolecule (DNA and Protein) 3D coordinate information. It consists
of structural information determined through experimental methods such as NMR spectroscopy
and X-ray crystallography. The PDB database can be searched by keyword or PDB identifier,
or by running a BLAST similarity search either from within the PDB website or through NCBI
BLAST.
2.2 Sequence analysis
In molecular biology, routine sequence analysis is carried out to infer the biological function of
newly sequenced DNA or protein sequences. For the purpose of inferring biological function
similarity searches against annotated sequence databases using pairwise alignment methods
such as BLAST and FASTA are in common use. Pairwise sequence alignment methods give
equal weighting to all aligned positions. However, in a multiple sequence alignment it can
be clearly seen that several positions within a family of proteins are under more evolutionary
pressure to be conserved than others. Thus pairwise sequence alignment methods are good
for fast searches of closely related sequences but are poor at detecting remote homology. In
contrast, methods based on position specific scoring and probability such as Profiles and hidden
Markov models are much more sensitive in detecting remote homology.
2.2.1 PSI-BLAST and multiple sequence alignment
In the present study position specific iterative BLAST (PSI-BLAST) has been used to identify
template structures for homology modelling (see Section 2.3.1). PSI-BLAST is an extension
of the normal protein-protein BLAST but it uses a position specific scoring matrix (PSSM) or
profile. This PSSM is generated from the multiple sequence alignment of the sequences found
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in a normal protein BLAST, which is the first iteration of PSI-BLAST. The PSSM is used and
refined in further iterations of PSI-BLAST, rather than a simple sequence. PSI-BLAST is more
sensitive in detecting distantly related sequences as compared to the normal protein-protein
BLAST.
In Section 3.2.1 multiple sequence alignments (MSAs) were used to identify conserved
residues which differentiate branching-ACPs from non-branching-ACPs. An MSA is created
with three or more sequences with the aim of identifying regions of sequence homology and
conserved positions, which may be used to characterize a protein family. MSAs are also used
for phylogenetic reconstructions as differences between sequences, can be used to estimate
how recently two proteins from a given family a common ancestor in a family of protein/DNA
sequences. As explained in Section 2.3.3.1 MSAs were also used for evolutionary trace analysis
to predict positions under evolutionary pressure within a clade as compared to between the
clades. The ClustalW and Muscle programs were used for generating MSAs.
2.2.2 Hidden Markov models (HMMs)
HMMs are models which represent a probability distribution of the occurrence of residues for
each position in a multiple sequence alignment allowing for the residue type to occur through
conservation, insertion, deletion, or some combination of the later two with the aim of encapsu-
lating the common features of a protein family that are necessary to recognize other members
of the family. HMMs are built on a set of aligned sequences belonging to a family of proteins.
Each column in an MSA is considered as a “state”which “emits”symbols (residues) according
to the emission probabilities. Each state is interconnected to other states called transitions with
state transition probabilities. The model produces the sequence of symbols based on the emis-
sion and transition probabilities and the probability of a given sequence being produced is the
product of all the emission and transition probabilities. The hidden part in a hidden Markov
model is the sequence of the states taken to produce the sequence of symbols. Its only the emit-
ted symbols which are visible, not the underlying state. In practice HMMs are generated (or
trained) using an MSA. To align a sequence to an HMM model the HMM can be seen as travers-
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ing all the possible sequences of states through the model to generate the target sequence. This
will assign the probability values to the sequences produced of which the best ones are selected
through a dynamic programming based algorithm such as the Viterbi algorithm.
2.2.2.1 HMM analysis of β-branching and standard ACPs
HMMs were used to classify a subclass of acyl carrier proteins (ACPs) called the branching
ACPs (for results see Section 3.2.1). The two HMM models were built using the HMMER
program from the 15 clusters with known pathways, with 38 and 178 sequences (sequences
provided by Dr. Anthony Haines) for the branching and the non-branching-ACPs respectively.
The training and the test set were scored with each HMM models and the scores were plotted on
a scatter graph to highlight two distinct clusters between branching and non-branching ACPs.
The non-branching HMM model was also searched against TrEMBL and RefSeq databases
which fetched 16,490 unique sequences with the length greater or equal to 60 amino acids.
These sequences were also scored with both the models and plotted in a separate scatter plot
along with the training set. The models were deposited with SMART since no domain predic-
tion software (SMART, Pfam etc.) had the capacity to distinguish these two types of ACP.
2.3 Molecular Modelling
The present study aims to model the polyketide synthase complexes which are large macro-
molecular complexes. Determining the structure of large protein complexes through experi-
mental methods such as X-ray crystallography and NMR spectroscopy is possible however at
times can be quite difficult and time consuming. On the other hand with the increase in comput-
ing capacity and the large amount of molecular biology data available it is increasingly possible
and efficient to use computational methods to predict structures based on the existing structural
data. Molecular modelling can be used for tasks such as protein structure prediction through ho-
mology modelling, understanding protein dynamics through molecular dynamics simulations,
protein protein interaction interface prediction and molecular docking to generate atomic reso-
lution three dimensional protein complex structures.
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2.3.1 Homology modelling
Homology modelling or comparative modelling is a computational method to generate three
dimensional protein structures of atomic resolution. As the name suggests homology mod-
elling is based on the fact that the proteins which perform similar functions tend to have similar
sequences with regions important for the function being conserved. Furthermore, the protein
structures of even divergent protein sequences, which share a common ancestry, tend to fold
into a similar three-dimensional structure. Thus a protein structure can be used to predict the
atomic resolution model of a homologous target sequence (Chothia and Lesk 1986). The the-
oretical models generated through homology modelling primarily rely on the quality of the
sequence alignment between the target sequence and the homologous sequence and the quality
of the homologous structure. Over the past few years several state of art computational tools
have emerged with increasing level of accuracy, which are continually being monitored by the
biannual CASP competitions (http://predictioncenter.org/).
In the present work, different versions of the Modeller (Sali and Blundell 1993) program
have been used to carry out the homology modelling for all the predicted structures. Mod-
eller generates the three dimensional models of the target protein sequence by satisfying spatial
restraints obtained from the sequence alignment of the target and the homologous protein tem-
plates. This method in principle is quite similar to employing the distance geometry approach
used in NMR experiments. The spatial restraints extracted from the sequence alignment are
expressed as probability density functions (PDFs) which are used to restrain Cα-Cα bond dis-
tance, N-O distance, main chain and side chain dihedral angles. Apart from the bond distance
restraints derived from the sequence-template alignment, stereochemical restraints are added
using a molecular mechanics force field. In the final model building step the model is generated
by minimizing the violation of all the restraints (Martı́-Renom et al. 2000; Eswar et al. 2006).
This method of model prediction has an advantage over many other tools for the same
purpose as it allows several restraints to be added by the user derived from various resources.
It is thus possible to apply restraints derived from experiments such as NMR spectroscopy,
fluorescence resonance energy transfer (FRET), crosslinking experiments as well as restraints
75
derived from Bioinformatics based experiments. The model building step can also be coupled
with model refinement steps using simulated annealing and molecular dynamics simulations.
However, in the present work many of the models were generated without any model refinement
step which allows a direct comparison with the template structure as the algorithm places the
side chains at the similar positions to the template.
2.3.1.1 Modelling of MupH + ligand complex
MupH was modelled using Modeller version 9.8 (Eswar et al. 2006). The MupH sequence
was used to search the PDB for the solved homologous structures, using PSI-BLAST. 10
structures were selected ranging from 27% to 32% sequence identity to generate the initial
alignment using ClustalW (Larkin et al. 2007). The structures chosen in similarity with the
MupH sequence were from the species Staphylococcus auereus, Enterococcus faecalis, Bras-
sica juncea, Streptococcus mutans and Homo sapiens thus providing a wide range of organisms
for comparisons. All the homologues found were HMG-CoA synthases. The secondary struc-
tures of the templates, determined by DSSP (Joosten et al. 2011), guided manual refinement
of the final alignment using Seaview (Galtier et al. 1996). The HMG-CoA synthase struc-
ture from Enterococcus faecalis (PDB ID 1X9E), having 87% query coverage with 32% se-
quence identity, was selected as the template. Modeller produced five structures which were
further tested for stereochemical quality using the PROCHECK (Laskowski et al. 1993) pro-
gram (http://nihserver.mbi.ucla.edu/SAVES/). The model with the best PROCHECK
score was selected for further analysis.
In order to dock the polyketide intermediate ligand in the MupH active site the modelled
MupH structure was superimposed on the 1X9E crystal structure and the X-ray determined
coordinates for the phosphopantetheine moiety from the bound ligand in 1X9E were copied.
The rest of the polyketide intermediate was built manually inside the MupH active site using the
PyMol program (http://www.pymol.org). To remove the steric clashes energy minimization
was carried out using Chimera (Pettersen et al. 2004). The AMBER99SB-ILDN (Hornak et al.
2006) force field and Antechamber program were used to assign the force field parameters to
the protein and ligand respectively.
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2.3.1.2 Modelling of ACP-mupA2
ACP-mupA2 (the ACP from the second module of MmpA in the mupirocin cluster) was mod-
elled using Modeller version 9.10. The ACP-mupA2 sequence (GenPept Acc No. AAM12909
range 1822 to 1916) was used to search against the PDB database using BLAST to identify the
template. The NMR structure of the Holo-Acpi Domain from the CurA module from Lyngbya
Majuscula (PDB ID 2LIU) was selected as the best template with 80% query coverage and
29% sequence identity. To generate the initial alignment for modelling, a multiple sequence
alignment was carried out using two template sequences, 2LIU, 2L22 (ACP-mupA3ab NMR
structure from the third module of MmpA in the mupirocin cluster) and other ACP sequences
from the mupirocin cluster. Sequence alignment was manually refined using secondary struc-
ture information as explained in Section 2.3.1.1 and the homology modelling was carried out
using 2LIU as the template, generating five structures. The structures were tested for stere-
ochemical quality using PROCHECK and the structure with the best PROCHECK score was
selected for further analysis.
2.3.1.3 Modelling of the KS-mupA2 dimer
KS-mupA2 (KS from the second module of MmpA in the mupirocin cluster) was modelled
using Modeller version 9.11. KS-mupA2 was modelled as a dimer along with the KS docking
domain also called as the linker region between the KS and AT domain in the cis systems. KS-
mupA2 sequences (GenPept Acc No. AAM12909.2 range 715 to 715 to 1288) was searched
against the PDB database using BLAST to identify the template. Two templates from the DEBS
system, the KS-AT dimer from module three and five (PDB ID 2QO3 and 2HG4) along with the
KS sequences from the mupirocin system, were used to generate the initial alignment which was
manually refined using secondary structure information and visual inspection of the alignment.
The DEBS structure 2QO3 with 88% query coverage and 39% sequence identity was used as
the template to generate five homology models. The structures were tested for stereochemical
quality using PROCHECK and the structure with the best PROCHECK score was selected for
further analysis.
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2.3.2 Molecular dynamic simulation
Molecular dynamic (MD) simulation is a computational method to simulate the time dependent
behaviour of a physical system. In molecular modelling, MD simulations of proteins and DNA
macromolecules are used to observe the changes in forces and structural dynamics with respect
to time. In a typical MD simulation of a physical system of N interacting atoms, such as a
protein immersed in a box of solvent, the atoms are allowed to move following Newton’s laws
of motion. Equation 2.1 represents the differential form of Newton’s second law of motion i.e.
F=ma, describing the motion of a particle i of mass mi, in the direction xi with the force Fxi
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The calculation of the forces highly depends on the parameters of the molecular mechanics
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The first term in the equation represents the energy of the covalent bonds. The second term
represents the energy of the bond angles. The third term represents the energy due to torsional
angles and the last term represents the energy due to non-bonded interaction between all the
atom pairs, which include van der Waals, and electrostatic energies.
In molecular dynamics simulation the equation of Newton’s second law of motion is solved
for the desired length of time. The change in the coordinates of the atoms due to the motion
is recorded at regular intervals. The coordinates with respect to time represents the trajectory
of the system. Once the system has reached the equilibrium state many macroscopic properties
can be studied by averaging over the equilibrium trajectory. MD simulations are widely used
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in molecular modelling to study folding and unfolding of the proteins, protein structure stabil-
ity, protein-protein interactions, free energy binding of drug-protein complexes, the effects of
mutations on the structural dynamics of the proteins etc.
In the present study the GROMACS 4 (Pronk et al. 2013) molecular dynamics program
has been used to study the protein dynamics in explicit solvent (water) and the protocol can be
summarized in three major steps.
Structure preparation
In the first step, the physical system to be simulated is represented in the computer. The
protein structure from X-ray or NMR experiments or through homology modelling con-
tains the coordinate information only. However, for running the MD simulation this co-
ordinate information needs to be expressed in terms of atomic coordinates, atom types,
bonds, electric charge distribution etc. This information is stored in a topology file along
with the necessary force field parameters from the selected force field and the water model
to be used for the explicit solvent simulation. There are several popular force fields sup-
ported by GROMACS, which includes GROMOS (Oostenbrink et al. 2004), AMBER
(Lindorff-Larsen et al. 2010), OPLSA (Jorgensen et al. 1996), and the CHARMM27
(MacKerell et al. 1998) force fields. During the structure preparation step hydrogen atoms
(if any are present) are usually removed from the coordinate file and added back accord-
ing to the specifications of the force field used. This rebuilding of hydrogen atoms may
cause some steric clashes which need to be relaxed through energy minimization.
For simulations in explicit solvent usually a simulation box is created with periodic
boundary conditions (PBC) which is filled with a suitable water model for example SPC,
TIP3P (Spoel et al. 1998). There are a few limited number of shapes in which the simula-
tion box can be created with a cube being the largest in terms of the volume and truncated
dodecahedron being the smallest. A truncated dodecahedron surrounds spherical globu-
lar proteins better because it does not accumulate huge amount of solvent at the corners
therefore it is computationally less expensive than e.g. a cube. The PBC means a single
unit is repeated infinitely in order to overcome the edge effects caused by the walls of
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the simulation box. For the Amber force field used in the present work the TIP3P water
model is considered a compatible model and was used here. At this point once the sol-
vation box is created and filled with the suitable solvent the net charge of the system is
neutralized by adding counter ions. The energy of the system is minimized either using
a steepest descent algorithm, conjugate gradient algorithm or both to remove any steric
clashes (Hess et al. 2008).
Equilibration and production run
In the second step, the system is equilibrated by running short MD simulations in which
the protein is restrained to the reference position while keeping the water molecules flex-
ible. This allows the water molecule to relax around the protein. It is a general practice
to first run a short simulation with only temperature coupling to equilibrate the system
at the desired temperature for example at 300K. Once the system is equilibrated at the
desired temperature another short simulation can be run with the pressure coupling as
well to equilibrate the system under both the temperature and pressure conditions. These
equilibration steps are usually performed for few hundred pico seconds depending upon
the size of the system.
In the final production run, MD simulation is carried out without any restrains on the pro-
tein under the influence of temperature and pressure, which can be of several nanoseconds
long depending upon the macroscopic property under study and the computational power
available (Hess et al. 2008).
2.3.2.1 Parameter determination
As mentioned above, the forces in the simulation depend on the parameters used. These pa-
rameters include atomic properties such as mass, partial charge and atom type, bond properties
such as equilibrium bond length, equilibrium bond angle and dihedral angle preferences and
parameters representing the partial charges and van der Waals interaction. Since, forcefields in
GROMACS are optimized for protein and nucleic acid simulation, parameters are given only
for the standard amino acids, nucleotides and a few counter ions. However, GROMACS allows
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the addition of extra parameters to represent systems which consist of atoms not represented
by the standard set of parameters. In order to include a molecule which is not a part of the
standard set, different methods based on either experimental data or quantum mechanics cal-
culations can be used to determine parameters. While working with the AMBER force fields
small molecules can be simulated using parameters from the general amber force field (GAFF).
GAFF was created to be compatible with the AMBER force fields (Wang et al. 2004) and is part
of the AMBER molecular dynamics package which is not included in GROMACS by default.
In the present study at several instances a ligand molecule was covalently attached to a
residue in the protein, for example a phosphopantetheine arm attached to the active site serine
in an ACP. To carry out molecular dynamics simulation with the phosphopantetheine and other
molecules attached to the serine on ACP a new residue type was created for each serine ligated
with ligand. Since, these new residues were not a part of the standard amino acid set, GRO-
MACS did not have the parameters to carry out the simulation. For this reason parameters from
the GAFF were added to the AMBER 99SB-ILDN (Lindorff-Larsen et al. 2010) force field.
The GAFF parameters were obtained from the AMBER molecular dynamics package and the
values which differed in units from GROMACS format where converted using several in house
perl scripts (see Appendix I A.4).
While using GAFF in AMBER molecular dynamics package, partial atomic charges (AM1-
BCC) are assigned using antechamber software included in the package. However, in GRO-
MACS suite there was no such software available which can assign partial atomic charges
to small molecule. Therefore, in order to derive partial atomic charges for the new residues,
AMBER force field compatible RESP charges were calculated using RED server (http://
q4md-forcefieldtools.org/REDS/ (Bayly et al. 1993; Dupradeau et al. 2010; Vanquelef
et al. 2011)). For the calculation of RESP charges the RED server requires the structure file
in a P2N format. The program Ante RED, available in the RED server, converts a PDB file
into the P2N format. The RED IV server was used to calculate RESP-A1A charges for all the
ligands, using the Gaussian 2009 D.01 quantum mechanics program. Fully automated mode
1 was chosen while running RED IV which performs geometry optimisation as well as charge
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fitting. Once the charges were calculated a new entry was created for each new residue type
in the aminoacids.rtp database of GROMACS. The new residue name was also updated in the
residuetype.dat database. For each new residue the corresponding hydrogen atoms were also
created in the aminoacids.hdb database. While determining charges for the new moiety attached
to an existing amino acid, the charges for the serine side chain were varied but the backbone
atoms of the parent residue were kept the same as that of the original forcefield. Section B.1
in Appendix II lists the ligands with the charges which were added to the AMBER99SB-ILDN
aminoacids.rpt database.
2.3.2.2 Molecular dynamics simulation of W44L mutant and wild type ACP-mupA3a
A) The mutation from W to L at the 44th position in the ACP-mupA3a NMR structure was
carried out using PyMol. The two constructs (wild type and the mutant) were subjected to
20 independent simulations for 10 ns each. The GROMACS 4 (Hess et al. 2008) molecular
dynamics engine with AMBER99SB-ILDN (Lindorff-Larsen et al. 2010) force field and TIP3P
water model was used to carry out the simulation with a time step of 2fs and in a water box
extending 5 Å beyond the surface of the protein. The simulation systems were each neutralized
with 2 Na+ counter ions, minimized for 1000 steps of conjugate gradient and 1000 steps of
steepest descent energy minimisation and were equilibrated for 100 ps. The final simulation
run was performed for 10 ns at 300K temperature and 1 atm pressure with other parameters set
as the GROMACS 4 defaults.
B) Another set of two independent simulations were setup for the W44L mutant and wild
type ACP-mupA3a for 1 microsecond each. The simulation systems were neutralized by adding
2 Na+ counter ions and the protocol and the setup was same as described in Section 2.3.2.3.
2.3.2.3 Molecular dynamics simulation of ACP-mupA3a with covalently bound phos-
phopantetheine
The ACP-mupA3a NMR structure was simulated with the phosphopantetheine covalently at-
tached to S38 of both the wild type ACP-mupA3a and W44L ACP-mupA3a mutant. In order to
simulate phosphopantetheine covalently attached to S38 a new residue named SPT was intro-
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duced in the GROMACS aminoacids.rtp database (Appendix II Section B.1.1). The structure
for SPT was drawn using Pymol by extending S38 coordinates from the NMR structure (PDB
ID 2L22). Parameters for the serine backbone atoms were kept the same as that of the orig-
inal AMBER99SB-ILDN forcefield and for the rest of the ligand (from phosphate onwards)
were derived from GAFF. Charges for the phosphopantetheine moiety were determined using
the RED server as described in Section 2.3.2.1. The structure file used for charge calculation
consisted of a phosphopantetheine moiety attached to the serine side chain oxygen with all the
atoms of the serine present and the backbone carbonyl carbon and amide nitrogen blocked with
methyl groups. After charge fitting with RED server, the charges on the serine backbone were
set to the same values ass the AMBER99SB-ILDN force field, the blocking methyl groups were
removed, and the remaining charges were adjusted in the third decimal places to keep the overall
charge of the molecule as -1 (Appendix II Section B.1.1).
The two constructs (wild type and the mutant) were subjected to 5 independent simulations
for 50 ns each. Simulations were carried out using TIP3P water with a time step of 2fs and
placed in an octahedron water box extending 10 Å beyond the surface of the protein. Each
simulation system was neutralized with 3 Na+ counter ions and minimized for 1000 steps of
conjugate gradient and 1000 steps of steepest descent energy minimisation. Following the en-
ergy minimisation each system was equilibrated with 100 ps of NVT and 100 ps of NPT simu-
lations keeping the position of the protein atoms restrained. The final simulation was performed
for 50 ns at 300K temperature and 1 atm pressure using V-rescale thermostat (Berendsen et al.
1984) and Parrinello-Rahman pressure coupling (Parrinello et al. 1980) respectively. Out of the
five simulations per construct one was extended for to 200 ns for both wild type and mutant
ACP-mupA3a.
2.3.2.4 Molecular dynamics simulation of ACP-mupA3a with its substrate
ACP-mupA3a wild type and W44L ACP-mupA3a mutant were simulated with their substrate
prior to β-branching (Figure 1.27). The ACP-mupA3a substrate was built directly onto the
phosphopantetheine of Section 2.3.2.3 by using PyMol. All the bond parameters and charges
for the phosphopantetheine moiety were kept the same as the previous calculations. Param-
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eters for the ACP-mupA3a substrate were obtained from GAFF and charges were calculated
using the RED server. The charge calculations were performed on the ACP-mupA3a substrate
attached to a sulphur and peptide moiety, representing the terminal atoms of the phosphopan-
tetheine arm, the peptide being blocked by the addition of a methyl group. Including the entire
phosphopantetheine in charge calculations was not preferred as it showed to bias the geometry
optimization in a U shaped conformation rather than an extended one and these interactions
would polarize the charges. HG-63G* charges already over polarize the charges compared to
gas phase, to mimic the effect of intermolecular interactions (Winn et al. 1997) Therefore, the
charges were calculated separately and then merged with the previously calculated charges for
the phosphopantetheine, keeping the overall charge on the molecule as -1. The new residue,
SPM, was added into the AMBER99SB-ILDN amoniacids.rtp database in GROMACS (Ap-
pendix II Section B.1.2). The simulation system was neutralized by adding 3 Na+ counter ions
and five independent simulations were carried out for 50 ns each following the same protocol
as described in Section 2.3.2.3. One of the simulations was extended to 1 µs for the wild type
ACP-mupA3a and upto 200 ns for the W44L ACP-mupA3a mutant.
2.3.2.5 Molecular dynamics simulation of ACP-mupA3a with a covalently bound satu-
rated carbon chain
ACP-mupA3a wild type was simulated with a covalently bound 14C saturated chain to the
phosphopantetheine. The carbon chain was of the same length as that of the ACP-mupA3a
substrate’s backbone. The parameters and the charges for the phosphopantetheine moiety were
the same as in the previous calculations. The parameters for the 14C saturated carbon chain was
obtained from GAFF and the charges were calculated using RED server. The new residue SPD
was added into the AMBER99SB-ILDN amoniacids.rtp database in GROMACS (Appendix
II Section B.1.3). The simulation system was neutralized by adding 3 Na+ counter ions and
three independent simulations were carried out for 50 ns each following the same protocol as
described in Section 2.3.2.3. One of the simulations was extended upto 200 ns.
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2.3.2.6 Molecular dynamics simulation of ACP-mupA2a with its substrate
ACP-mupA2a wild type was simulated with its substrate (Figure 1.27). All the parameters for
the phosphopantetheine moiety were the same as in the previous calculations. Parameters for
the ACP-mupA2 substrate were obtained from GAFF with charges calculated using the RED
server. The new residue SPB was added into the AMBER99SB-ILDN amoniacids.rtp database
in GROMACS (Appendix II Section B.1.4). The molecular dynamics simulation procedure was
as in the Section 2.3.2.3. The simulation system was neutralized by adding 5 Na+ counter ions
and three independent simulations were carried out for 50 ns each following the same protocol
as described in Section 2.3.2.3. One of the simulations was extended to 200 ns.
2.3.2.7 Molecular dynamics simulations of ACP-mupA3a:MupH complex
The starting configuration for MD simulation of the ACP-mupA3a:MupH complex was a repre-
sentative complex from the in silico docking described in Section 2.3.4.1 and Chapter 3 Section
3.2.6. ACP-mupA3a had its substrate attached to the phosphopantetheine. An acetyl molecule
was covalently attached to the C115 in the MupH active site. The force field parameters for
the phosphopantetheine and ACP-mupA3a substrate were taken from the previous calculations
as described in section 2.3.2.4. Parameters for the acetyl molecule attached to the C115 were
obtained from GAFF with the charges calculated by using the RED server. A new residue type
CYA for C115Acetylated-cysteine was introduced into the AMBER99SB-ILDN amoniacids.rtp
database in GROMACS (Appendix II B.1.5). The simulation system was neutralized by adding
16 Na+ counter ions and three independent simulations were carried out for 50 ns each follow-
ing the same protocol as described in Section 2.3.2.3. One of the simulations was extended upto
100 ns.
Another set of simulations were carried out for ACP-mupA3a:MupH complex but with
MupH as a dimer. All the parameters were kept the same as that for the ACP-mupA3a:MupH
monomer complex. However, new topologies were generated including the MupH dimer. The
ACP-mupA3a:MupH dimer system was neutralize by adding 29 Na+ counter ions. Three inde-
pendent simulations were carried out for 50 ns each following the same protocol as described
85
in Section 2.3.2.3.
2.3.2.8 Molecular dynamics simulations of MupH and MupH acetylated at C115 in iso-
lation
Three independent simulations for MupH and MupH acetylated at C115 were carried out for
50 ns each. The force field parameters for the acetyl molecule attached to the C115 were from
previous calculations (as described in Section 2.3.2.7). The simulation systems for both the
structures were neutralized with 13 Na+ counter ions and were carried out following the same
protocol as described in Section 2.3.2.3.
2.3.2.9 Calculating the RMSD and RMSF of ACP-mupA3a and ACP-mupA2 from their
reference starting structure
Root mean square deviations (RMSD) of the backbone atoms from the reference starting struc-
ture were calculated for all the extended simulations of ACP-mupA3a and ACP-mupA2 using
the GROMACS module g rms. Below is an example command to run g rms, which requires
a MD simulation input file and a MD simulation output trajectory file. The RMSD was cal-
culated at every 10 ps of the simulation. The RMSD plots were visualized using the program
Grace (http://plasma-gate.weizmann.ac.il/Grace/).
g_rms -s md.tpr -f md.xtc -o rmsd.xvg
Root mean square fluctuations (RMSF) were calculated for the backbone atoms, averaged
per residue, for all the extended simulations of ACP-mupA3a and ACP-mupA2 using the GRO-
MACS module g rmsf. Below is an example command to run g rmsf, which requires a MD
simulation input file and a MD simulation output trajectory file. The RMSF was calculated
from points in the trajectory at 10 ps intervals. A combined scatter graph was plotted for all the
simulations using a spread sheet program.
g_rmsf -s md.tpr -f md.xtc -o rmsf.xvg -res
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2.3.2.10 Calculating RMSD of the ACP-mupA3a and ACP-mupA2 from the reference
FAS ACP structure
The GROMACS suite has a module to calculate RMSD of a set of atoms from a reference
structure, but it does not perform well with a reference structure which is not identical to the
structure in the simulation. The task in this analysis was to calculate the RMSD of the con-
formational states of the ACP-mupA3a and ACP-mupA2 (wild and mutant) structures at every
ns of the simulation from the reference FAS ACP structure (PDB ID 1L0I). To perform this
task not natively supported by GROMACS, conformational states at every ns of the simulation
were extracted using VMD (Visual Molecular Dynamics) (Humphrey et al. 1996). I wrote a
Perl script (Appendix I Section A.5) to extract the individual conformational states from a mul-
tiple structure concatenated file and aligned each of them with the reference FAS ACP structure
using the Matt structural alignment program (Menke et al. 2008). My script also extracts the
RMSD value from each alignment result file and outputs the results on the screen with the time
frame of the simulation. A scatter graph was plotted of the RMSD values against time for each
simulation system using a spread sheet program.
2.3.2.11 Calculating cavity volume during the course of ACP-mupA3a/mupA2 simula-
tions
To detect the formation and change in the volume of the proposed cavity in the ACP-mupA3a /
mupA2 structure during the course of molecular dynamics simulations a third party GROMACS
plugin trj cavity was used (Paramo et al. 2014). It takes a GROMACS topology and trajectory
as the input and an optional seed value in the form of Cartesian coordinates to initiate the cavity
detection at a particular position on the protein. Here, the seed value was calculated using the
PASS program from the MetaPocket server (Huang 2009). Another important parameter is a
dimension value which is 5 by default which means that the algorithm requires void space in 5
of the 6 possible directions (that is +/- x, y, z coordinates) till it encounters protein atoms. The
program gives the flexibility of choosing the grid size in Åwhich is 1.4 by default, to represent
the size of a water molecule, and the atomic radii. In this analysis a gird size of 1.3 and the
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atomic radii from the AMBER99SB-ILDN force field were used. The grid size of 1.3 was
decided after the observation that with a grid size of 1.4 there was no cavity detected in many of
the frames where a human would deem there to be one. As the proposed cavity is highly surface
exposed the void spaces were not deep enough to find protein in all the five directions. The grid
size of 1.3 did not eliminate the possibility of no cavity detection but upon visual inspection
of the trajectories there were fewer frames found with no cavity mapped. Upon decreasing the
dimension size to 4 and keeping the grid size to default 1.4 more frames were detected with
cavities but there were more instances of spill overs. Here, spill overs mean that the probe
couldn’t find protein in five directions and hence ran off the intended cavity space until it finds
the edge. This could be controlled with a cutoff distance, various cutoff distances were tried
but there wasn’t much improvement. Upon decreasing the grid size lower than 1.3 lead the
probe go through the protein interior thus mapping the whole or the majority of the structure
as a potential cavity. Grid sizes lower than 1.3 with an increased atomic radii were also tried
but again there wasn’t much improvement and at the same time the system seem to be more
unrealistic. Therefore, after comparing different parameter sets the final set of parameters were
decided to be dimension of 5, 1.3 grid spacing, 9 cutoff distance, AMBER99SB-ILDN atomic
radii and a corresponding seed value for different structures. The command below shows an
example of the parameters assigned. A scatter graph was plotted of the cavity volumes against
time for each simulation system using a spread sheet program.
trj_cavity -s em.gro -f md_cat-fit.xtc -seed 46.804 50.162 30.501 -o
cavity_max_dim5_ff1.3.pdb -ov volume_max_dim5_ff1.3.xvg -mode max -dim 5
-ff_path amber99sb-ildn.ff/ -ff_radius -spacing 1.3 -cutoff 9
2.3.2.12 Calculating hydrogen bonds and solvent accessible surface area (SASA) during
the course of ACP-mupA3a and ACP-mupA2 simulations
To detect and quantify the interaction of the phosphopantetheine and the acyl chain with the
protein surface and the solvent, the number of hydrogen bonds and solvent accessible surface
area (SASA) were calculated. Two built in modules in the GROMACS suite g hbond and g sas
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were used for calculating the hydrogen bonds and SASA respectively. New GROMACS index
groups were made for the phosphopantetheine and acyl chains to represent them as different
moieties, from the atoms starting from phosphate till the sulphur as the phosphopantetheine and
from the first carbon after the sulphur till the terminal carbon as the acyl chains respectively.
The hydrogen bonds were calculated during the course of simulation at 10 ps intervals between
each index group and the protein as well as with the solvent for both the phosphopantetheine
and the acyl chains (excluding phosphopantetheine). Separate scatter graphs were plotted of the
number hydrogen bonds detected and the SASA values against time for each simulation system
using a spread sheet program. Below are the example commands to calculate hydrogen bonds
and SASA using g hbond and g sas module respectively.
g_hbond -f md_1-cat.xtc -s em.tpr -n index.ndx -num sol_hbnum.xvg -dist
sol_hbdist.xvg
g_sas -s em.tpr -f md_3-cat.xtc -n index.ndx -o sas_area.xvg -tv sas_volume.xvg
2.3.2.13 Calculating the distance between the two loops on the MupH surface
To detect the loop movement at the MupH cavity during the simulation g dist module of the
GROMACS suit was used. The distance between the CA atom of three residues on the loop I
(L150, M151 and I152) were measured from each of the three residues on the loop II (P208,
D208 and S209), at every 5 ns of the simulation. Six index groups were created for the three
residues on the loop I and the three on the loop II to differentiate them as different entities for
the distance measurement. In case of the MupH dimer complex the residues were selected on
chain A. The distance between one residue on the loop I with each of the three residues on loop
II was represented as an average. A scatter graph was plotted for the three distance averages
calculated between the loop I and loop II for every simulation. Below is an example command
to calculate the distance between two atoms or groups in GROMACS using g dist module.
g_dist -f md.xtc -s md.tpr -n loopres.ndx -o dist_0_P207_L150.xvg
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2.3.3 Interface prediction
At present the available protein interface prediction methods can be divided into two classes.
The first class of methods predicts the residues most likely to be at an interface using multiple
sequence alignment. Since there is evolutionary pressure for conservation of the interface, for
example the Evolutionary Trace method (ET) (Lichtarge et al. 1996), which is ideally mapped
onto the surface of the protein structure. The second class of the methods do not rely on any
evolutionary information and are solely based on geometrical, physiochemical and statistical
properties of the surface of the protein structure, for example the PIER (Protein Interface Recog-
nition for Structural Proteomics) method (Kufareva et al. 2007). In the present work both ET
and PIER have been used to predict the most likely interacting interfaces, which were either
used to drive the docking experiments and/or to validate the docking results (Section 3.2.6.2).
Predicting interacting interfaces can help to reduce the sampling required for docking experi-
ments as the surface areas that are least likely to be at the interface can be excluded from the
analysis, although here they were used to support results obtained by docking calculations that
did not incorporate those predictions.
2.3.3.1 Evolutionary trace (ET)
Evolutionary trace (ET) analysis ranks the positions in a multiple sequence alignment of a fam-
ily of protein sequences according to their evolutionary importance. ET analysis is based on
two hypotheses. First, in an evolutionary related family of proteins the functionally important
residues, such as in active sites and at protein-protein interaction interfaces, are conserved. Sec-
ond, some mutations may lead to new functions, or functional variants and sequences showing
these features may form a clade with the residue associated with the subtype of function under
pressure to be conserved (Lichtarge et al. 1996).
To generate an evolutionary trace from a multiple sequence alignment the first step is to
generate a the phylogenetic tree and partition it into different clades based on sequence identity.
On a dendogram a clade is defined as a set of sequences arising from the same node. This
partitioning of the clusters is carried out by the partition identity cutoff (PIC) (Du and Alkorta
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1994). Once each cluster is identified through partitioning, a consensus sequence is derived
for each and every clade. This consensus sequence represents a residue type for the conserved
positions or a blank (neutral) for positions which are not conserved within a clade. In the next
step these consensus sequences are aligned to determine residues conserved within clades but
which might vary between clades, and this is the ET. If any of the consensus sequences contain
a neutral or a gap position then that position is considered to be neutral in the trace. Finally the
functionally important residues obtained from the trace are mapped onto the structure.
Partitioning plays an important role in the ET analysis. A few large clusters are obtained
at a lower PIC value which could be good enough to highlight broad functional features of a
protein family. However, to highlight finer functionality within a subgroup higher PIC values are
needed. The number of sequences in the alignment is also an important criterion for a successful
trace. A high PIC value will generate a large number of clusters with a single sequence which
are excluded from the analysis. When there are very few sequences in a cluster these may not
represent the true variation within the group and many positions that are in reality neutral will
be highlighted as functionally important.
Oliver Lichtarge and co-workers (Lichtarge et al. 1996) have shown that the evolutionary
trace identifies ligand binding sites in the three protein domains SH2, SH3 and the DNA binding
domains of nuclear hormone receptor. The results obtained at lower and higher PIC values show
agreement with experimental observations.
As explained earlier the consensus sequence derived for each and every clade represents
alignment positions which are conserved within a clade and if these are conserved within each
clade, but not necessarily between them, ET ranks them as important. However, this procedure
suffers from the limitation that the positions which are not considered to be conserved and
hence not included in the ET ranking, may also be important, on the basis that they might
not be conserved at that position in only one sequence or clade. This lack of conservation
may arise for example due to a sequencing error, even if its not a sequencing error throwing
away the whole column because one sequence did not have the identical residue might lose
important information. To over come this limitation and make the ET more robust, a hybrid
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method called real value evolutionary trace (rvET) was developed (Mihalek et al. 2004). Real
value evolutionary trace is a combination of ET with information entropy. Information entropy
allows the ranking of the importance of a position by counting the frequency of different residue
types in a column. Hence by combining the ET with information entropy those columns which
lack absolute consensus but are highly conserved may also be ranked as important, the rvET
score is lower for columns with partial conservation in a clade as compared to the columns in
which a particular residue is absolutely conserved in one clade and differ in another clade.
Real value evolutionary trace analysis can be performed using ET viewer (Morgan et al.
2006) which is an easy to use graphical user interface java applet. The applet runs the trace
remotely on a server in the Lichtarge group and requires a reference protein structure and a
sequence alignment. Both the structure and the sequence alignment can be uploaded by the
user manually or be obtained automatically by the server from the PDB website and through an
automated blast search respectively. In the present work both the structure and the alignment
were uploaded manually and the rvET was carried out with default parameters.
2.3.3.2 Protein Interface Recognition for Structural Proteomics (PIER)
PIER (http://abagyan.ucsd.edu/PIER/) is a computational method to predict the interface
residues based on the local statistical properties of the protein surface at the atomic group level
(Kufareva et al. 2007). PIER predictions do not analyse sequence conservation information
although in the original publication of the method evolutionary information was supplemented
but this produced marginal or no additional improvement in the predictions. The PIER predic-
tion model is based on the data obtained from 748 protein complexes available in the PDB at the
time of its publication. This diverse set consists of 490 homodimeric, 62 heterodimeric, and 196
transient interfaces. In order to validate the model Kufareva et al. (2007) randomly divided the
dataset of 748 complexes into three equally distributed sets. Each set was used to train a model
and which was tested on the other two sets. PIER has shown a precision (positive predictive
value) of 60% at the recall (sensitivity) rate of 50% in identifying the interface residues. Where
precision can be defined as the ratio of the total number of true positives (TP) to the size of the
predicted patch (TP+FP), FP means false positive, and the recall rate is the ratio of total num-
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ber of true positives (TP) to the size of the true interface (TP+FN), FN means false negative.
Through the statistical analysis of the data set, Kufareva et al. (2007) identified 12 significant
atom groups (Table 1 in the original paper (Kufareva et al. 2007)) with a high probability of
being found at an interface. The analysis revealed that stable permanent complexes are mostly
formed by side chain interactions. Whereas in transient complexes backbone - backbone and
backbone - side chain interactions are dominant.
The PIER algorithm predicts interface residues in a four step process. a) It generates the
surface patches on the given protein based on solvent accessible surface area. b) For each patch
it assigns 12 physical descriptors for the 12 significant atomic groups based on the total solvent
accessible area of all atoms of a group. c) It calculates the PIER value for each patch. d) Transfer
the calculated patch PIER value to the residues. The PIER value represents the chances of a
residue to be on the interface, higher the score for a residue more likely it to be at the interface.
In the present study the PIER values are mapped onto the structures using the b-factor column
of the PDB file. The structures are coloured with the rainbow colouring scheme. Where the
residues coloured as red are most relevant and violet as the least.
2.3.4 Molecular docking
In silico docking is a computational method to predict the most likely stable conformation
of two molecules with respect to each other. Molecular docking can be performed to predict
atomic resolution models of protein small molecule, protein-DNA, protein-RNA and protein-
protein complexes. Broadly, for any of the above mentioned purposes, docking can be of two
types. First, rigid body docking in which the two interacting molecules are considered as solid
structures and the resulting complex is a function of shape complementarity between the two
monomers. The second approach called the flexible docking allows for certain or all the parts
of the interacting molecules to be flexible and dynamic. Both approaches have their own merits
and demerits, rigid body docking is faster than flexible body and can be applied to larger com-
plexes however; flexible docking is more accurate but can be quite computationally expensive
for large molecules (Teague 2003). Both processes require a search algorithm which sets the
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search space for all the possible molecular orientations and an energy term which calculates
the intermolecular energy of the pair, this energy term is usually based on a molecular mechan-
ics force field. A clustering algorithm can also be used to rank and cluster the complexes into
clusters of similar orientation and comparable energies. Both rigid body and flexible docking
can be of a global or local type. In global docking one molecule is kept stationary while the
other molecule is allowed to roll over the entire surface of the stationary molecule to find the
best match. The global docking algorithms do not require any prior knowledge of the interact-
ing interface or residues for example the ZDOCK server (http://zdock.umassmed.edu/)
(Pierce et al. 2014). Whereas, in local docking the docking interface or patch is roughly pre-
defined and the docking algorithm tries to optimize the match for example the HADDOCK
server (http://haddock.science.uu.nl/) (Vries et al. 2010). This predefined patch would
usually be residues identified to be on the interface through various protein protein interaction
studies, mutation experiments or Bioinformatics analysis such as ET or PIER.
More recent docking software also supplements the scoring procedure with biochemical
and/or biophysical data such as chemical shift perturbation data obtained from NMR exper-
iments, mutagenesis data or Bioinformatics analysis. HADDOCK (High Ambiguity Driven
Docking) (Dominguez et al. 2003) is one such software which carries out the docking by ex-
pressing the interface information as ambiguous interaction restraints (AIRs). An AIR can be
defined as the ambiguous distance between all the interacting residues. HADDOCK has contin-
uously been ranked as one of the best software available for docking in the CAPRI competitions
(http://www.ebi.ac.uk/msd-srv/capri/). In practice the HADDOCK software can be
accessed through an easy to use webserver (Vries et al. 2010) (http://haddock.science.
uu.nl/) which gives access ranging from easy to guru level interface. The latest version of
HADDOCK can also perform multi body interface docking which can be used to dock upto six
proteins structures (Karaca et al. 2010).
HADDOCK requires a list of “active” and “passive” residues which are likely to be on
the interface. For example the active residues can be the ones which show significant chemical
shift perturbation upon complex formation in an NMR experiment and also have a high solvent
94
exposure in the free form of protein. Whereas, the passive residues are the one which surrounds
the active residues and have a less significant chemical shift but still with high solvent exposure.
The docking is driven by assigning an AIR between any atom in active residue of one protein
to the atoms in the active and passive residues of the other protein with the aim to maximize the
interaction. The AIRs are defined as an ambiguous intermolecular distance with a maximum
value of 3 Å. Apart from assigning active and passive residues to generate AIRs HADDOCK
can also utilize unambiguous distance restraints within the same structure or in between the two
structures.
The overall docking protocol consists of three stages. In the first stage the orientation of the
two molecules is randomized followed by docking by rigid body energy minimization. This step
is faster and generates approximately 1000 docking solutions of which the top 200 complexes in
terms of intermolecular energies are further refined. The second stage is a three step semi rigid
simulated annealing refinement. In the first step the two proteins are considered as rigid bodies,
in the second step the side chains at the interface are allowed to be flexible and in the third step
both the side chain and the backbone is allowed to be flexible. The resulting complexes are then
subjected to the steepest descent energy minimization. The final stage of the docking is carried
out with refinement at the interface in Cartesian space using molecular dynamic simulation in
TIP3 explicit solvent with OPLS all atom force field. The final complexes are clustered using
pairwise backbone RMSD where a cluster consists of at least two complexes with the RMSD
smaller than 1 Å at the interface.
2.3.4.1 ACP-mupA3a/b + MupH docking
ACP-mupA3a was docked using HADDOCK server in two different ways to a MupH structure
modelled as described in Section 2.3.1.1. The Easy interface was used for docking with a list of
active and passive residues. The active and passive residues (explained in Section 2.3.4) were
determined using the PIER program (as described in Section 2.3.3.2). The list of active and
passive residues obtained from PIER are mentioned in the results section of Chapter 3, in Table
3.4.
In the second method the expert interface was used to dock ACP-mupA3a/b with MupH
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using distance restraints. A distance restraint of 2.0 Å was used between the phosphorous of
phosphopantetheine bound in the active site of MupH and the Oγ of the serine (S38/142) residue
of ACP-mupA3a or mupA3b. An additional restrain of 9.13 Å (Steussy et al. 2005) was placed
between the sulphur of the thioester linkage in the ligand and the Cα of the catalytic cysteine
(C115) of MupH.
2.3.4.2 Docking the natural substrate into KS-mupA2 dimer
The natural substrate of the KS-mupA2 was docked into the modelled KS-mupA2 homodimeric
structure (modelling described in Section 2.3.1.3) using the HADDOCK server Multi-body in-
terface, with distance restraints. Docking was performed to mimic the decarboxylation stage of
the Claisen condensation (see Section 1.2.4.3 for KS reaction mechanism). A distance restraint
of 1.8 Å between the SG of the catalytic cysteine C158 and the first carbon of the substrate was
used to mimic the acyl chain transfer step. To mimic the oxyanion hole formation, the backbone
NH atoms of residues C158 and A403 were used to restrain the first carbonyl of the substrate
with a distance restraint of 2.93 Å each. To mimic the decarboxylation step, atom HD1 of H293
and HE2 of H333 were used to restrain the carbonyl of the malonate and atom OZ of F219
was used to restrain the carboxylate of the malonate with a distance restraint of 3.0 Å each.
To keep the phosphopantetheine attached to the malonate in a fully extended state a modelled
ACP-mupA2 structure was also docked with a distance restraint of 2.0 Å between the atom OG
of S38 on the ACP-mupA2 and the phosphate of the phosphopantetheine.
2.4 Kalimantacin ACP swap experiment
2.4.1 Bacterial strains and Plasmids
The wild type mupirocin producer Pseudomonas fluorescens NCIMB 10586 strain was used
as a control. A Pseudomonas fluorescens ∆acp4 strain, which was deleted for the acp4 (ACP-
mupA3b) was used as the starting point for ACP swap experiments since it carries just the
ACP-mupA3a in the 3rd module of MmpA. A Pseudomonas fluorescens ∆mupH strain, which
has a deletion in mupH, was used as the host strain for swapping the ACP-mupA3ab with the
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ACP-k24a from the kalimantacin cluster. Escherichia coli DH5α was used as the host for all
cloning experiments, Escherichia coli S17-1 was used for the conjugal transfer of plasmids to
Pseudomonas fluorescens. Bacillus subtilis 1064 was used as the detection organism for the
overlay bioassay. Plasmid pAKE604 was used to clone the kalimantacin ACP together with the
ACP-mupA3ab flanking regions from the mup cluster. Previously-prepared pJH10 derivatives
were used to express mupH, batC and batC L218M mutant in trans. Table 2.1 lists the bacterial
strains and plasmids used in this study along with their genotype.
Table 2.1: Bacterial strains and plasmids used in this study
Bacterial strain Genotype and properties Reference
Pseudomonas fluo-
rescens NCIMB 10586











Pseudomonas fluorescens NCIMB 10586 with
mupH deleted
Wu et al. (2007)
Escherichia coli DH5 Φ80lacZ∆M15, recA1, endA1, gyrA86, thi-
1, HsdR17(r−k , m
+
k ), supE44, rrelA1, deoR,
∆(lacZYA-ArgF)U169
Gibco BRL
















Bacillus subtilis 1064 trpC2amyE::(spec Pxyl-gfp-lacl)
chr::pSG1196(rmD0lacO cat)
Moir et al. (1979)
Plasmid




pJH10 Size 14.5 kb, IncQ. pOLE1 IncC1 deleted.
TetR (from pDM1.2) oriT
El-Sayed et al.
(2001)
2.4.2 Cell culture media and growth conditions
Four types of culture media were used in this project:
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L-broth which contains yeast extract (10 g/l), tryptone (5 g/l), NaCl (10 g/l) and glucose (1
g/l);
L-agar which contains all the ingredients from the L-broth along with agar (15 g/l);
M9-Minimal medium which contains (per liter) 1.5 % w/v water agar (400 ml), 2XM9 salts
(400 ml), 1M thiamine (800 µl), 1M MgSo4 (800 µl), 1M CaCl2 (800 µl) and 40% glucose (4
ml);
Mupirocin secondary stage medium (SSM), for HPLC, which consists of (per litre) soy flour
(25 g), spray dried corn liquor (2.5 g), (NH4)4SO4 (5 g), MgSO4.7H2O (0.5 g), Na2HPO4 (1 g),
KH2PO4 (1.5 g), KCl (1 g), CaCO3 (6.25 g), glucose (4 %). The SSM was prepared, autoclaved
and pH adjusted to 7.5 prior to adding glucose.
For selection of resistance all the media were supplemented with the antibiotics ampicillin
(50 µg/ml dissolved in water), tetracycline (15 µg/ml dissolved in 70% ethanol) and kanamycin
(50 µg/ml dissolved in water) used individually or in combination. Pseudomonas fluorescens
strains were grown at 30°C whereas Escherichia coli and Bacillus subtilis strains were grown
at 37°C.
2.4.3 Competent cell preparation
Competent E. coli bacteria were prepared using the calcium chloride method (Cohen et al.
1973). E. coli cells were grown overnight in 5 ml L-broth at 35°C at 200 rpm. Overnight
cultures were diluted 1 in 100 using fresh L-broth and were grown again at 37°C at 200 rpm
until the optical density of the culture at 600 nm reached 0.4-0.6. Cells were pelleted by cen-
trifugation at 5000 X g for 7 min at 4°C. After discarding the supernatant, the cell pellet was
re-suspended in pre chilled 100 mM calcium chloride (2 ml per 5 ml culture) and incubated on
ice for 20 min. Cells were pelleted again by centrifugation at 5000 X g for 7 min at 4°C and
the pellet was re-suspended in pre chilled 100 mM calcium chloride (0.5 ml per 5 ml culture)
to make the cells competent. These competent cells were stored in 4°C and used within two
weeks.
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2.4.4 Polymerase Chain Reaction
Standard polymerase chain reactions (PCR) were performed to amplify regions of chromosomal
or plasmid DNA, both for cloning or for testing the cloned products. For cloning purpose Q5
High Fidelity (HF) kit was used, because this enzyme has proof-reading ability which ensures
accurate DNA replication. However, it also generates DNA fragments with blunt ends. For
testing purposes the Taq Polymerase kit from Invitrogen was used. Taq does not have proof
reading ability but it is cheaper than Q5 HF enzyme and hence better for testing. Table 2.2 lists
the ingredients needed for a single PCR reaction using a Q5 or Taq DNA polymerase.
Table 2.2: PCR reaction master mix for Q5 and Taq DNA polymerase
Q5 Taq
Ingredient Quantity Ingredient Quantity
Water 25.5 / 14.5 µl Water 12.4 µl
Q5 buffer 10 µl 50% glycerol 10 µl
10 mM dNTPs 4 µl 10 X PCR buffer 5 µl
10 µM forward Primer 5 µl 50 mM MgCl2 1 µl
10 µM reverse primer 5 µl 10 mM dNTPs 4 µl
Q5 polymerase 0.5 µl 10 µM forward Primer 6 µl
Template DNA 1 µl 10 µM reverse primer 6 µl
Enhancer (optional) 0 / 10 µl Taq DNA polymerase 0.6 µl
Template DNA 5 µl
Total volume 50 µl 50 µl
For amplifying the three fragments, i.e. ACP-K24a and the two ACP-mupA3ab flanking re-
gions from the mup cluster, six primers were designed. The primers were designed (Table 2.3)
to perform Gibson assembly in the next step therefore the gene-specific primer sequence (high-
lighted in blue) also included the overlap region (highlighted in red) (more details in section
2.4.6). All the primers were obtained from Alta Biosciences, University of Birmingham.
To amplify the kalimantacin ACP-K24a, purified kalimantacin chromosomal DNA supplied
by our collaborators the group of Prof. Rob Lavigne in Belgium, was used as the template.
The reaction mix was prepared for the Q5 polymerase as mentioned in the Table 2.2, with
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Table 2.3: Primers for amplifying ACP-K24a, left and right flanking regions.










F and R denotes forward and reverse; mup-L/R denotes left and right flanking regions.
Product size is the intended length of the amplified fragments including the length of the
homology region (red).
and without the optional enhancer. The annealing temperature for the primers were calculated
using the NEB TM calculator (http://tmcalculator.neb.com). Since the primers were
designed to be used with the Gibson assembly in the next step two annealing temperatures
were calculated, the annealing temperature for the gene specific primer sequence was 57°C and
the annealing temperature for the whole sequence including the overlap sequence was 72°C.
Table 2.4 shows the programme used for the kalimantacin ACP-K24a amplification using Q5
polymerase kit.
Table 2.4: The PCR program used for amplifying ACP-K24a with the Q5 polymerase kit.
Steps Temperature (°C) Time (sec) Cycle
Initial denaturation 98 30 1
Denaturation 98 10 2
Annealing 57 20 2
Extension 72 30 2
Denaturation 98 10 28
Annealing & Extension 72 40 28
Long extension 72 120 1
To amplify DNA for available bacterial strains, individual colonies were picked and sus-
pended in 50 µl of sterile distilled water. The suspension was boiled for 10 mins and then
centrifuged to 15000 X g for 5 mins, 2 µl of the supernatant was used as the template DNA
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and the rest of the ingredients were as described in the Table 2.2. For the left arm, annealing
temperature calculated for the gene specific primer region including the overlap region, was
72°C. Table 2.5 shows the program used for the left arm PCR.
Table 2.5: The PCR program used for amplifying the left arm with the Q5 polymerase kit.
Steps Temperature (°C) Time (sec) Cycle
Initial denaturation 98 30 1
Denaturation 98 10 30
Annealing and extension 72 60 30
Long extension 72 120 1
To amplify the right arm, the annealing temperature initially calculated for the gene specific
primer region was 68°C and including the overlap region was 70°C. However, I found that while
using two different annealing temperatures at different stages of the PCR cycle, working at the
calculated temperatures sometimes does not produce good results. To explore temperatures that
might produce better results, a gradient PCR was setup. In 1°C steps on the PCR block and
6 samples were placed with gaps to give 60, 62, 64, 66, 68 and 69°C. Table 2.6 shows the
programme used for the right arm.
Table 2.6: The PCR programme used for amplifying the right arm with the Q5 polymerase kit.
Steps Temperature (°C) Time (sec) Cycle
Initial denaturation 98 30 1
Denaturation 98 10 2
Annealing 65.5 (5.5 gradient) 20 2
Extension 72 50 2
Denaturation 98 10 28
Annealing 67.5 (5.5 gradient) 20 28
Extension 72 50 28
Long extension 72 120 1
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2.4.5 Agarose gel electrophoresis
Agarose gel electrophoresis were performed to verify the size of the DNA fragments generated
either by PCR or restriction digestion reactions. 100 ml of 1% agarose gels were prepared by
melting 1 g of agarose in 98 ml of distilled water followed by addition of 2 ml of 50X tris
acetate EDTA (TAE) buffer and 2 µl of ethidium bromide solution (concentration 2.0 µg/µl). 1
kb DNA Ladder from Thermo Scientific was used as the molecular weight marker.
2.4.6 Gibson Assembly
Gibson assembly is a method that can efficiently join multiple overlapping DNA fragments in
a single isothermal reaction as illustrated in Figure 2.1. It requires that the DNA fragments
contain ≈20-40 base pair overlap with adjacent DNA fragments. The Gibson assembly master
mix consists of three different enzymes in a single buffer, which include: an exonuclease, which
creates single stranded 3’ strand which serves as the overlapping region complementary to the
adjacent DNA fragment; a polymerase enzyme, which extends the gaps within each annealed
fragment; and a DNA ligase which seals the nicks in the assembled DNA. To get the DNA
fragments for the Gibson assembly, i.e. ACP-K24a from the kalimantacin cluster and the two
five hundred base long DNA fragments from both the sides of ACP-mupA3a (left and right
arm), PCR was performed as explained in the section 2.4.4.
Once fragments of the desired size were obtained, the three PCR products were purified
using the GE Healthcare Life Sciences Illustra-GRX PCR DNA and gel band purification kit
and the concentration of DNA in the solution was estimated using the Nanodrop instrument.
Simultaneously suicide plasmid vector pKAE604 was digested using Hind III and Sal I restric-
tion enzymes. The digested product was purified and the concentration of the plasmid DNA
was measured. For Gibson assembly NEB recommends a total DNA concentration of 0.2 to 1.0
pM when 4 to 6 DNA fragments are to be assembled. Therefore, for 4 fragments 0.25 pM is
required and the weight in ng for each of the four fragments can be calculated with equation
2.3. This allowed the volume required in µl of the extracted DNA solutions to be determined.
NEB recommends incubation of the Gibson Assembly master mix for an hour at 50°C.
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Figure 2.1: Overview of the Gibson assembly method. Picture reproduced from the NEB Gibsson as-
sembly master mix instruction manual NEB #E2611S/L
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weight in ng =
pmols × base pairs × 650 daltons
1000
(2.3)
2.4.7 Transformation and validation
Following the Gibson assembly the ligated product was transformed into freshly prepared E.
coli DH5α competent cells. As recommended by the NEB Gibson assembly protocol, the lig-
ated product was diluted 4 fold (5 µl of ligation in 15 µl of deionised distilled water) prior to
transformation. For transformation 2 µl of the diluted product was added to 100 µl of the com-
petent cells and was held on ice for an hour. After an hour the cells were heat shocked for 90
sec at 42°C and then briefly returned to ice. The culture held on ice was mixed with 500 µl of
L-broth and was incubated at 37°C for an hour. Finally 200 µl and 400 µl of the culture was
plated on to L-agar plates with kanamycin and grown at 37°C overnight.
PCR was performed on the colonies picked from the transformation plates, using the left arm
forward primer and the right arm reverse primer. The method for PCR was same as mentioned
in the section 2.4.4 using the Taq polymerase enzyme. Table 2.7 shows the PCR programme
used for validating the ligation of the four fragments using Gibson assembly. The PCR product
were analysed by 1 % agarose gel electrophoresis.
Table 2.7: The PCR programme used for validating the product of Gibson assembly with the Taq DNA
polymerase kit.
Steps Temperature (°C) Time (sec) Cycle
Initial denaturation 94 180 1
Denaturation 94 30 30
Annealing and extension 72 90 30
Long extension 72 600 1
Successful PCR products were purified and sequenced using primers designed previously
by Dr. Joanne Hothersall. Those primers bind on the region outside the multiple cloning site in
the pAKE604 plasmid. The validated sample(s) was used to transform freshly prepared E. coli
S17-1 competent cells and were grown on L-agar plates with kanamycin selection and a sample
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of the successful transformant was stored in the -80°C freezer.
2.4.8 Conjugal transfer of the suicide vector into P. fluorescens
For mating, overnight cultures were prepared for the transformed E. coli S17-1 and the two P.
fluorescens host strains. 1 ml of each of the two P. fluorescens host strains was mixed separately
with 1 ml of the transformed E. coli S17-1 strain. 1 ml of the culture mixture was filtered
through a millipore nylon filter using a syringe and the filters were placed face up on to an
L-agar plate without any antibiotic and grown overnight at 30°C. The bacteria were washed off
the filters with 1 ml of saline. 10−5 fold serial dilutions were made using 100 µl of the cells
washed in saline followed by plating 100 µl of each dilution onto minimal medium plates with
kanamycin selection. The plates were grown at 30°C for three to four days till the colonies were
visible and big enough to be picked easily.
To detect the successful transfer of the plasmid into the P. fluorescens ∆ACP4 and ∆MupH
cells, colonies were subjected to PCR (as described in Table 2.7) with ACP-K24a specific
primers using Taq DNA polymerase. The PCR products were analysed using 1% agarose gel.
2.4.9 Sucrose selection and excisant validation
After mating, the P. fluorescens trans conjugants were subject to sucrose selection. For the P.
fluorescens ∆ACP4 trans-conjugants, colonies were grown overnight in L-broth without any
selection. For each of the overnight cultures, five serial dilutions of 10−1 were made for a final
dilution of 10−5 and 100 µl of culture from each of the five dilution tubes was plated on L-
agar plates with sucrose selection. The cells were grown at 30°C for 24 hrs. To confirm that
the plasmid had successfully excised out of the P. fluorescens strains, colonies were patched
onto two plates carrying ampicillin and kanamycin respectively. The colonies which grew on
the ampicillin plates but not on the kanamycin plates were the ones which had successfully
excised the plasmid. Successful excisions were subjected to PCR (as described in Table 2.7)
with ACP-K24a specific primers using Taq DNA polymerase, in order to detect the integration
of the ACP-K24a into P. fluorescens ∆ACP4 chromosome.
The previous steps validated the integration of the ACP-K24a into the P. fluorescens ∆ACP4
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chromosome but did not detect whether the integration had happened at the correct position in
the mup cluster. To validate that ACP-K24a had integrated at the correct position another PCR
using Taq DNA polymerase was carried out. Primers designed previously by Dr. Anthony
Haines, which bind to the positions outside the left and right arms were used with the annealing
temperature of 53°C (as described in Table 2.7, with separate annealing and extension steps).
P. fluorescens NCIMB 10586 and P. fluorescens ∆ACP4 were used as the controls. The PCR
products were further subjected to restriction digests using enzymes Blp I and Stu I. Blp I cuts
in the middle of the ACP-K24a but not does not cut anywhere in ACP-mupA3a and Stu I cuts
in the middle of the ACP-mupA3a as well as at the rear ends of the two arms. A 20µl restriction
digestion reaction mixture consists of DNA (5µl), Buffer (2µl), BSA (1µl), enzyme (conc. 5
units/µl) and enough sterile distilled water to make the total volume of 20µl. The restriction
digest fragments were analysed by electrophoresis on 1% agarose gel, an uncut fragment was
used as the control.
For P. fluorescens ∆MupH trans-conjugants sucrose selection was performed following the
same steps as that for the P. fluorescens ∆ACP4 trans-conjugants. However, to validate the ex-
cisions and integrants, samples were subjected to PCR using the primers designed to bind to
the region outside the two arms. The steps of PCR with ACP-K24a specific primers and sub-
sequent restriction digestions were excluded, since running a PCR using only the outer primers
and sequencing the PCR products gave the same result in fewer steps and less time as compared
to the above mentioned steps.
2.4.10 Overlay Bioassay for in trans expression of MupH, BatC and BatC
L218M mutant
For the bioassay 20 ml measured L-agar plates were made. The P. fluorescens ∆H-6d strain
carrying one of MupH, BatC or Batc L218M in trans and the ∆4-1a strain carrying the BatC in
trans were grown overnight in 5 ml L-broth with ampicillin selection. P. fluorescens NCIMB
10586, ∆MupH, ∆ACP4, ∆H-6d and ∆4-1a were also grown without any plasmids, as controls.
100 µl of the overnight cultures were diluted with 900 µl of L-broth. To keep the concentration
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of the cells the same in all the cultures, the optical density of the samples was measured at 600
nm. Using equation 2.4, further dilutions were made keeping the total volume of the sample as
1 ml.




10 µl of the diluted samples were spotted onto the 20 ml L-agar plates and were grown
for 24 hr on the bench at room temperature. Simultaneously an overnight culture of Bacillus
subtilis 1064 strain was grown at 37°C. To prepare the overlay medium 4 ml of Bacillus subtilis
culture were mixed in 100 ml of molten L-agar and 500 µl of TTC (5% w/v). 15 ml of the
overlay medium were poured over the spots from the 24 hr grown P. fluorescens strains and were
allowed to settle till the agar solidified, followed by a 24 hr incubation at 30°C. The diameters
of the clearance zones were measured in two different directions, subtracting the diameter of
the central disk.
2.4.11 High performance liquid chromatography analysis
To order to detect the pseudomonic acids produced by the in trans expression of mupH, batC
and batC L218M in the ACP-K24a mutant P. fluorescens strains, high performance liquid chro-
matography (HPLC) was performed. P. fluorescens NCIMB 10586 and P. fluorescens ∆H-6d
and ∆4-1a with an empty pJH10 plasmid were used as controls. The seed cultures were pre-
pared by growing the strains for 16 hr in L-broth at 25°C, 200 rpm. From the seed cultures,
1.25 ml of each sample was inoculated into 25 ml of the secondary stage medium (SSM). The
inoculated cultures were grown at 22°C, 200 rpm for 40 hr. The cultures were pelleted in Fal-
con tubes by centrifugation at 5000 X g, at 25°C for 40 min. The supernatant was separated
and filtered using 0.2 µm Acrodiscs Nylon filters (Pall-Gelman, labs) before injection into the
HPLC machine.
The HPLC machine (Gilson) was supplied with HPLC grade water (Fisher) and 100% aceto
nitrile (Fisher) as mobile phase. The two solvents were added with 0.01% formic acid (v/v)
for pH adjustment and were degassed using an aspirator to remove any dissolved air prior to
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injection into the machine. The machine was set at 0.002 AUFS (absorbance units full scale)
sensitivity and the detection was carried out at the wavelength of 233 nm. A Supelco reverse
phase C18 column (15cm X 4.6 mm, 5µm), which had hydrophobic alkyl chains covalently at-
tached to the silica beads, was used to bind the hydrophobic compounds. Elution was performed
by using a 5-70% acetonitrile-water gradient at 1ml/min flow rate for 1 hr. Unipoint software
was used to run the programme and analyse the chromatograms.
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Chapter 3
ACP-HCS interaction in β-branching
3.1 Introduction
Some type I Polyketide biosynthesis systems, for example producing mupirocin, thiomarinol,
kalamanticin, or myxovericins, are found to incorporate a branch on the third (i.e. β) carbon
in the growing polyketide chain, referred to as a β-branch. This β-branching mechanism is
thought to be catalysed via an “HMG-CoA synthase (HCS) cassette”, consisting of an HMG-
CoA synthase homologue and further auxiliary enzymes. In the mupirocin system the HCS
cassette is a set of 5 proteins of which MupH (the HMG-CoA synthase homologue) is the first
enzyme to interact with an acyl carrier protein (ACP) from the MmpA subunit. This interaction
between ACP and MupH initiates the β-branching reaction.
At the start of the present work little was known about the HCS cassette structure and func-
tion or how it interacts with the proteins in PKS? It was not understood what allows MupH
to recognize the ACPs with substrates for β-branching, as opposed to the several other ACPs
involved in a typical PKS pathway where branching is not required. We also did not know
whether HCS proteins have a subtype or if they always work as one set of only five proteins as
found in the mupirocin cluster. However, a recent study of the myxovirescin system (Simunovic
et al. 2006) shows two HCS clusters involved in β-branching at two position in the synthesis
pathway. These two stages are catalysed by two non-complimentary pairs of HMG-CoA syn-
thase homologue and ACP interactions, which suggests the possibility of HCS subtypes. In a
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study of the curacin system, it was found that the HCS proteins can also work in conjunction
with a halogenase. This halogenase activity adds a halogen (chlorine in case of curacin) on the
4th (γ-carbon) carbon of the growing polyketide chain (Busche et al. 2012).
A number of questions arise. 1) How different are the ACPs which interact with the HCS
cassette from other ACPs found in the pathway? 2) Is it possible to predict the molecular
features responsible for the ACP-HCS recognition? 3) And can these molecular features be
exploited for the engineering of β-branching function in mupirocin biosynthesis pathway or
other systems? I have used computational methods to address these exciting questions. The
work started using the preliminary data available from Prof. Christopher M. Thomas lab.
In a sequence analysis carried out by Dr. Anthony Haines on the ACPs from various PKS
systems, in β-branching ACPs a conserved tryptophan motif is found (Figure 3.2) at the position
6 residues downstream of the catalytic serine. This position is not found to be conserved in
the non-branching ACPs. It was also found that upon mutating this conserved tryptophan to
leucine in the mupirocin system the production of pseudomonic acid A is significantly lowered.
Thus, it was hypothesized that this conserved tryptophan could be the recognition motif. These
preliminary observations lead Dr. Mathew Crump from the University of Bristol to solve the
solution structure of the ACP di-domain from module 6 of the MmpA subunit in the mupirocin
biosynthesis pathway. This NMR structure (PDB ID 2L22) has been used in the present work
to carry out the predictions on the ACP-HCS interaction mechanism.
3.1.1 HMG-CoA synthase cassette
The HCS cassette in the mupirocin biosynthesis pathway, is a set of 5 proteins consisting
of an ACP (mACPc), a 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase homologue
(MupH), a decarboxylase (MupG) and two proteins (MupJ, MupK) from the crotonase super-
family. MupH homologues, our focus here (Wu et al. 2007), are found in various polyketide
biosynthesis pathways and are thought to be involved in β-branching mechanisms along with
the other enzymes in the HCS cassette. It is hypothesized that acyl carrier proteins from the
ACP di-domain (ACP-mupA3a and ACP-mupA3b), in the MmpA subunit of the mupirocin
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biosynthesis pathway, make the first point of contact with the MupH, initiating the β-branching
reaction. This interaction between the ACPs and MupH is thought to be governed by a set of
specificity determinants in the interacting residue pairs, which allows the ACPs involved in the
β-branching systems to recognise and interact with the proteins in the HCS cassette. To un-
derstand better what governs the interaction between the ACPs and MupH, a structural model
of the ACP-mupH complex determined either through experimental or computational methods
could help to design mutagenesis experiments. The solution structure for the ACP-mupA3ab
di-domain has been recently resolved (PDB ID 2L22), however there is no structure available
for MupH. To predict a reliable structure of MupH and to understand its structural properties it
was necessary to first understand the structural properties and the reaction mechanism catalysed
by its homologue HMG-CoA synthase.
3.1.1.1 HMG-CoA synthase reaction mechanism
HMG-CoA synthases (EC 2.3.3.10) are 42 KDa proteins found in a wide range of organisms
from bacteria to mammals and play a central role in fatty acid, polyketide, and isoprenoid
biosynthesis. The enzyme belongs to the thiolase superfamily and can be broadly classified into
the bacterial isoforms, the eukaryotic cytosolic isoforms and the mammalian specific mitochon-
drial isoform (Shafqat et al. 2010).
HMG-CoA synthase catalyses a three step reaction that involves a conserved Cys-His-Glu
catalytic triad and an acyl-enzyme intermediate. As in Enterococcus faecalis HMG-CoA syn-
thase (PDB Id 1X9E) the first step is a deacetylation of the substrate Ac-CoA, H233 is thought
to act as a catalytic base or H-bond donor for the nucleophilic C111, which attacks the carbonyl
carbon of Ac-CoA , thereby transferring the acetyl group to the Cys-S atom and releasing the
reduced CoASH (Figure 3.1) (Steussy et al. 2005).
In the second step, the methyl group of acetylated-Cys is deprotonated by the general
base G79 to form a carbanion which attacks the distal (β) carbonyl of the incoming AcAC-
CoA (second substrate), following the condensation of Ac-Co and AcAC-CoA forming an
enzyme:HMG-CoA intermediate.
In the final step the resultant enzyme:HMG-CoA intermediate is hydrolyzed to release the
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Figure 3.1: The reaction mechanism of HMG-CoA synthase. proposed in (Steussy et al. 2005)
.
product HMG-CoA and regenerate the reduced Cysteine. G79 is shown to mediate the hydrol-
ysis step. The similar reaction mechanism is also observed in Staphylococcus aureus, Brassica
juncea and Human HMG-CoA synthases (Theisen et al. 2004; Shafqat et al. 2010).
It is assumed that the β-branching mechanism of MupH would be similar to that of HMG-
CoA synthase and thus can be used to guide the modelling.
3.2 Results
3.2.1 ACP sequence analysis
The initial sequence analysis carried out by Dr. Anthony Haines on the seven well-characterized
PKS clusters known to be involved in β-branching (Figure 3.2) revealed the presence of a con-
served tryptophan 6 residues downstream of the catalytic serine. A W was not seen at this posi-
tion in the non-branching ACPs. Dr. Haines further used the sequence motif (DSXXXXXW) as
a search pattern for PHI-BLAST and found further ACPs that he confirmed from the literature
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Figure 3.2: Alignment of the ACP sequences from HCS cassette containing systems provided by Dr.
Anthony Haines. The conserved W is indicated by a *.
were associated with β-branching (Haines et al. 2013). This sequence motif predicted ACPs
from all the known systems involved in β-branching with the exception of two ACPs from vir-
giniamycin and leinamycin clusters each. Which suggests that although this sequence motif is
a strong predictor of β-branching associated ACPs it might not be enough to predict all of them.
Therefore in the present study a stronger predictor, based on the statistical method of Hidden
Markov models (HMM), was developed to classify ACPs into β-branching and non-β-branching
types.
The sequences provided by Dr. Anthony Haines were used to build HMMs using 38 and
178 sequences from 15 well characterised pathways for the β-branching and non-β-branching
ACPs respectively. These models were tested using a test set of ACPs (provided by Dr. An-
thony Haines) from other clusters which were not part of the training set. These results were
plotted on a graph of non-β-branching HMM score against β-branching HMM score (Figure
3.3). The graph was divided by the y = x line where the models predict an ACP as having the
same likelihood of being a β-branching ACP or standard ACP. The majority of ACPs from the
remaining clusters with at least one identified β-branch-associated ACP locate to one or other
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of these clusters (Figure 3.3).
β-branching ACPs from the virginiamycin cluster were identified as the outliers which are
just above the y = x line and adjacent to the ‘branching’ cluster. Other outliers were the
two β-branching ACPs from the leinamycin cluster one of which was just below the line and
the other actually fallen within the non-branching cluster. Except for leinamycin, classifying
ACPs using HMMs agrees with the available information about their likely presence in the β-
branching or non-β-branching modules. The model for non-β-branching ACPs (standard) was
used to fetch the ACP sequences from the UniProtKB/TrEMBL (20127441 seq) and Refseq
microbial (6408654 seq) databases, database version on 9th March, 2012. I developed a couple
of Perl scripts (see Appendix I) to remove all the sequences which were shorter than 60 aa or
duplicates or sequences without the phosphopantethinylated serine which resulted in a set of
16,490 unique sequences. To ensure that these sequences cover the full length of the model,
they were extended by 7 residues on both the ends. The extended sequences were scored using
both the HMM models and a scatter diagram was plotted (Figure 3. Scatter diagrams showing
the separation of ACPs into two clusters by their fit to the β-branch-associated ‘branching’ ACP
HMM and the non-branching ‘standard’ ACP HMM. (b)). In Figure 3.3 the scatter plots shows
the separation of ACPs into two clusters by their fit to the β-branch-associated ‘branching’ ACP
HMM and the non-branching ‘standard’ ACP HMM. These scatter plots were rendered by Dr.
Anthony Haines using the data provided by the HMM analysis carried out by Rohit Farmer (this
graph is also presented in (Haines et al. 2013)).
The newly found ACPs in the screen could be classified as likely β-branching or non-
branching. On the graph, close to the y = x line, an HMM score of above 45 represents the
ambiguous regions where the branching state of an ACP cannot be predicted below 45 seems
to be indicative of non branching. One ACP from the leinamycin cluster was found in this re-
gion, the other in the non-branching region. The two β-branching ACPs from the myxovirescin,
cluster, which are associated with different MupH homologues, can be clearly identified. This
suggests that the HMM model can be used to identify the ACPs associated with the β-branching
but cannot be used to predict the ACP subtypes if they exist.
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Figure 3.3: Scatter diagrams showing the separation of ACPs into two clusters by their fit to the β-
branch-associated branching ACP HMM and the non-branching standard ACP HMM. (A) ACPs from 26
pks clusters with at least one known or predicted branching ACP. () Training set for HMM using known
branching ACPs. () predicted branching except (N) virginiamycin cluster branching ACPs and (×)
leinamycin cluster β-branch-associated module ACPs (♦) Training set for HMM using non-branching
ACPs () predicted non-branching ACPs. (B) 16,490 ACP-like sequences identified by screening the
TrEMBL and RefSeq protein databases using the standard ACP HMM. Sequences which did not pass
the branching HMM cut-off were conferred a score of 10 so they could be plotted. () branching ACP.
() unlisted variants in similar clusters (×) known branching, (H) predicted branching, identified in this
screen (+) ACPs which may add branches in a non-type I-pks pathway. (•) insufficient sequence context
or conflicting information. (N) predicted non-branching (·) not examined. Graph and parts of the figure
legend copied from Haines et al. (2013).
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>ACP-tmlD3a-59.8
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Figure 3.4: The ACP-tmlD3a sequence scored 59.8 against β-branching HMM model and would require
5 mutations at the positions 6, 7, 11, 14 , and 20 counting from the active site serine (0) to reach the
score 82.9 and 6th mutation at position 27 to score 85.7. Figure 3 .9 shows the relative positions of the
residues required to be mutated on the ACP-tmlD3a:MupH complex
3.2.1.1 Minimum changes required to shift ACP-tmlD3a from non-β-branching to β-
branching cluster.
It was observed in the HMM analysis that the β-branching ACPs and the non-β-branching ACPs
(standard) cluster in different zones, which raises a question as to the minimum changes neces-
sary to shift an ACP from standard ACP cluster to β-branching ACP cluster, as scored by the
HMM models? These mutations might allow us to make a non-branching ACP function like a
β-branching ACP.
To address this question I wrote a Perl script (Appendix I, Script A.3) to mutate each and
every position in the sequence to the other 19 proteinogenic amino acids. A non branching
ACP (ACP-tmlD3a) from the thiomarinol cluster was taken as the sequence of reference. ACP-
tmlD3a was chosen because experiments from Prof. Thomas group showed no mupirocin pro-
duction upon replacing ACP-mupA3a/b with ACP-tmlD3a/b. The script generated all possible
substitutions at each of the 67 positions in the sequence, giving 19 X 67 = 1273 sequences.
From the previous analysis it was observed that the β-branching ACP sequences typically
score in the range of 82.2 to 109.6 using β-branching HMM model (wacp.hmm). This suggests
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that if any sequence scores 82.2 or above using β-branching HMM model, should fall under
the β-branching cluster. Utilizing this observation the 1273 sequences were scored using β-
branching model thus generating a first generation of mutated sequences. The sequence with
the highest score was selected for the next generation of mutations and the process was iterated
till a score of 82.2 or above was reached. For ACP-tmlD3a it took 5 generations (iteration) to
reach the score of 82.9 and 85.7 in 6 generations.
This experiment suggests that it would need to make a minimum of 6 mutations at the
positions shown in Figure 3.4 and listed in Table 3.1, to shift the ACP-tmlD3a from the non-
branching ACP cluster to the β-branching ACP cluster. Unsurprisingly, the highest scoring
amino acid change in the first generation of mutated sequences was tryptophan (W). All the
other mutations were observed downstream from the active site serine are mainly towards helix
III (Figure 3.5). The same method could be applied to the other ACPs as well however, the
number of mutations (iterations) required may be different.
Table 3.1: Muations required for ACP-tmlD3a sequence to score more highly with the HMM trained on
branching ACPs than with the non-branching ACPs








3.2.2 ACP structure analysis
The NMR determined apo ACP-mupA3ab (PDB ID 2L22) structures consists of a typical four
helical bundle. The NMR experiments showed that the conserved tryptophan identified in the
sequence analysis lies buried in the ACPs core between helix I and helix II rather than forming
an exposed patch. The burial of the tryptophan inside the ACP core raised the question of how
this residue permits an interaction between the ACPs and the HMG-CoA synthase homologue.
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Figure 3.5: Mutations required reaching the score of 82.2 or above when scored with β-branching
HMM model mapped on the structure. ACP-tmlD3a (red) in complex with MupH (Blue) superimposed
on the mupA3a:MupH complex 1 from cluster 1. The residues displayed as sticks are the positions for
the mutations V44W, V65P, L52Y, S49I, A45I and T58A that are needed for the ACP-tmlD3a sequence
to score more highly in the HMM trained on β-branching ACPs than in the HMM trained on non-β-
branching ACPs (see Table 3.1)
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As mentioned earlier that on the basis of the W to L mutation experiments which showed a
substantial decrease in the pseudomonic acid A production.
The orientation of the tryptophan seen in ACP-mupA3a is almost perpendicular to that in
ACP-mupA3b, Figure 3.8 shows ACP-mupA3a and ACP-mupA3b superimposed on helix II,
however, both the configurations are in trans Figure 3.6 shows that the conformation of W is
consistent with the ensemble for each ACP. Figure 3.9 shows the 20 NMR structures of an ACP
homologue from the curacin system (PDB ID 2LIU). Figure 3.10 shows the structural compari-
son of the curacin ACPs (2LIU, 2LIW) with the mup ACPs. The tryptophan side chains can be
seen to form a continuum rather than being biased towards a preferred orientation. Notably in all
the above mentioned ACP structures the tryptophan side chain tends to orient similarly within a
given NMR ensemble but is different between ensembles. However, the curacin ACP (2LIU and
2LIW) ensembles are more similar to each other than ACP-mupA3a and ACP-mupA3b to each
other. Table 3.2 lists the rotameric values for the tryptophan side chain in the above mentioned
four ACP structures. The tryptophan side chain atom numbering scheme is based on the Rec-
ommendations for the presentation of NMR structures of proteins and nucleic acids (Markley
et al. 1998). Another notable difference in the ACP-mupA3a/b structure is the position of the
helix III (Figure 3.11).
Table 3.2: Backbone dependent tryptophan side chain rotameric values











mupA3a -62 -38.5 -158.8 77.3 -103.8
mupA3b -59.5 -54.7 -178.2 10.9 -170.6
2LIU -65.3 -36.5 -168.6 59.8 -118.6
2LIW -66.8 -34 -169.3 45.2 -132.4
These measured rotamer values for the tryptophan side chain atoms were compared with
the values given in the default set of the 2010 backbone-dependent rotamer library (Shapovalov
and Dunbrack 2011) from Ronald Dunbrack’s group. By looking into the Dunbracks rotamer
library it was not obvious what causes the difference in the orientation of the tryptophan as the
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Figure 3.6: The 20 ACP-mupA3a NMR models superimposed on each other. Tryptophan highlighted as
sticks.
calculated values lie within the rotamer probability distribution. To supplement the observation
the NMR structure of ACP-mupA3a/b had all side chains removed and the SCWRL4 software
(Krivov et al. 2009), which uses the Dunbrack rotamer library, was used to put the side chains
back on the ACP backbone. SCWRL4 placed the side chains at similar positions to those of
the original side chains in the NMR structure for both ACP-mupA3a/b, which suggests nothing
unusual about the W residues.
3.2.2.1 Affect of W to L mutation on ACP molecular dynamics
To investigate the possible effect of the W to L mutation on the structural dynamics of ACP-
mupA3a, molecular dynamics simulations of the wild type and mutant ACP in water were
carried out (see methods section 2.3.2.2) . Figure 3.12 shows the averaged root mean square
fluctuation (RMSF) of 20 simulations for wild and mutant type each. The RMSF values suggest
significantly greater motion in the mutant than in the wild type, with the largest effects being
around helix III and in the loop between helix I and helix II.
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Figure 3.7: The 20 ACP-mupA3b NMR models superimposed on each other. Tryptophan highlighted as
sticks.
Figure 3.8: ACP-mupA3a (green) and ACP-mupA3b (cyan) superimposed on helix II. Tryptophan high-
lighted as sticks
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Figure 3.9: Curacin ACP responsible for halogenase activity via β-branching mechanism (PDB ID
2LIU), NMR models superimposed on each other. Tryptophan highlighted as sticks.
Figure 3.10: Superimposed representative structures of ACP-mupA3a (green), ACP-mupA3b (cyan),
curacin ACPS 2LIU (magenta) and 2LIW (yellow). Tryptophan highlighted as sticks.
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Figure 3.11: Superimposed ACP-mupA3a (green) and ACP-mupA3b (cyan) highlighting the difference
in helix III position.
Figure 3.12: Graph of the average over 20 simulations of the root mean squared fluctuation (RMSF)
of the backbone calculated for each simulation of the wild type (blue) and W44L mutant (red) of ACP-
mupA3a. The error bars represent the least significant difference at the 95% confidence level; i.e. where
the error bars of the two lines do not overlap they are signifcant in a t-test with 95% confidence. Residues
29-35 (central part of the loop between helix I and helix II), 41, 44 (in helix II), 57-59 (N-ter of helix III),
and 64 (C-ter of helix 3) show significantly greater motion in the mutant than in the wild type, with the
largest effects being around helix III and in the loop between helix I and helix II. Graph reproduced from
Haines et al. (2013).
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3.2.3 MupH structure prediction
As the MupH structure was not available in the PDB database, homology modelling was used
to predict its three dimensional structure. A structural homologue from Staphylococcus auereus
(PDB ID 1X9E) was used as the template for the protein structure prediction as well as for
the docking of the mupirocin intermediate in the predicted structure (details in section 2.3.1.1).
The predicted structures were verified for their stereochemical qualities and energy minimized
to stabilise the docked ligand inside the active site (Figure 3.13). To verify the correct orien-
tation of the ligand inside the MupH active site the residues within 5 Å of the docked ligand
(Figure 3.14) were compared with conserved and functionally important residues in the MupH
homologue structures (Figure 3.15 ).
3.2.4 Similarity between MupH and HMG-CoA homologues in sequence
and structure
Despite the low level of sequence identity among MupH homologues, the key catalytic and sub-
strate binding residues mentioned in the literature are highly conserved (Figure 3.16). Residues
that are conserved and identified as important in the literature are listed in Table 3.3. The con-
served residues can be divided into four categories, (1) catalytic triad (2) residues responsible
for substrate orientation in the active site (3) tunnel residues (4) gate Keeper residues (Misra and
Miziorko 1996; Bahnson 2004; Theisen et al. 2004; Steussy et al. 2005; Shafqat et al. 2010).
3.2.4.1 Catalytic triad and the essential residues responsible for substrate orientation in
the active site
In the sequence and structure comparison of all the HMG-CoA homologue structures from
Staphylococcus auereus, Enterococcus faecalis and Homo sapiens used in this study and MupH,
the catalytic triad (Cys - His - Glu) is found to be conserved. The residues in the active site
responsible for the correct orientation of the substrate are also absolutely conserved with some
minor variation in MupH.
The acetyl moiety bound to the catalytic cysteine (Figure 3.18) is constrained by interactions
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Figure 3.13: Homology model of MupH complexed with the mupirocin intermediate based on the HMG-
CoA synthase X-ray structure from Enterococcus faecalis (PDB ID 1X9E).
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Figure 3.14: Residues within a 5 Å radius of the mupirocin intermediate. The residues of the catalytic
triad are shown as sticks, other active site essential residues are shown as lines with green backbone, tun-
nel lining residues are shown as spheres, the gate keeper residues are shown as line with cyan backbone.
The term catalytic triad, other essential residues, tunnel lining residues and the gate keeper residues are
further discussed in detail in the Section 3.2.4. C115 and E83 are placed close the β-carbon thus the











































































































































































































































































































































































































































































































































































































































































































































































































































































































HMG-CoA orthologue x x x
PDB ID 2WYA 1XPL, 1XPK 1X9E, 1YSL MupH
Active Site GLU 132 GLU 79 GLU 79 GLU 83
CYS 166 CYS 111 CYS 111 CYS 115
HIS 301 HIS 233 HIS 233 HIS 251
Other essential active site
residues
ASN 380 ASN 275 ASN 275 ASN 297
ASP 240 ASP 184 ASP 184 ASP 201
PHE 241 PHE 185 PHE 185 THR 202
SER 258 SER 201 SER 201 SER 217
SER 414 SER 307 SER 308 SER 329
LEU 88 ILE 37 ILE 37 LEU 39
Tunnel Residues TYR 200 TYR 143 TYR 143 PHE 149
TYR 262 TYR 205 TYR 205 TYR 221
PHE 304 PHE 236 TYR 236 PHE 254
TYR 382 TYR 277 TYR 277 MET 299
TYR 412 TYR 305 TYR 306 TYR 327
PRO 303 PRO 235 PRO 235 PRO 253
MET 307 MET 239 MET 239 MET 257
Gate Keeper Residues LYS 83 LYS 32 LYS 32 ARG 34
LYS 266 LYS 238 LYS 238 GLY 256
LYS 310 LYS 242 LYS 242 GLY 260
* Residues highlighted in bold are conserved and identified as important in the literature (Theisen et al.
2004; Steussy et al. 2005; Shafqat et al. 2010). The non-bold residues are from the alignment
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with Tyr 143, Phe 185, His 233, Asn 275, Ser 307 (Staphylococcus aureus, PDB ID 1XPK).
Tyr 143 and Phe 185 residues are in hydrophobic contacts with the ligand as depicted in Figure
3.15(A). In the MupH these residues are mutated to Phe 149 and Thr 202 respectively, however
they are still in contact (Figure 3.15(B)). The others are conserved, which may help to constrain
the acetyl moiety and the rest of the substrate in the PKS bound intermediate. It was hypoth-
esised that the orientation of the acetylated cysteine in the Staphylococcus auereus (PDB ID
1XPK) HMG-CoA synthase structure helps to form a hydrogen bond between the backbone
amide of Ser 307 and the carbonyl oxygen of the thioester for stabilizing the oxyanion formed
during the transfer of acetyl to the catalytic cysteine (Figure 3.1) (Theisen et al. 2004). In MupH
this Ser 329 is also conserved which suggests a similar role.
The HMG moiety of HMG-CoA occupies the catalytic pocket such that its β-hydroxyl group
hydrogen bonds to His 301 as in Human HMG-CoA synthase structure (PDB ID 2WYA) and
Asn 380 while the terminal carboxyl interacts with Glu 132 and the backbone amide of Ser
414 (Shafqat et al. 2010). In Figure 3.15(B), MupH His 251 and Asn 297 can be seen forming
hydrogen bonds with the β-hydroxyl group of the ligand. However, since there is no termi-
nal carboxyl in the mupirocin intermediate close to the corresponding Glu and Ser there is no
interaction found.
3.2.4.2 Tunnel residues
A set of hydrophobic residues populates the middle portion of the active site tunnel forming a
hydrophobic lining. No direct hydrogen bonds are made between the enzyme and the CoA as
it passes through this hydrophobic sleeve. MupH is also found to have similar residues (Figure
3.16) and the homology model indicates a hydrophobic interaction with the ligand along the
tunnel sleeve (Figure 3.15(A)). These residues seem to interact with the phosphopantetheine
arm of the CoA specifically, as the gate keeper residues are responsible for stabilizing the nu-
cleotide moiety in the CoA. In avian HMG-Coa synthase, several of these residues have been
mutated to leucine with only modest changes in enzyme kinetics.
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3.2.4.3 Gate keeper residues
In the standard HMG-CoA enzymes, the solvent exposed outer edge of the active site tunnel
is populated by a number of basic residues, Lys 32, Lys 238, Lys 242 (PDB ID 1X9E), which
hydrogen bond with ribose phosphate from the CoA moiety but not the phosphopantetheine
moiety. These residues are not found to be conserved in MupH as shown in the alignment
(Figure 3.16). This variation in the gate keeper residues may be because the likely substrate
of MupH, unbranched monic acid is directly attached to the catalytic serine of the ACP via
the phosphopantetheine arm and lacks the nucleotide moiety and associated phosphates that are
found in CoA.
Figure 3.17 represents the sequence alignment between the MupH orthologs as found by PSI
-blast search against the NCBI’s protein database for sequences with sequence similarity above
60% and with keyword polyketide in the query, to make sure that the sequences are true MupH
orthologs. The alignment highlights all the key conserved residues as found in the alignment
of HMG-CoA orthologs. The alignment also highlights the conservation of the residues among








































































































3.2.5 Proposed MupH reaction mechanism
The similarities between the sequence and structure of HMG-CoA synthase and MupH, and
the conservation of key catalytic residues, may suggest a similar reaction mechanism for both
enzymes. The acetyl moiety attached to mAacpC condenses with the β-ketothioester moiety
bound to PKS (i.e. mACP3a and mACP3b). In the proposed mechanism, MupH His 251 (cat-
alytic base) seems to attack catalytic Cys 115 which in turn would attack the carbonyl carbon of
Ac-mAcpC, thereby transferring the acetyl group to the Cys-S atom and releasing the mAcpC-
SH.
In the second step, the methyl group of acetylated-Cys is deprotonated by the general
base Glu 83 to form a carbanion which attacks the β-carbonyl of the incoming thioester moi-
ety of ACP-mupA3a/b bound intermediate (second substrate), followed by the condensation
of Ac-S-Cys and β-ketothioester moiety of the PKS bound intermediate, which forms an en-
zyme:glutaryl thioester. Ser 329 seems to play a primary role in the formation of an oxyanion
hole that stabilises the tetrahedral intermediate in this reaction (Wu et al. 2007). The resultant
enzyme:glutaryl thioester is hydrolysed to release the product glutaryl thioester and regenerate
the reduced cysteine. Glu 83 mediates the hydrolysis step.
The glutaryl thiolester is dehydrated by MupJ thus producing glutaconate intermediate,
which on MupK mediated decarboxylation gives the 3-methylbut-2-enoyl thioester moiety in


































































































































































































































































































































































































3.2.6 MupH and ACP (mupA3a and mupA3b) interaction
The modelled MupH and the NMR determined ACP structures were docked to predict the prob-
able interaction between them. The HADDOCK (Vries et al. 2010) program was used to carry
out the docking analysis in two different ways (as described in Section 2.3.4.1). In the first
method HADDOCK utilizes a set of active and passive residues in which it aims to maximise
the interaction of each active residue with as many of the atoms of all passive and active residues
as possible. Active residues should have a high degree of evidence that they are at the inter-
face of the complex, e.g. residues with high chemical shift perturbation during NMR titration.
Passive residues are typically residues with weaker evidence of involvement in the interface, or
surface exposed residues neighbouring the active residues. The definitions thus make no presup-
position that an interaction will occur and the system of ambiguous interaction restraints (AIR)
is used to optimise the interaction of the active residues with all other residues (see Section
2.3.4 for details).
The active residues were the catalytic serine (Ser 38) of ACP-mupA3a and Arg34, Leu 39,
Glu 154 and Ala 214 of MupH, these residues were chosen based on the expected position in the
MupH acive site tunnel opening of the phosphopantetheine, which must be covalently bound
to serine of ACP-mupA3a. Passive residues were residue contiguous with the active residues
and predicted by the program PIER as being part of the interacting interface (Table 3.4) . PIER
uses the physicochemical properties of the atomic groups at the protein surface. Here all the
residues for the ACP-mupA3a and MupH which had a PIER Value of 30 or above were defined
as interface residues. Figure 3.19 shows the docked state of MupH and ACP-mupA3a along
with the ligand inside the active site of MupH.
In the second method the docking of each of the ACP-mupA3a and ACP-mupA3b with
the MupH ligand complex was carried out using the HADDOCK webserver with a distance
restraint of 2.0 Å between the phosphorous of phosphopantetheine bound in the active site of
MupH and the OG of the serine (S38/142) residue of ACP-mupA3a or mupA3b. To anchor
the ligand in the active site, an additional restraint of 9.13 Å was placed between the sulphur
of the thioester linkage in the ligand and the Cα of the catalytic Cysteine (C115) of MupH.
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SER 38 ARG 34, LEU 39, GLU 154, ALA 214
Passive Passive
ALA 15, MET 17, LEU 18, TYR 19, ILE 40,
TYR 62, THR 63
LEU 30, PHE 35, LEU 38, GLY 153, GLY 155,
GLY 156, SER 168, GLY 212, ASP 213, ASP
215, SER 217, LEU 218, PHE 254, MET 257
Figure 3.19: The ACP (cyan) - MupH (green) complex structure predicted by HADDOCK. Yellow: ac-
tive residue on ACP, Purple: passive residues on ACP, Red: active residues on MupH and Blue: passive
reisudes on MupH . The ligand (sticks) shows the location and probable orientation of the phosphopan-
tetheine + mupirocin intermediate in the active site.
HADDOCK produced a single cluster for ACP-mupA3a and 3 clusters for ACP-mupA3b, each
cluster represented by four complexes.
3.2.6.1 Interface analysis
The residues at the interface of the ACP and MupH docked complex using distance restraints
were determined using a PyMol script (http://www.pymolwiki.org/) (Table 3.5). The inter-
acting pairs of residues between ACP-mupA3a/b and MupH were determined using the CON-
TAC module of WHATIF (Vriend 1990) (Table 3.6). Two of the ACP-mupA3b clusters mimic
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the binding seen in the ACP-mupA3a:MupH complex, whilst the other ACP ACP-mupA3b clus-
ter binds to MupH at the opposite side of the active site entrance (a rotation of approximately
180 degrees around the ligand bind site, see figure 3.20). Despite this variation, the residues
Ser 38/142, Val 39/143, Asp 59/163, Tyr 62/166, Thr 63/167 of ACPs ACP-mupA3a/mupA3b
were found at the interface of all 16 complexes, the latter three residues being on the surface of
Helix III, and S38 being the active site serine. A representative complex is shown in figure 3.21
with an emphasis on helix III residues and their corresponding interacting residues Arg 34, Met
257 and Arg 263 on MupH. The central position of helix III of the ACPs in the complex, higher
levels of conservation around this helix, and its shifted orientation compared to other ACPs all
point to it being critical to the recognition of the ACPs by MupH and its orthologues.
ACP-mupA3b MupH
Figure 3.20: The representative complex of MupH:ACP-mupA3b. The representative complex of
MupH:ACP-mupA3b from the cluster 1 (green) with the representative complex from cluster 2 super-
posed (cyan). The cluster 2 representative is similar in position to the binding orientation of cluster
3 and cluster 4 of MupH:ACP-mupA3b and of the representative cluster of MupH:ACP-mupA3a. The
docked states of ACP-mupA3b in cluster 1 are almost 180 degrees rotated around the ligand binding
pocket of MupH compared to the other clusters.
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Table 3.5: List of residues found at the interface of the predicted ACP-mupA3a:MupH complexes and of
predicted ACP-mupA3b:MupH complexes
MupH (total 16 com-
plexes, 4 with ACP-





















ARG 34 16 ARG 30 PHE 135 GLY 139
LEU 38 16 LEU 32 GLY 139 MET 140
LEU 30 15 SER 38 SER 142 SER 142
ALA 214 15 VAL 39 VAL 143 VAL 143
ARG 263 15 ALA 42 ASP 163 ASP 163
ASP 31 14 ARG 46 TYR 166 ILE 165
GLN 33 14 ALA 58 THR 167 TYR 166
ASP 215 13 ASP 59 THR 167
ASN 37 12 TYR 62 PRO 169
MET 219 12 THR 63
LEU 218 11 TYR 64
GLY 256 10 PRO 65







a Residues in common with the interface of the predicted complexes of the ACP-mupA3b:MupH
in cluster 1, 2 and 3 and the ACP-mupA3a:MupH cluster are highlighted in bold. In addition all
ACP-mupA3b clusters have G139 at the interface.
b Each cluster is comprised of 4 complexes, ACP-mupA3b clusters 2 and 3 bind MupH in a similar
orientation to ACP-mupA3a, ACP-mupA3b cluster 1 is rotated through 180 degrees around the































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.21: A representative complex with ACP-mupA3a. A representative complex with ACP-mupA3a
(red), polyketide intermediate bound to S38 in ACP (spheres) and MupH (blue) showing interface
residues on ACP V39, D59, Y62 and T63 and their interacting partners R34, M257 and R263 on MupH.
C115, H251and E83 are the catalytic triad in MupH.
3.2.6.2 Real value evolutionary trace and PIER analysis
It is commonly observed that functionally important residues such as catalytic residues are
evolutionary conserved within a protein family. This evolutionary pressure is also seen in the
residues which are involved in protein-protein interactions responsible for their function. There-
fore, the conservation of the interface residues predicted in the HADDOCK docking experiment
was determined using real value evolutionary trace analysis. Real value evolutionary trace anal-
ysis (Lichtarge et al. 1996) for ACP-mupA3a/mupA3b and MupH was performed using Evo-
lutionary Trace Viewer (Morgan et al. 2006) (http://mammoth.bcm.tmc.edu/traceview/
index.html). This trace gauges conservation within the context of the phylogenetic tree such
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that residues that are conserved within a clade but vary between them score highly as do to-
tally conserved residues (details in Section 2.3.3.1). The multiple sequence alignment for real
value evolutionary trace analysis was carried out using ClustalW with 95 and 75 sequences for
ACP-mupA3ab and MupH respectively. Figure 3.22 and Figure 3.23 show the real value evolu-
tionary trace scores mapped on a representative complex structure of ACP-mupA3a and MupH.
The scores are coloured through the spectrum from red to blue, with red indicating predicted
importance and blue lack of importance. The ACP is shown as a pink ribbon. The figure shows
three views of the same complex; Front View shows the hot (red) patch at the ACP+MupH
complex interface. Left view is the clockwise 90 degree rotation from the front view. And
the right view is the anti-clockwise 90 degree rotation from the front view. Right View also
shows a hot patch at the MupH structure. This hot patch could be a dimer forming interface as
the HMG-CoA homologues commonly exit as homodimers, Figure 3.23 shows the structure of
the HMG-CoA homologue dimer (PDB ID 1X9E) superimposed, on the MupH+ACP complex.
The strong evolutionary conserved patch at the interface supports the existence of MupH as a
homodimer.
Left View Front View Right View
Figure 3.22: Real value evolutionary trace of MupH homologues. The different view shows the func-
tional patch on the predicted interface of MupH. The left view is a 90 degree rotation anticlockwise with
respect to the centre, the right view a 90 degree rotation clockwise. Residues on the surface of the MupH
are coloured through the spectrum from red to blue, with red indicating predicted importance, blue lack
of importance, the ACP is shown as a pink ribbon.
The PIER values calculated in the previous step for MupH were also mapped on the struc-
ture and coloured through the spectrum from red to blue, Figure 3.24(A). It was interesting to
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Figure 3.23: HmgCoA synthase homo-dimer (grey) from Enterococcous faecalis (PDB accession code
1X9E) superimposed on the MupH:ACP-mupA3a complex 1 from cluster 1. Residues are coloured by
their real value evolutionary trace score, which highlights residues likely to be of functional importance;
a rainbow colouring is used from red (most important) to violet (least important). As well as highlighting
the ACP:MupH interface, the analysis also highlights some residues on the MupH surface that are distal
from the proposed ACP binding site; these are where most HmgCoA synthases form homo dimmers. (Y
62, D 59 and T 63 are identified as being in the top 5.71%, 22.85% and 23.80% respectively of residues
for evolutionary importance).
see that the residues predicted the important in the real value evolutionary trace analysis also
agree with the PIER calculations and similar hot and cold patches can be seen on the surface.
However, PIER scores show an additional hot patch on the left view which was not identified
in the real value evolutionary trace. For comparison the MupH homologues from kalamanticin
(BatC) and thiomarinol (TmlH) clusters were also submitted to PIER analysis Figure 3.24(B)
and (C) respective. The structures of BatC and TmlH were predicted using the same template
and alignment as that used for MupH and were superimposed on the MupH+ACP-mupA3a rep-





Left View Front View Right View
Figure 3.24: PIER analysis of MupH, BatC and TmlH. The different view shows the functional patch
on the predicted interface of (A) MupH, (B) BatC and (C) TmlH. The left view is a 90 degree rotation
anticlockwise with respect to the centre, the right view a 90 degree rotation clockwise. Residues on the
surface of the MupH are coloured through the spectrum from red to blue, with red indicating predicted
importance, blue lack of importance, the ACP is shown as a pink ribbon.
interface formation, including the additional hot patch of unspecified function.
3.2.6.3 Loss of function with Y to F/A mutation in ACP-mupA3a
The above mentioned docking results which were also supported by PIER and real value evo-
lutionary trace analysis emphasized on the importance of helix III for the formation of the
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ACP:MupH interaction. This helix III carried Y62 which was conserved in 95% of the β-
branching ACPs and it can be seen pointing towards MupH at the interacting interface and
possibly making a favourable methionine to aromatic contact, methionine aromatic interaction
were recently reported as important interaction in protein structure (Valley et al. 2012). M257
was conserved in all the MupH homologue studied except TaF (myxovirescin system). Muta-
genesis experiments were carried out by colleagues in Prof. Thomas group to mutate Y62 to
F and A in ∆ACP-mupA3b. Phenylalanine was the most commonly occurring residue at this
position in non branching ACPs. Mutating Y62 to F and A lowered the mupirocin production
by three to four folds and up to ten folds respectively (Haines et al. 2013).
3.2.7 BatC complementation failure
BatC is the MupH equivalent protein from the kalamanticin cluster and it was thought that it
should be able to complement MupH and produce the beta-branch in mupirocin. However,
the complementation experiments showed that batC expressed in trans in a ∆mupH strain
greatly decreases mupirocin production. Therefore, to answer the question of why BatC did
not complement MupH, bioinformatics and molecular modelling analysis was carried out us-
ing the previously modelled BatC structure. Assuming that ACP-mupA3a docks to BatC in
the same orientation as it docks to MupH, the BatC structure was superimposed on to the ACP-
mupA3a+MupH complex and the ACP-mupA3a+BatC model produced was analysed by CON-
TAC module from WhatIf package. The contacting residues found were conserved and similar
to the ACP-mupA3a+MupH complex (Table 3.7).
Since the contacting pairs of the residues in the BatC+ACP-mupA3a complex were found to
be similar to the MupH+ACP-mupA3a complex in the CONTAC analysis it was thought that it
is possible that due to superimposing the BatC structure on the MupH+ACP-mupA3a complex
the analysis was biased towards the similar positions. In order to address this issue modelled
BatC structure was docked to the ACP-mupA3a using the similar distance restraints as it was
used for the MupH+ACP-mupA3a complex. The BatC+ACP-mupA3a docked complex came
out to be almost 180 degree flip of the MupH+ACP-mupA3a complex. It was not clear why
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it happened as the BatC interface when superimposed on MupH+ACP-mupA3a complex was
visually similar. However, in the MupH docking to ACP-mupA3b one of the clusters out of the
four was similar to the BatC docking therefore, the 180 degree flip orientation was plausible but
it was not dominating. In BatC docking all the complexes from both the clusters had the same
orientation. To answer this question it was thought that it might be the electrostatic potentials
on the interface which are different for MupH and BatC. The electrostatic potential shows the
electrostatic properties on the surface of a molecule in solution. Therefore, for two molecules
to interact with each other they should have complementary electrostatic potential. Similar
potentials will obviously repel each other.
To test this hypothesis the APBS (Baker et al. 2001) plugin in PyMol was used in conjunc-
tion with PDB2PQR (Dolinsky et al. 2004). The electrostatic potentials were calculated sepa-
rately for MupH, BatC and ACP-mupA3a (docked as well as BatC superimposed on MupH+ACP-
mupA3a complex) and the structures were superimposed to their respective complexes for com-
parison. The orientation of the MupH or BatC was kept the same. Three figures were rendered
for each of the complex in three different orientations for the solvent accessible and the iso
surfaces. The first is the “front view”, which shows the interacting interface as flat as possible.
The other two are in left and right orientation around Y axis. The degree of rotations used were
slightly different for MupH and BatC in order to highlight their interesting features as far as
possible.
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The electrostatic potentials for both BatC and MupH were found to be very similar with
only a few subtle differences. Those few differences might be significant but it was difficult to
find any difference in the specificity of MupH and BatC based on the electrostatic potentials on
the protein interface.
3.2.7.1 Gain of function with L to M mutation in BatC complementation
The above mentioned docking and electrostatic potential analysis failed to project any strik-
ing difference between the interface of MupH with ACP-mupA3a compared to the equivalent
interface between ACP-mupA3a and BatC. However, a possible answer to the riddle was in
the previously determined contacting pairs of residues between the MupH/BatC and the mup
ACPs. CONTAC analysis was carried out twice using a different VDW distance to define a
contact each time (i.e. 0.25 Å and 1.25Å). Upon mapping those positions on a sequence align-
ment of MupH homologue from well studied systems it was revealed that the position 219 on
the MupH sequence alternates between methionine and leucine an (observation made by Prof.
C. M. Thomas). Interestingly TmlH, which successfully complements MupH, carried a methio-
nine whereas BatC which failed to complement MupH carried a leucine. Looking back at the
docked structure it was found that this position was at the edge of the interface and was found
to be interacting with the arginine 30 of the ACP-mupA3a in 2 complexes out of 4. This me-
thionine was not found in any of the 12 complexes with ACP-mupA3b. Figure 3.28 shows the
position of the residues found in the CONTAC analysis as well as the key residues interacting
with the ligand in the MupH active site. Mutating BatC M219L expressed in trans in the mup
cluster restored mupirocin production (Haines et al. 2013).
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MupH Front BatC Front ACP Front
MupH Left BatC Left ACP Left
MupH Right BatC Right ACP Right
Figure 3.25: Electrostatic potential mapped on the solution accessible surface of MupH, BatC and ACP.
BatC was superimposed on the MupH + ACP-mupA3a complex. The three different orientations (Front,
Left and Right ) were made to clearly show the mapped potentials at the interface. The scale at the
bottom shows the intensity of the negative (red) and positive (blue) potential.
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MupH Front BatC Front ACP Front
MupH Left BatC Left ACP Left
MupH Right BatC Right ACP Right
Figure 3.26: Electrostatic potential mapped as the iso surface on MupH, BatC and ACP. BatC was
superimposed on the MupH + ACP-mupA3a complex. The three different orientations (Front, Left and
Right ) were made to clearly show the mapped potentials at the interface. The scale at the bottom shows
the intensity of the negative (red) and positive (blue) potential.
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ACP Front
BatC Left BatC Right
ACP Left ACP Right
BatC Left BatC Right
ACP Front ACP Left ACP Right
Figure 3.27: Electrostatic potential mapped on the BatC and ACP-mupA3a docked complex. The ori-
entation of the BatC is kept same as that of the previous figures while the ACP can be seen as docked
in almost 180 degree flip orientation. Both the solution accessible surface as well as the iso surface are
shown in three different orientations (Front, Left and Right). The scale at the bottom shows the intensity

































































































































































































































































The aim of the present work was be able to identify β-branching protein in PKS cluster and to
elucidate the specificity mechanism involved in the ACP-HCS interaction, with a longer-term
goal being to selectively introduce β-methylation or other HCS modifications such as cyclo-
propane, as part of the re-engineering of polyketide biosynthetic pathways for novel purposes.
In the mupirocin biosynthesis pathway β-branching is initiated by the interaction between
mupA3ab tandem ACPs in module 5 of the MmpA subunit, with MupH, (the HMG-CoA ho-
mologue) in the HCS cassette. However, little was known about what governs this interaction.
Sequence analysis by Dr. Anthony Haines showed that branching ACPs possess a conserved
tryptophan six residues downstream of the catalytic serine but non-branching-ACPs do not.
NMR studies on the tandem ACPs from the mupirocin biosynthesis pathway showed that the
tryptophan and other highly conserved residues lie in the core (including L10/114, L14/118,
L18/122 and F31/135) of the ACPs rather than on or near the surface. These observations
raised the question as to what determines the specificity between the branching-ACPs and the
MupH in the HCS cassette? Is it just the core motifs which are responsible for this specificity,
if so how, or do the residues at the ACP-HCS interface also play some critical role?
In the present work, based on the previous preliminary data on the sequence analysis car-
ried out by Dr. Anthony Hains and the NMR structures solved by Dr. Matthew Crump, further
sequence analysis and molecular modelling was carried out to elucidate the specificity deter-
minants in ACP-HCS interaction. Hidden Markov models (HMMs) were created to describe
the set of branching-ACPs and the non-branching-ACPs, and were used to predict the clus-
tering pattern between the two classes. It was seen that the HMMs were able to separate the
branching-ACPs and the non-branching-ACPs into two distinct clusters with very few excep-
tions. The HMM models were also used to fetch more sequences from the public databases and
the newly found sequences were characterised as branching or non-branching. These HMM
models can be used for the annotation of newly found PKS clusters and the β-branching ACP
HMM is now in corporated into the SMART database. The HMM models were also used to
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calculate the number of mutations that would be required to shift a non-branching-ACP to a
branching-ACP cluster i.e. across the HMM score of 82. TmlD3-ACP from the thiomarinol
cluster would require 6 mutations, with the mutation of valine to the tryptophan found con-
served in the branching-ACPs being the first change.
The observation that the conserved tryptophan lies in the conserved core suggests that it
might be responsible for the packing and stability of the ACP structure. Molecular dynamics
simulations for the wild type and the mutant ACP in which the tryptophan was mutated to
leucine showed relatively high flexibility in and around helix III in the mutant as compared to
the wild type ACPs. Mutation studies carried out on T4 lysozyme structures have shown various
general properties of protein folding and stability. Mutation of residues packed in the core of
T4 lysozyme lowered the melting temperature of the protein whereas changes in the surface
residues had little effect. These core residue changes were from “hydrophobic to charged”
residue, M102K (PBB ID 1L54), “small to large” residue, A98F and A98W, “large to small”
residue, L99G (PDB ID 1QUD) and R95A disrupting various interactions made by arginine
(Rennell et al. 1991; Tokuriki and Tawfik 2009). A “large to small” residue change in the core
of the T4 lysozyme seems to be similar to the W44L change in the β-branching ACPs. And so
this suggests that we would expect W44L to destabilise the structure. Computational studies
on T4 lysozyme structures also showed that the mutations primarily caused backbone shifts
rather than changes in the side chain rotamers (Hurley et al. 1992; Dahiyat et al. 1997; Mooers
et al. 2003). Molecular dynamics simulations carried on β-branching ACPs have also showed
increased flexibility in the backbone atoms of the helix III.
Docking analysis of ACPs with MupH revealed this helix III to be at the ACP-MupH inter-
face. Helix III contains a tyrosine at the position 62 in ACP-mupA3a, which is highly conserved
amongst β-branching ACPs, and which was found to interact with a methionine in a cleft at the
MupH interface. This interaction is supported by a recent study done on methionine and aro-
matic residue interactions and their effect on protein structure stability (Valley et al. 2012).
Helix III in the HCS interacting ACPs was also identified to be important for halogenase activ-
ity in the curacin system (Busche et al. 2012), also mediating an interaction with an HMG-CoA
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homologue. Experiments done by colleagues in Prof. Christopher M. Thomas’ group mutated
Y62 on helix III in ACP-mupA3a to F and A in the ∆ACP-mupA3b strain and showed reduced
mupirocin production by three to four fold and ten fold respectively.
Cross complementation experiments from Prof. Christopher M. Thomas’group found that
MupH orthologues TmlH and BatC from thiomarinol and Kalimanticin clusters respectively
do restore MupH activity in an NCIMB 10586 ∆mupH strain. However, the pseudomonic
acid yield by BatC complementation is much lower than TmlH. Analysis of the predicted
MupH:ACP interface residues, along with sequence analysis by Prof. Chris Thomas, sug-
gest M219 as a specificity determining residue, being M in MupH and TmlH but L in BatC.
batC L218M was found to complement ∆mupH, with 3 fold more antibiotic production than
with wild type batC complementation. This observation leads to a further question, if there
exists a pair wise specificity between the branching ACPs and the HCS as well as a general
determinant of β-branching ACPs the global properties of branching ACPs then replacement
of ACP-mupA3ab with the ACP(s) from the kalimantacin system should either fail completely
or perform poorly. However, as the mutation in the BatC helped to enhance the favourable
interaction with the mupirocin ACPs analogous mutations on the kalimantacin ACP or on the
mupirocin ACP should be able to help from favourable interactions between them and MupH
or BatC respectively.
Thus it can be concluded that the conserved core residues in the branching-ACPs helps in
the correct packing of the branching ACPs. This packing helps the active site serine to present
the substrate to the MupH active site and directing the angle of helix III which acts as another
anchor at the interface. This two pin model in which the orientation of the active site serine acts
as one pin and the tyrosine on the helix III another pin provides the general specificity to the
ACP-MupH interaction. However, other residues found at the interface may be responsible for




Kalimantacin ACP swap in mupirocin cluster
4.1 Introduction
The predicted structure of the ACP-MupH complex, described in the previous chapter, high-
lighted various key residues important for the ACP-HCS recognition required for β-branching.
Tyrosine 62 on helix III in ACP-mupA3ab was predicted to be at the interface of the interacting
models. Mutating Y62 to F or A in the ∆ACP-mupA3b strain reduced mupirocin production
by four and ten fold respectively, as determined by HPLC. This loss in function confirmed the
importance of helix III of the β-branching ACPs for the formation of a functional complex with
an HCS protein. However, later experiments showed reduced complementation by batC (kali-
mantacin cluster) in a ∆mupH strain. Interface residues identified in the ACP-MupH complex
included residue 219 on MupH which was a methionine in MupH and TmlH (thiomarinol clus-
ter) but a leucine in BatC. BatC L218M has an improved ability to complement ∆mupH, with
three fold more mupirocin production compared to wild type BatC. This observation suggested
that although the β-branching ACPs usually have a conserved tryptophan in the core, and a Y on
helix III forming the interaction interface, there exists ACP-HCS pairwise subtype specificities.
This pairwise specificity can be observed in the myxovirescin system where there are two sets
of HCS cassettes that interact with their cognate ACPs.
Extending the observation that batC failed to complement ∆mupH in the mupirocin cluster
due to a difference in the interaction specificity, it seemed that swapping ACP-mupA3ab in the
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mupirocin cluster with the β-branching ACP(s) from the kalimantacin cluster should also fail.
However, it should be possible for complementation of ACP-mupA3ab by kalimantacin ACP(s)
upon changing the residues at its interface, or if the kalimantacin ACPs were expressed together
with the wild type batC in the mupirocin system. Thus here, the kalimantacin ACP (ACP-
K24a; K=kalimantacin, 2=second protein, 4=fourth module, a=first ACP) was amplified from
a purified DNA sample obtained from our collaborators. The idea behind selecting ACP-K24a
was that it was one of tandem ACPs similar to the branching ACPs in the mupirocin cluster and
it seemed to be performing only the addition of a methyl branch without any other modifications
that were present in the other β-branching sites in the kalimantacin cluster. Two host strains,
P. fluorescens ∆acp4 and P. fluorescens ∆mupH were used. The P. fluorescens ∆mupH strain
lacks mupH in the HCS cassette and was used to express mupH, batC and batC L218M in trans,
described in detail in section 2.4.1.
4.2 Results
4.2.1 Plasmid preparation and transfer for Suicide Mutagenesis
4.2.1.1 Amplification of DNA fragments for ligation into a pAKE 604 suicide plasmid
Replacement of the branching ACPs in the mupirocin pathway with kalimantacin ACP-K24a
was through homologous recombination via suicide mutagenesis. A pAKE604 plasmid was
used to clone DNA fragments from the mupirocin and the kalimantacin cluster. To ensure that
sequence amplified for ACP-K24a includes all the secondary structures for an ACP, a sequence
length equivalent to the length of the solved ACP-mupA3a structure was taken for PCR primer
construction. For homologous recombination to happen ACP-K24a needs to be attached to the
≈500 nucleotide long arms either side of the mupirocin cluster ACP-mupA3ab. The left and
the right arms were amplified from both the ends of the ACP-mupA3a sequence using the P.
fluorescens ∆acp4 strain as the template. The details of the PCR setup and the primers used are
described in section 2.4.4.
The amplified fragments were analysed using 1% agarose gel electrophoresis and were pu-
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rified using the GE Healthcare Life Sciences Illustra-GRX PCR DNA and gel band purification
kit. Figure 4.1 shows the purified fragments for the left arm, right arm and ACP-K24a on the
agarose gel. The concentration of the purified samples were quantified using the Nanodrop
instrument in order to calculate the volume of samples to be used in the Gibson assembly reac-
tion described later. Simultaneously, a pAKE604 vector was cut using two restriction enzymes
(HindIII and SalI) at the multiple cloning site and the concentration of the purified product was







Figure 4.1: Purified fragments for the left arm, right arm and ACP-K24a on agarose gel. The size of the
fragments include the homology regions required for Gibson assembly.
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4.2.1.2 DNA fragments ligation into pAKE604 using Gibson assembly
Gibson assembly is a method to ligate several DNA fragments in a single reaction (details in
section 2.4.6). In order to perform the ligation of the ACP-K24a to the two ACP-mupA3ab
flanking arms and the multiple cloning site of pAKE604, a Gibson assembly kit from NEB was
used. The DNA concentration calculated for ACP-K24a was 68.1 ng/µl, for the left arm it was
50.8 ng/µl, for the right arm it was 98.1 ng/µl and for the digested pKAE604 it was 121 ng/µl.
For the ACP-K24a of length 297 the volume required was 0.8 µl, for the left arm of length 487
was 1.5 µl, for the right arm of length 532 was 0.9 µl and for pKAE604 of length 7219 was
9.7 µl. Since the total amount of solution required for one Gibson assembly reaction was 20
µl which include 10 µl of the Gibson assembly master mix the total volume of the three DNA
fragments excluding vector was scaled down to 3 µl from 3.2 µl and the volume for the vector
was scaled down to 7 µl from 9.7 µl. Volume equal to two Gibson assembly reactions was
measured and split into three tubes of 13 µl, 14 µl, 13 µl each and were incubated at 45°C, 50°C
and 55°C respectively for one hour. The standard NEB manual protocol did not yield any ligated
product so an alternative method for Gibson assembly was tried. The reaction mix prepared for
the total volume of two reactions was divided into three tubes, which were incubated at three
different temperatures. The three temperatures were 45°C, 50°C (recommend by NEB) and
55°C. The contents of the three reaction tubes were then pooled into a single tube and the mix
was then used for transforming the freshly prepare E. coli DH5α competent cells (section 2.4.3
and 2.4.7) as recommended in the NEB Gibson assembly protocol. The idea behind pooling all
the content into one tube was to reduce the transformations to be done for each temperature, if
the Gibson assembly worked for any of the temperatures then the assembled plasmid should be
taken up by the competent cells and only the transformed cells would survive the kanamycin
selection. A disadvantage of this method is that which temperature(s) actually worked amongst
the three remains unknown.
The transformation plates showed fourteen colonies in total which were streaked to single
colonies. From the streaked plates fourteen colonies were picked, one for each of the original
fourteen streaks, and the PCR was performed using the left arm forward primer and the right
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arm reverse primer. Out of the fourteen samples, eleven gave DNA fragments of the required
size as analysed on 1 % agarose gel electrophoresis (Figure 4.2). Four of the eleven successful
PCR products were purified and two of these were sequenced using primers designed previously
by Dr. Joanne Hothersall, which bind to the region outside the multiple cloning site of the
pAKE604 plasmid. Of the two samples the forward and reverse reads for the second sample
showed the expected sequence. The validated second sample was used to transform freshly
prepared E. coli S17-1 competent cells.






Figure 4.2: Gibson assembly product on agarose gel. Eleven out of fourteen samples showed the right
size band of roughly 1.5 Kb in size. P. fluorescens NCIMB 10586 was used as control and the amplified
product contains both ACP-mupA3a/b.
4.2.1.3 Conjugal transfer of the suicide plasmids into P. fluorescens host strains
The suicide plasmid pAKE604 carrying the construct “left arm - ACP-K24a - right arm” in E.
coli S17-1 was transferred to two different P. fluorescens strains through mating. The strains
were P. fluorescens ∆acp4 and P. fluorescens ∆mupH (details in section 2.4.8). Trans conjugants
were subjected to PCR using the ACP-K24a specific primers to detect the successful transfer of
the plasmid into P. fluorescens ∆acp4 and ∆mupH cells.
For P. fluorescens ∆acp4 trans conjugants eight colonies were subject to PCR along with
non mated P. fluorescens ∆acp4 and transformed E. coli S17-1 strains as negative and positive
controls respectively (Figure 4.3). All the colonies as well as the positive control showed the
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presence of the plasmid sequence.





Figure 4.3: Validation of P. fluorescens ∆acp4 trans-conjugants. All the eight colonies as well as the
positive control showed the presence of the plasmid carrying the ACP-K24a. No band was detected for
the negative control.
For P. fluorescens ∆mupH trans-conjugants ten colonies were subjected to PCR along with
a transformed E. coli S17-1 strain as a positive control (Figure 4.4). Nine out of ten colonies as
well as the positive control showed the presence of the plasmid sequence.





Figure 4.4: Validation of P. fluorescens ∆MupH trans-conjugants. Nine out of ten colonies as well as
the positive control showed the presence of the plasmid.
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4.2.2 Sucrose selection and excisant validation
After mating P. fluorescens integrants were grown overnight in L-broth without any selection
(see details in section 2.4.9). This would have allowed the integrated plasmid to excise out,
leaving behind the desired gene integrated into the chromosome. These overnight cultures were
further grown on the L-agar plates with sucrose selection. The pAKE604 plasmid contains
a sacB gene, which confers sensitivity to sucrose, so that if the plasmids have excised out
successfully then the cells would grow, otherwise the sacB gene would cause accumulation of
the polymer levan in the periplasm which is toxic to Gram negative bacteria. The excision
of the plasmid can occur in two ways, by leaving the ACP-K24a behind integrated into the
chromosome or by the host chromosome reverting back to its original state. To detect that
ACP-K24a was successfully integrated into the chromosome and not taken away at the time of
excision, the colonies which grew on ampicillin and not on kanamycin plates were subjected
to PCR with ACP-K24a specific primers. For P. fluorescens ∆acp4 excisants, twelve colonies
were subjected to PCR and the products were analysed using 1% agarose gel electrophoresis;
the right size band was detected in five out of twelve excisants. Assuming that the plasmids
excised correctly and were destroyed in the cell, these five bands suggest that ACP-K24a has
integrated into the chromosome in the mupirocin cluster (Figure 4.5).





Figure 4.5: P. fluorescens ∆acp4 integrants validation. Five out of twelve colonies as well as the positive
control showed the presence of the ACP-K24a.
The previous steps validated the integration of the ACP-K24a into the P. fluorescens ∆acp4
chromosome but it did not detect whether the integration happened at the correct position in the
mupirocin cluster. In order to validate the integration of the ACP-K24a at the correct position
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another PCR was carried out on the five integrants. Primers were used that bind to positions
outside the left and right arms, which had been previously designed by Dr. Anthony Haines.
P. fluorescens NCIMB 10586 and P. fluorescens ∆acp4 were used as the controls, with P. fluo-
rescens ∆acp4 expected to give a band equivalent in size to the five integrants since they have
a single ACP at the branching position, whereas P. fluorescens NCIMB 10586 would give a
slightly bigger band because of the two tandem ACPs (Figure 4.6).






Figure 4.6: Five P. fluorescens ∆acp4 integrants tested for correct location of ACP-K24a integration.
The primers bind at locations outside the 500 bp arms thus the five integrants as well as ∆acp4, have
a band closer to 1.5 kb, which includes two arms of ≈1 kb and an ACP of 331 nucleotides while the
wild type P. fluorescens NCIMB 10586 which contains two ACPS and the linker region between them has
slightly larger band. The primers also seem to mis-prime some where in the chromosome thus generating
a smaller band of ≈500 bp.
The PCR product for the five integrants were further subjected to restriction digests using
enzymes Blp I and Stu I. Blp I cuts approximately at the middle of the ACP-K24a but does
not cut anywhere in ACP-mupA3a and Stu I cuts at the middle of the ACP-mupA3a as well
as at the rear ends of the two arms. The restriction digest fragments were analysed with 1%
agarose gel electrophoresis, an uncut fragment was used as the control. Two samples verified
by the restriction digestion of the PCR products were used for sequencing in the forward and
reverse direction using the primers used in the previous step. Glycerol stocks of the two verified
samples (two replicates for each i.e. ∆ 4-1a (tube 1 and 2) and 4-2b (tube 1 and 2)) were stored
at -80°C.
For P. fluorescens ∆mupH trans-conjugants sucrose selection was performed following the
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Figure 4.7: Restriction digestion of the five P. fluorescens ∆acp4 integrants using restriction enzymes
Blp I and Stu I. BlP I cuts approximately at the middle of the ACP-K24a and Stu I cuts approximately
at the middle of the ACP-mupA3a as well as at the rear ends of the two arms. The first five wells shows
ACP-K24a cut approximately at the middle whereas the next five shows the fragments which were cut
only at the rear ends of the arms. The last well shows the actual size of the uncut DNA fragment.
same steps as for the P. fluorescens ∆acp4 trans-conjugants. To validate the excisions and in-
tegrants, nine samples were subjected to PCR using the primers designed to bind at the region
outside the two arms (Figure 4.8), one of which was of the right size and was sequenced. Com-
pared to the treatment of the P. fluorescens ∆acp4 integrants, the steps of PCR with ACP-K24a
specific primers and subsequent restriction digestions were excluded, because running a PCR
using only the outer primers and sequencing the PCR products gave an equivalent result in
fewer steps and less time. Glycerol stocks of the sample (two replicates i.e. ∆ H-6d (tube 1 and
2)) were stored at -80°C.
4.2.3 Overlay Bioassay to test for antibiotic production in the constructed
strains
To test the two hypothesises that the ACP-K24a from the kalimantacin cluster would not work
with MupH but will work with BatC, three previously prepared pJH10 plasmids containing
mupH, batC or the batC L218M mutant were expressed in trans in the newly constructed P.
fluorescens ∆H-6d strain. One pJH10 plasmid containing batC was also expressed in trans in the
newly constructed P. fluorescens ∆4-1a strain (see details in section 2.4.10). Since, ∆H-6d strain
lacks mupH in the HCS cassette, the in trans expression of any of mupH, batC or batC L218M
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Figure 4.8: Nine P. fluorescens ∆mupH integrants tested for correct location of ACP-K24a integration.
The primers used bind at the locations outside the 500 bp arms only one out of nine showed the band
closer to 1.5 kb which includes two arms of ≈1 kb and an ACP of 331 nucleotides while P. fluorescens
∆mupH which contains two ACPS and the linker region between them has slightly larger band along
with all the other samples which probably reverted back to the wild type state during plasmid excision.
The primers also seem to mis-prime some where in the chromosome thus generating a very faint band of
≈500 bp.
mutant in this strain would test for a functional interaction with ACP-K24a. It was thought that
the interaction of ACP-K24a with mupH, whether in trans or on the chromosome (as in ∆4-1a
strain), would be unfavourable. On the other hand the interaction of ACP-K24a with batC in
trans should be favourable in the ∆H-6d strain and it should also have some favourable effect
in ∆4-1a strain, since the batC expressed in trans would compete with the chromosomal mupH
to interact with ACP-K24a. The three plasmids that were previously transformed into the E.
coli S17-1 strain were used for the conjugal transfer of the plasmids into P. fluorescens ∆H-6d
and 4-1a cells. The trans-conjugants were purified over minimal media to get rid of the E. coli
S17-1 strain and were validated by plasmid extraction and gel electrophoresis.
For the bioassay three replicates of each strain were spotted and the antibiotic efficacy was
measured as the diameter of the clearance zone, excluding the size of the central disc. The
average of two diameters was calculated and the standard deviation between the averages of
the three replicates were plotted as error bars in a bar graph (Figure 4.9). A bioassay for each
sample was carried out with and without IPTG induction.
The bioassay results showed the ∆4-1a strain had a diameter for the clearance zone that
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Figure 4.9: Bioassay results for in trans expression of mupH, batC or the batC L218M mutant with and
without IPTG induction. P. fluorescens NCIMB 10586 is the wild type mupirocin producer, ∆H-6d and
∆4-1a carry ACP-K24a in place of mupA3a&b-ACP in the mupirocin cluster. ∆H-6d lacks chromosomal
mupH. mupH, batC and batC L218M were the genes on pJH10 plasmid expressed in trans. Error bars
represents the standard deviation of three replicates with two diameters measured per strain.
was 50 % of WT. A similar change was observed in the ∆H-6d strain which does not contain
chromosomal mupH in the HCS cassette. Upon expressing batC in trans in the ∆4-1a strain the
clearance zone diameter was found to be almost half of that of the ∆4-1a strain without batC,
both with and without IPTG induction. Expressing mupH in trans in the ∆H-6d strain gave a
clearance zone slightly smaller with IPTG and much smaller without IPTG, as compared to the
∆4-1a strain. The clearance zone of the ∆H-6d strain with in trans expression of batC did not
differ greatly from ∆H-6d with mupH in trans. A similar clearance zone was also observed for
∆H-6d with batC L218M expressed in trans. Figure 4.10 shows the plate bioassay for one of

















































































































































































4.2.4 HPLC analysis for in trans expression of MupH, BatC and BatC
L218M mutant
In order to detect pseudomonic acids produced by the in trans expression of mupH, batC or
batC L218M in P. fluorescens ∆H-6d and ∆4-1a strains, HPCL were performed. P. fluorescens
NCIMB 10586 and P. fluorescens ∆H-6d and ∆4-1a with blank pJH10 plasmid were used as
controls (see methods section 2.4.11). The chromatograms plotted in Figures 4.11 to 4.18 were
zoomed in on the 5 min to 30 min retention time. Figure 4.11 shows a representative chro-
matogram of the elution profile of pseudomonic acid A produced by P. fluorescens NCIMB
10586. For the three replicates the average retention time and peak area were 20:21 min and
48273600 respectively. Figures 4.12 to 4.15 show the chromatograms of the elution profile for
the products produced by P. fluorescens ∆H-6d strain , and Figures 4.16 to 4.18 show the chro-
matograms of the elution profile for the products produced by P. fluorescens ∆4-1a strain. No
observable peak was detected for any of the known pseudomonic acids in any of these figures,
however, a distinct peak for an unknown product was observed at around 17:57 min retention
time for all P. fluorescens ∆4-1a strain (Figure 4.16 to 4.18).
Figure 4.11: HPLC trace for P. fluorescens NCIMB 10586.
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Figure 4.12: HPLC trace for P. fluorescens ∆H-6d strain with blank pJH10 plasmid.
Figure 4.13: HPLC trace for P. fluorescens ∆H-6d strain with mupH expressed in trans.
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Figure 4.14: HPLC trace for P. fluorescens ∆H-6d strain with batC expressed in trans.
Figure 4.15: HPLC trace for P. fluorescens ∆H-6d strain with batC L to M mutant expressed in trans.
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Figure 4.16: HPLC trace for P. fluorescens ∆4-1a strain
Figure 4.17: HPLC trace for P. fluorescens ∆4-1a strain with blank pJH10 plasmid.
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Figure 4.18: HPLC trace for P. fluorescens ∆4-1a strain with batC expressed in trans.
4.2.5 Molecular dynamics simulation of ACP-mupA3a+MupH complex
Molecular dynamics simulations were carried out on the ACP-mupA3a + MupH complex ob-
tained from HADDOCK (see section 3.2.6). The starting conformation was setup to mimic the
condensation stage in the HMG-CoA reaction mechanism (see Figure 3.1), with monic acid at-
tached to the phosphopantetheine arm of ACP-mupA3a and acetyl attached to C115 of MupH,
to mimic the β-branching step. Three independent simulations were run for 50 ns each. Coor-
dinate files were extracted at every 4 ns from the trajectory and residues in ACP-mupA3a that
were within 5 Å distance of M219 (MupH) were selected. Residue R30 and L32 were found to
be highlighted in all the frames whereas Y62 and P65 were highlighted in most of the frames
(Figure 4.19).
Based on this observation it was proposed that either these positions or their neighbours were
responsible for the ACP recognition specificity associated with position M219 of MupH and its
homologues. To test this hypothesis and plan mutagenesis experiments Dr. Anthony Haines
segregated the β-branching ACPs from well characterised clusters into two groups based on
whether their cognate HCS protein carried a methionine or a leucine. Figure 4.20 shows the
alignment of the two groups. Figure 4.21 shows sequence logos built from these alignments.
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Figure 4.19: ACP-mupA3a +MupH complex interface refined by molecular dynamics simulation. Blue:
complex I of the ACP-mupA3a +MupH docked complex; Green: first frame (10 ps) of the ACP-mupA3a
+ MupH simulation; Grey: last frame (50 ns) of of the ACP-mupA3a + MupH simulation. R30 and L32
were highlighted within 5 Åof M219 in all the frames whereas Y62 and P65 were mostly highlighted.
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Neither the R30 or the L32 position equivalent or their neighbouring positions were differen-
tially conserved in one set compared to the other.
>bacL3a    AVLTESLADVLYMDADDIDADDTFIDIGMDSITGLEWIKSVNKAYGTSLTVTKVYDYPTIRQFAAFL
>bacL3b    DELSKALADVLYMERHEVDIDEAFIDLGMDSITGLEWIKAVNKRYGTDCNVTKVYDYPTIRQFADFL
>tmlA3a    MFLRESLASALMMSADEITDNTMFSDIGLDSIVGVEWVRAINDKYHLPMAVDLVHEHPSINRLYDYL
>tmlA3c    EFLRTSLANILMMGVQEIKPTRCFADFGLDSITGMEWVKLINQTMQLGLDADIVYEHNTLERFSLYI
>tmlA3b    DTIVTTLADALLLDKEDIRAQSRFVDLGLDSIVGVEWVRAINKLYDINIEANAVYEYTTAEDFCHYL
>mupA3a    QFLRQSLAAMLYCEPGQIRDGSRFLELGLDSVIAAQWIREINKHYQLKIPADGIYTYPVFKAFTQWV
>mupA3b    DYLKQSLGELLFLDPGQLRSGAQFLDLGMDSVTGTQWMRGVSRHFSIQLAADAIYTWPTLKSLADEV
>elaK4a    ETLRKSLALALGLEESEILADKNFIDLGLDSIMGVEWIKSINTAFGIELGAARLYDYPELRKLAAFI
>elaK4b    EELTRSLAGALSLLPGEISPDRNFVDMGLDSIIGVEWIHQINARYGTAVIVTKIYDHATINEFAKFL
>taiL5a    PALRALLADALYVDAQTIDANAEFVSLGVDSIIGVEWIDAVNRRFGVALSATTIYDHPTLSSFARHL
>taiL5b    AALRETLADALFADAHDIEPDATFQDLGVDSIIGVEWVQAINRRYGTSIPAPQIYQYPTLRAFGGLV
>taiE3a    AFLAGSLAAALMATTDEIDREQTFNALGVDSIVGVEWVRAINDRYGTALPATVIYDHPSVRAMARHV
>taiE3b    AHLVDSLAQALYVEPAEIGVDQPFAELGLDSIVGVEWITAVNRRFGTALPAVAIYDHPSVVALARFV
>difL2a    EELRTSLADILFLSPEDIDADEPFIDMGLDSIIGVEWIQSVNKTYHTEVTANKVYEHPTLEELAEYI
>difL2b    KELKDSLADILFLKPEDIDEHEAFIEMGLDSIIGVEWVQSINKTYQASITANLVYEYPTIATLAGYL
>etnD1a    QELTGSLAEALFMDRADVEPDRPFMELGLDSIVGVEWVRVINTTYGLSLPATCVYDHPTIRRLAAHL
>etnD1b    EGLTSSLAEALYTDRAEIDPDRPFTELGLDSIVGVEWIRAINKAYGLSLPATCVYDHPTIGRLARHL
>etnD1c    VELAKSLADALYMEPGDVDVDRPFVDLGLDSIVGVEWTRAINKAYGVSLPATRLYDHSTVRRLAAHL
>etnE3a    GRLRASLARALCTDEADLDQDAVFNDLGLDSVIGVEWARSIERELDVPLTASTLYDHPTLTRLSAHV
>etnE3b    AGLTQTLAAALYADASDIDPDRLFVDHGVDSVISVEWVRRINATFHLDLKATVLFDHPTIHQLAEHL
>onnB3a    QELRRFLAEELHMTPDMVEEDIEFVKMGLDSIIAVSWVQKINQAFGLALGATIVYTYTNLLDLLQHI
>onnB3b    VKLRQLLAEELHMTPEAVEDDVSFVEMGLDSIIAVSWIQKINQAYGLSLEATVVYTYTTLLDLAQHI
>bryB4    SLLRESLALELDLDADELDESISFTELGLDSINGVIWIRKINSHYELSITVSKVYDYPNIIELAEFL
>bryA4    TMLRESLEFELDIEPGMLDELKPFTDLGLDSINGVTWIRKINSHYGLSMTATKVYDYPNIIELAEFL






>kal3-3   MELAESLAKVLYLENDDVDMDTAFSELGLDSVTGVGWIRELNQRYGTSLGASQLYDYPTIKVLASHL
>kal3-4   AELCEMLSSTLFMPVTAADCEKPFSELGVDSIIGLEWIQAVNRRYQTSLTASMLYQHATLKRFTLFL
>jamE1b    QVLKEQLAEALYTEESEIAEDQKFVDLGLDSIVGVEWTTTINQTYNLNLKATKLYDYPTLLELAEYI
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Figure 4.20: Sequence alignment of the β-branching ACPs segregated into two groups based on their
cognate HCS protein. Green/Yellow: residue position which was always/mostly highlighted with 5 Å of




Figure 4.21: Sequence logo built on the alignment of the β-branching ACPs segregated into two groups
based on their cognate HCS protein. Arrows shows the residue positions which were always/mostly
highlighted with 5 Å of M219 in all the frames of molecular dynamics simulation.
4.3 Discussion
These experiments were designed to gain a deeper understanding of the interaction of β-branching
ACPs with the HCS proteins by replacing the mupirocin β-branching ACPs with one from the
kalimantacin cluster. It was proposed in the previous chapter that β-branching is a phenomenon
that is dependent on the recognition specificity of a subclass of ACPs by proteins in the HCS
cassette and it was demonstrated that this subclass required a conserved tryptophan in the core
of the ACP, six residues downstream of the catalytic serine. This tryptophan packing in the core
of the ACP appears to allow helix III to be presented at an angle which facilitates its interaction
with MupH. It was also found that a residue at the position 219 on MupH alternates between a
methionine and a leucine in the MupH orthologues. Moreover MupH and TmlH, which comple-
ment a ∆MupH strain, have methionine, whereas BatC, which doesn’t complement ∆MupH, has
leucine. Mutating this leucine in BatC into methionine does allow complementation of ∆MupH.
This gain of function experiment, along with other mutations, supported the computationally
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predicted ACP-MupH complex and suggested the possibility of engineering β-branching into
different positions in PKS pathways. It also suggested that there exists an ACP-HCS subtype
pairwise specificity. Pairwise specificity is indeed observed in the myxovirescin system, where
the two HCS cassettes interact with different cognate ACPs, without apparent cross talk.
The next obvious question was to test whether the β-branching ACPs from the kalimantacin
cluster can complement the β-branching ACPs in the mupirocin cluster. It was hypothesised
that, as batC was very poor at complementing ∆mupH mutant in the mupirocin cluster, ACP-
K24a will not complement β-branching ACPs in the mupirocin cluster. However, either by
expressing batC in trans or upon mutating ACP-K24a to favourably interact with MupH there
should be an increase in the production of pseudomonic acids. To test this hypothesis, β-
branching ACP-mupA3a and ACP-mupA3ab in the P. fluorescens ∆acp4 and ∆mupH strains
respectively were replaced with ACP-K24a from the kalimantacin cluster. Suicide mutagenesis
lead to the formation of the P. fluorescens ∆H-6d strain which lacked mupH and acp-mupA3ab
on the chromosome but had acp-K24a incorporated into the chromosome, and the P. fluorescens
∆4-1a strain which had mupH and acp-K24a on the chromosome, but no acp-mupA3ab. Bioas-
say and HPLC analysis was carried out by expressing mupH, batC or batC L218M mutant in
trans in the ∆H-6d strain and BatC in trans in the ∆4-1a strain.
Bioassay results showed the ∆4-1a strain had a diameter for the clearance zone that was
50% of WT, this observation was consistent with the original hypothesis that there would be
either no or an unfavourable interaction between ACP-K24a and MupH. However, a similar
drop was also observed in the ∆H-6d strain which does not contain chromosomal mupH in
the HCS cassette. It was also thought that in trans expression of batC in ∆4-1a strain might
increase the antibiotic production as BatC will compete with MupH for ACP-K24a and would
make a more favourable interaction. However, the clearance zone was found to have almost half
the diameter of that of the ∆4-1a strain without batC expressed in trans, both with and without
IPTG induction. ∆H-6d with in trans expression of mupH should have given a similar clearance
zone to that of the ∆4-1a strain as the only difference was that mupH is on the pJH10 plasmid in
the former and on the chromosome in the latter. However, the clearance zone was much smaller
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without IPTG and slightly smaller with IPTG, as compared to the ∆4-1a strain. ∆H-6d strain
with in trans expression of BatC, which was thought to have a favourable interaction with ACP-
K24a, did not have any results that were different from ∆H-6d with MupH in trans. Similar
clearance zones were also observed for ∆H-6d with BatC L218M expressed in trans. Thus,
because of the mixed results in the bioassay, it was difficult to conclude whether the hypothesis
stands true or not. HPLC performed on the control samples showed the characteristic peak of
pseudomonic acid A at an average time of 20:21 min. However, no peaks for pseudomonic acids
were detected in any of the ∆H-6d samples. No observable peak was detected for pseudomonic
acids in the ∆4-1a strain but all the samples had a small peak at around 17:57 min retention
time. The samples were sent to our collaborators in Bristol for the structural elucidation of the
metabolite produced at this previously unknown retention time.
It was hypothesised that owing to the proposed pairwise specificity between the branching
ACPs and their cognate HCS proteins there would be an incompatibility between ACP-K24a
and MupH, however, ACP-K24a should be able to perform well with the batC expressed in
trans in the mupirocin cluster. Previous experiments showed that BatC L218M mutation was
capable of functioning well with the HCS proteins in the mupirocin cluster, which suggests that
the incompatibility may not be because of the BatC but because of the ACP-K24a which was
unable to interact efficiently with the other domains in the mupirocin cluster. There could be
many possibilities that caused ACP-K24a not to allow production of pseudomonic acids in the
mupirocin cluster. It is possible that the ACP-K24a did interact with MupH or its orthologues
but failed to interact with the other HCS cassette proteins. It is also possible that the ACP-K24a
failed to interact with its cognate KS and hence it couldn’t transfer the extender unit for the
Claisen condensation. It could also be possible that the ACP-K24a was successful in interacting
with the KS as well as with the HCS cassette protein thus producing a β-branch but that it failed
to pass on the product to MmpB. If it fails to pass on the β-branched monic acid moiety to
MmpB then it is possible that some of the methylated-monic acid would leak out of the ACP
and that would explain the small peak observed in the ∆4-1a samples. Monic acid being less
hydrophobic would elute earlier as compared to the pseudomonic acid A. However, this leak
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would also be observed in the ∆H-6d strain with MupH expressed in trans. The efficiency of
MupH being expressed in trans or on the chromosome may be in question. Thus, it would only
be conclusive once the structure of the metabolite produced at the retention time around 17:57
min is solved by our collaborators.
An alternative method for investigating pairwise specificity might be to make changes in
the ACP-mupA3ab β-branching ACPs native to the mupirocin cluster, to allow them to func-
tion efficiently with the batC when expressed in trans. In earlier experiments the BatC L218M
mutant showed successful complementation which implies its suitability in the mupirocin clus-
ter. Therefore, to identify residues on the ACPs that might be responsible for determining the
specificity of the interaction with BatC, molecular dynamics simulations were carried out on
the ACP-mupA3a + MupH complex (as described in Section 2.3.2.7), to refine the structure
and identify ACP residues interacting with M219. MD simulation highlighted four positions
which were always or mostly present within 5 Å distance of the M219. These four positions
R30, L32, Y62 and P65 in ACP-mupA3a were proposed to Dr. Anthony Haines in order to
plan mutagenesis experiments. In order to find out to what residue type these positions should
be mutated, Dr. Haines built two separate sequence alignments of the β-branching ACPs from
well studied clusters, one alignment for each of the two types, MupH homologues which carry
an M219 and the ones which carry an L at the equivalent position. The sequence alignment of
these two groups of ACPs did not reveal any information about the difference between them,
there being no obvious correlation between ACP residues predicted to interact with L/M219
and the presence of L or M..
Assuming that ACPs can be sub grouped according to their cognate HCS protein type, a
more sophisticated method such as hidden Markov models could be used to cluster the ACPs.
As mentioned in the previous chapter HMMs were successful in clustering the β-branching
ACPs from the standard ACPs, constructing HMM models for the two above mentioned se-
quence alignments and scoring them against each other may reveal the ACP subgroups. Uti-
lizing the technique mentioned in section 3.2.1.1 it would be possible to identify the minimum





On the dynamics of acyl carrier protein
5.1 Introduction
Acyl carrier proteins play an important role in shuttling substrates and products in fatty acid and
polyketide biosynthesis. Inspite of being expressed in a minuscule amount (e.g. ≈0.25% of all
the soluble proteins in an E. coli cell), the dynamic nature of these proteins helps them to interact
with several different core and auxiliary domains in the FAS and PKS machinery. An ACP is a
four helix bundle with three helices I, II and IV running parallel to each other, while helix III
runs perpendicular to the others. A holo ACP is an ACP charged with phosphopantetheine, a
prosthetic linker derived from coenzyme A, which is transferred to the ACP by ACP synthases.
The Holo ACP then tethers an acyl group to the terminal sulfhydryl of its phosphopantetheine
via a thioester linkage. Experiments and molecular dynamics studies on FAS ACPs have shown
the sequestering of acyl substrates within the hydrophobic core formed by the four helix bundle.
However, it is not known if there is a similar mechanism in PKS ACPs.
Chan et al. (2008) conducted molecular dynamics simulations on apo, holo, and acyl forms
of E. coli FAS ACP which suggested a mechanism for acyl chain binding inside the ACP core.
Simulations were performed using an experimentally determined holo FAS ACP structure (PDB
ID 1L0I) with a butyryl molecule trapped inside the core of a holo ACP. Several different lengths
of acyl chain were constructed by extending the butyryl molecule by two carbons at a time up to
eighteen carbons. Simulations were conducted starting with the acyl chains in solvent exposed
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as well as in buried states and solvent exposed acyl chains up to ten carbons long easily found
their way into the hydrophobic core of the ACP, stably residing in the core till the end of a 50
ns simulation. However, longer acyl chains found it difficult to find there way into the ACP
core, and were not consistently stable in the core till the end of simulations. Chan et al. (2008)
proposed an eight carbon acyl chain as the optimal for stable accommodation by this FAS ACP
(PDB ID 1L0I). They also found a novel binding pocket in which the acyl chain was directed
towards helix I as opposed to the binding pocket in the solved structure. Simulations also
highlighted residues T39 and E60 as stabilizing the position of the phosphopantetheine linker
through hydrogen bonds at the opening of the hydrophobic tunnel.
Here, molecular dynamics (MD) simulations of the apo, holo, and acyl forms of ACP-
mupA3a and the acyl form of ACP-mupA2a from the mupirocin cluster are presented in order
to investigate the dynamic behaviour of the PKS ACPs upon phosphopantetheine and acyl chain
attachment. The main property of interest was to detect the formation of a cavity or tunnel that
could sequester a PKS substrate, similar to that seen in the FAS ACP. MD simulation trajectories
were analysed to calculate the hydrogen bonds formed by the phosphopantetheine and by the
substrates, in the holo and acyl forms respectively, with the protein surface and the solvent.
MD trajectories were also analysed to calculate the solvent accessible surface area (SASA)
of the phosphopantetheine and the substrates in the holo and acyl forms respectively. To test
whether the PKS ACPs become more like FAS ACPs in their holo and acyl forms, root mean
square deviations (RMSD) of the PKS ACPs from the reference FAS ACP (PDB ID 1LOI) were
calculated.
5.2 Results
5.2.1 Molecular dynamics simulation setup and parameter determination
In order to carry out molecular dynamics simulations of the apo, holo, and acyl forms of ACP-
mupA3a and the acyl form of ACP-mupA2a, the first step was to generate the starting structures
and assign the force field parameters.
For ACP-mupA3a two structures were used, a wild type (WT) and a W44L mutant. For the
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apo ACP-mupA3a WT, the NMR determined structure (PDB ID 2L22) was used as the starting
conformation. For the apo ACP-mupA3a W44L, the same ACP-mupA3a structure was used but
with the point mutation created by PyMol. To create the holo ACP structures, the catalytic S38
of their respective apo structures was extended with a phosphopantetheine. Two acyl forms of
ACP-mupA3a WT were created, the first structure consists of the cognate substrate of the ACP-
mupA3a (as shown in Figure 5.1) built directly onto the phosphopantetheine and was referred
to as “Acyl ACP-mupA3a WT”. The second acyl form consists of a fourteen carbon saturated
chain built directly onto the phosphopantetheine of the holo ACP-mupA3a WT and was referred
to as “Acyl 14C ACP-mupA3a”. One acyl form of ACP-mupA3a W44L was also created by
extending the phosphopantetheine of the holo ACP-mupA3a W44L with the cognate substrate
of ACP-mupA3a and was referred to as “Acyl ACP-mupA3a W44L”.
For ACP-mupA2a, as there was no experimentally determined structure available, a homol-
ogy model was generated using as the template the ACP (PDB ID 2LIU) from the CurA module
of the curacin system in Lyngbya Majuscula (as described in Section 2.3.1.2). To create the acyl
form of ACP-mupA2 the catalytic serine of the modelled structure was extended with the phos-
phopantetheine followed by its cognate substrate (as shown in Figure 5.1) and was referred to
as “Acyl ACP-mupA2”.
Following the structure preparation the force field parameters were assigned to the atoms.
Parameters from the AMBER99SB-ILDN force field were used for the protein atoms and GAFF
parameters were used for the phosphopantetheine and the acyl chains with charges calculated
using the RED server (Vanquelef et al. 2011). A detailed description of the molecular dynamics
simulations protocol and the procedure used to determine the parameters for the ligands is given
in Section 2.3.2 and Section 2.3.2.1 respectively.
Multiple independent simulations were carried out for 50 ns for each of the holo and acyl
forms, and one of the simulations that showed a transition into the binding mode was extended to
200 ns. One simulation for the Acyl ACP-mupA3a WT was further extended to 1 µs. Simulation
for the apo ACP-mupA3a WT was also extended to 1 µs as a control. Table 5.1 summarizes the
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Figure 5.1: Cognate substrates for ACP-mupA2 and ACP-mupA3a in the mupirocin pathway.
Table 5.1: ACP simulation setup summary
Structure Ligand Simulation Method
Section
Apo ACP-mupA3a WT - 1 X 1 µs 2.3.2.2 B
Apo ACP-mupA3a W44L - 1 X 200 ns 2.3.2.2 B
Holo ACP-mupA3a WT phosphopantetheine 4 X 50 ns
1 X 200 ns
2.3.2.3
Holo ACP-mupA3a W44L phosphopantetheine 4 X 50 ns
1 X 200 ns
2.3.2.3
Acyl ACP-mupA3a WT ACP-mupA3a cognate sub-
strate
4 X 50 ns
1 X 1 µs
2.3.2.4
Acyl ACP-mupA3a W44L ACP-mupA3a cognate sub-
strate
4 X 50 ns
1 X 200 ns
2.3.2.4
Acyl 14C ACP-mupA3a fourteen carbon saturated
chain
2 X 50 ns
1 X 200 ns
2.3.2.5
Acyl ACP-mupA2 ACP-mupA2 cognate sub-
strate
2 X 50 ns
1 X 200 ns
2.3.2.6
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5.2.2 ACP backbone dynamics over time
All the simulations were stable, as indicated by the RMSD and RMSF calculations. The RMSD
values of the backbone atoms from the reference starting structures remained below 2.5 Å
for all the simulations and plateaued within the first 50 ns. The root mean square fluctua-
tion (RMSF) calculated for the backbone atoms, averaged per residue (as described in Section
2.3.2.9), showed a higher fluctuation in the mutant structures as compared to the wild type. This
observation is consistent with the MD simulations mentioned in the Chapter 3, Section 3.2.2.1.
However, upon attaching the cognate substrate of ACP-mupA3a, 200 ns and µs simulations of
the acyl ACP-mupA3a WT showed more fluctuation than the 200 ns simulations of acyl ACP-
mupA3a W44L (Figure 5.2). Acyl 14C ACP-mupA3a also showed more fluctuation than the
acyl ACP-mupA3a W44L. However, the residues showing most fluctuation were different in the
acyl ACP-mupA3a WT and the acyl 14C ACP-mupA3a. Interestingly, fluctuations in the simu-
lation of acyl ACP-mupA3a WT across 1 µs remained similar to the fluctuations observed in an
independent 200 ns long simulation of the acyl ACP-mupA3a W44L. Most of the differences in
fluctuations between the simulations of the wild type and the mutant ACPs were in the region of















































































































































































































5.2.3 Formation and change in cavity volume in PKS ACPs over time
After verifying the quality of the simulations, the first macroscopic property of interest was to
detect the formation of a cavity similar to that seen by Chan et al. (2008). The cavity volume
calculation was performed by using a third party GROMACS plugin trj cavity as described in
Section 2.3.2.11. Monitoring the change in the cavity volume over time in ACP-mupA3a and
ACP-mupA2a ACPs revealed the formation of larger cavities in the holo and acyl forms. Table
5.2 shows the mean and modal cavity volumes formed by the different structures over time, the
apo form having the lowest volume with a mean value of 62.856 Å3 in the 1µs long simulation.
The holo as well as the different acyl forms in both ACP-mupA3a (wild and mutant types)
and ACP-mupA2a showed higher mean volumes than the apo ACP-mupA3a structures. Thus,
suggesting the role of the prosthetic linker as well as the acyl group attachment in the induction
of a larger cavity. It was also observed, that the mean cavity volume in holo ACP-mupA3a
W44L and acyl ACP-mupA3a W44L structures, were lower than their wild type counter parts.
The mean cavity volume of the apo ACP-mupA3a W44L was found to be larger than the apo
ACP-mupA3a WT structure however, the modal cavity volume was smaller in the mutant than
the wild type. This observation suggests, the mutation at the core of the ACP might have
changed the packing of the helices, thus affecting the cavity formation at the surface. Although
there is an induction of cavity formation and a change in the volume during the simulations of
holo and acyl states, in both cases the cavity is a solvent exposed groove (see example in Figure
5.4 A & B) rather than a buried tunnel (see example in Figure 5.3 A). Figures from C.1 to C.10
in the Appendix III shows graphs of the change in the cavity volume (non zero time frames)
over time, along with the running average over 500 frames and a mean value line.
The largest cavity (avoiding any cavity with spill overs) recorded among all the structures
was 266 Å3 in acyl ACP-mupA3a WT (Figure 5.4). Here, spill overs means that the probe
couldn’t find protein in five directions and hence ran off the intended cavity space until it finds
the protein. This usually happens with flatter and surface exposed cavities. The parameters
used should detect a cavity in as many time frames in the simulation as possible including the










































































































































































































































































































































































































































































finding perfect parameters to detect a cavity in all the time frames whilst avoiding any spill overs
was difficult. On visual inspection of 10000 time frames for 100ns of apo ACP-mupA3a WT
simulation, showed fewer instances of spill overs with the chosen parameters compared to the
other parameters tried, as detailed in Section 2.3.2.11. Table 5.3 lists the largest as well as the
modal cavity volumes (for comparison) recorded for all the structures. Using the same cavity
detection parameters, the volume for the FAS ACP (PDB ID 1L0I) structure was found to be
253 Å3. Comparing this FAS cavity size from the crystal structure with the largest recorded in
the PKS acyl ACP-mupA3a WT, the difference is ≈13 Å3 (around 5 %). However, the shape of
the FAS ACP looks more like a narrow deep tunnel as compared to the shallow but wide surface
exposed channel of ACP-mupA3a. Figure 5.3 (A) shows a space filled drawing of the cavity
volume detected in the FAS ACP and Figure 5.3 (B) shows the orientation of the butyryl acyl
group attached to the phosphopantetheine inside the FAS ACP hydrophobic tunnel. Comparing
largest and modal cavities from the simulations of other PKS ACP structures also revealed shal-
low but wide surface exposed channels (see Figures from C.11 to C.17 in the Appendix III). Not
having a deep tunnel shaped cavity means that the ligand was partially accessible to the solvent
throughout the ACP-mupA3a simulations. This observation was supported by measuring the
change in the solvent accessible surface area (SASA) of the ligands (phosphopantetheine and
the acyl groups) over time. Table 5.2 shows the mean of the SASA for different ligands which
was found to range in between 4 to 6 nm2 (see Figures from C.40 to C.46 in the Appendix III).
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Figure 5.3: Cavity volume detected in the reference FAS ACP (PDB ID 1L0I) structure. (A) space filled
(yellow spheres) drawing of the cavity detected (B) orientation of the butyryl acyl group attached to the
phosphopantetheine inside the FAS ACP hydrophobic tunnel. Helices are shown as cartoon drawing and
numbered.
5.2.4 Change in RMSD of PKS ACPs from FAS ACP over time
In watching movies of the simulations it seemed that holo and acyl forms of the PKS ACPs
become more like FAS ACPs in structure. It seemed that the structure might be responding to
the presence of the ligands to produce a cavity. To quantify whether there was a relationship
between cavity volume and similarity to FAS structure the correlation was calculated between
the cavity volume at every ns and the RMSD of the backbone atoms of the PKS ACPs from
the FAS ACP reference structure (Table 5.4). A weak negative correlation was observed in all
the structures except in the acyl ACP-mupA2a i.e. as the volume increases the similarity to
FAS increases, albeit only slightly. The correlations were slightly stronger in the ACP-mupA3a
W44L structures with the strongest in holo ACP-mupA3a W44L simulation. Comparing the
Figures 5.5 and 5.6 shows a high rise in the RMSD between 120 and 160 ns which strongly
correlates with the sudden dip in the cavity volume in the same time frame. Figures from C.18
to C.27 in the Appendix III show the change in the RMSD of the backbone atoms of each PKS
ACP from the FAS ACP over time. Taken individually these correlation coefficients might seem
insignificant but the fact that they are all negative does point to a small but significant effect.
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Figure 5.4: Largest cavity detected in the acyl ACP-mupA3a WT. (A & B) space filled (yellow spheres)
drawing of the largest and the modal cavity volume respectively. (C & D) orientation of the ligand in the
cavity formed in two different views.
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Figure 5.5: Formation and change in cavity volume over time in the holo ACP-mupA3a W44L. The time
frames which had a zero value for the volume were omitted from the plot. Red line represents the running
average over 500 frames and green line represents the mean.
Figure 5.6: RMSD between FAS ACP and the holo ACP-mupA3a W44L over time. Green line represents
the mean.
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151.593 52.728 173.563 50.531
Apo ACP-mupA3a
(1µs)
151.593 52.728 - -
Holo ACP-mupA3a 228.488 109.85 243.867 92.274
Acyl ACP-mupA3a
(200ns)
265.837 103.259 243.867 57.122
Acyl ACP-mupA3a
(1µs)
265.837 72.501 - -
Acyl 14C ACP-
mupA3a
195.533 96.668 - -
Acyl ACP-mupA2a 248.261 92.274 - -
5.2.5 Hydrogen bonding between the phosphopantetheine, acyl groups
and protein/solvent
In watching movies of the simulations, the phosphopantetheine and acyl chains were seen to
interact with the protein. However, as the cavity detected during the simulation was shallow
and solvent exposed the ligands seemed to be in partial interaction with the solvent as well. To
detect the interaction of the ligands with the protein and solvent hydrogen bonds were measured
between the ligands and the protein/solvent throughout the simulation. Table 5.2 shows the
mean number of hydrogen bonds per frame formed with the protein and solvent (columns 3
and 4 respectively) by the phosphopantetheine and the acyl groups. It was observed that the
phosphopantetheine constantly makes hydrogen bonds with the solvent, with a very slight drop
in the average number when an acyl group is attached, as compared to without substrate. No
significant correlation was found between the cavity volume and the hydrogen bonds formed
between the ligand and the protein. However, a negative correlation was observed between the
hydrogen bonds formed by the ligand with the protein and the solvent. This negative correlation
showed a general trend of a rise of hydrogen bonds made by the ligand with the protein and fall
of hydrogen bonds made by the ligand with the solvent over time (see Figures from C.28 to
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C.39 in Appendix III). A general trend where for every hydrogen bond formed between ligand
and protein one between ligand an solvent is lost would be expected.
5.2.6 Structural and sequence comparison of the E. coli FAS ACP and
ACP-mupA3a
In order to understand what might be preventing ACP-mupA3a from forming a deep tunnel
shaped cavity, FAS ACP (PB ID 1L0I) and ACP-mupA3a structures were compared by struc-
tural and sequence alignments. Figure 5.7 shows the superimposed structures of the reference
FAS ACP (PDB ID 1L0I) and apo ACP-mupA3a WT. Two noticeable differences in the residue
positions were observed which might be associated (amongst others) with the tunnel shaped
cavity found in the FAS ACPs. Residue 59 on helix III of the FAS ACP is an alanine, but is
equivalent to I61 in the ACP-mupA3a. In Figure 5.7 (B) the bulky isoleucine can be seen as a
hindrance in the path leading to the deep tunnel. Similarly A34 in the FAS ACP is equivalent to
L36 in ACP-mupA3a, this position corresponds to the residue between G and D in the GXDS
motif and is usually a bulky residue in PKS ACPs.
Figure 5.7: Structural comparison of an FAS ACP (PDB ID 1L0I; green) and an apo ACP-mupA3a WT
(cyan). (A) positions A59/I61, L42/W44 and a butyryl molecule attached to the phosphopantetheine in the
FAS ACP are drawn as sticks and position A34/L36 as lines. (B) surface drawing of the FAS ACP (green)
highlighting the orientation of the ligand and opening of the tunnel shaped cavity I61 (cyan sticks) can










































































































































































































































































































































In order to understand the sequence conservation of these positions in the FAS and PKS
ACPs two sets of similarity searches were carried out using PHI BLAST against the NCBI’s non
redundant protein database. The first search used the sequence of FAS ACP (PDB ID 1L0I) as
the query along with the motif GADS, a highly conserved motif in the FAS ACPs. This search
matched 1055 unique sequences with 95% query coverage or greater (sequences with large
insertions were removed from the alignment). These 1055 unique sequences represented species
from 473 genera with an average sequence identity of 65%. Figure 5.8 shows the sequence logo
built on the multiple sequence alignment of the 1055 unique FAS ACP sequences. A59 of
helix III was found to be absolutely conserved in all the sequences, along with the two highly
conserved glutamic acid residues immediately before and one highly conserved glutamic acid
residue immediately after position 59 (i.e. an EEAE motif). Searching the FAS ACP sequence
against the NCBI’s non redundant protein database with the EEAE motif yielded 472 unique
sequences with at least 95% query coverage. Figure 5.9 shows the sequence logo built using
the multiple sequence alignment of the 472 unique FAS ACP sequences with the EEAE motif.
It was interesting to observe that by searching with the GADS motif A59 was found absolutely
conserved and while searching with the EEAE motif A34 was found absolutely conserved as
well. Comparing the two sequence logos one can say that the FAS ACPs are highly conserved
with an average sequence identity of 65% and 76% when searched with the GADS and EEAE
motifs respectively. The FAS ACP sequence was also searched against the PDB database with
the GADS and EEAE motifs, which matched 11 and 8 FAS ACP structures respectively with
the similar sequence conservation pattern as shown in sequence logos in Figures 5.8 and 5.9.
Searching with the E. coli FAS ACP sequence (PDB ID 1L0I) without any additional mo-
tif constraint against NCBI’s non redundant protein database matched 2078 unique sequences
with 95% or greater query coverage. Alignment of these sequences revealed three broad groups:
group one contains the GADS motif (1280 sequences), group two contains a GLDS motif in-
stead of the GADS motif (257 sequences) and group three has neither a GADS or a GLDS motif
(541 sequences). The third group also lacked the conservation of G in the GXDS motif. Figures
from C.47 to C.49 in Appendix III show the sequence logos built on the above mentioned three
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Figure 5.8: Sequence logo built on 1055 unique FAS ACP sequences containing a GADS motif (position
34-36).
Figure 5.9: Sequence logo built on 472 unique FAS ACP sequences containing a EEAE motif (position
57-60).
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sets of sequences. The sequences which carry a GADS motif show a high conservation of ala-
nine at the 59th position of the FAS ACP structure. The sequences which carry a GLDS motif
have a position 59 with predominantly A, L and R but also other residues. The alignment/logo
of FAS ACP sequences which did not carry either of these motifs indicates poor conservation
at most of the positions.
FAS ACP sequences carrying a GLDS motif are more like PKS ACPs with a bulky residue
at the X position in the GXDS motif and another bulky reside at the equivalent position of I61 in
ACP-mupA3a, equivalent to A59 in the FAS ACP structure discussed in the previous paragraph.
Figures 5.10 and 5.11 show the sequence logos built on the ACPs from 15 well characterised
PKS clusters grouped into ACPs associated with β-branching and standard ACPs as used in
Chapter 3. Both the sequence logos show the presence of a bulky residue at the X position in
the GXDS motif, which co-occurs with the bulky reside at the equivalent position of I61 (ACP-
mupA3a). These observations suggest that having a less bulky residue at the position A59/I61
is correlated with a sequence being an FAS ACP and presumably allows the formation of a deep
tunnel shaped cavity in the FAS ACPs. Owing to a high level of sequence conservation in the
FAS ACPs this structural feature would be shared widely.
Figure 5.10: Sequence l ogo built on the β-branching ACP sequences from 15 well characterized polyke-
tide synthase clusters. - - - - - indicates the GXDS position and * indicates the position 55 equivalent to
A59 in the FAS ACPs or I61 in MupA.
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Figure 5.11: Sequence logo built on the standard ACP sequences from 15 well characterized polyketide
synthase clusters. - - - - - indicates the GXDS position and * indicates the position 55 equivalent to A59
in the FAS ACPs.
5.3 Discussion
In order to investigate the possible formation of a cavity and the sequestering of phosphopan-
tetheine and acyl chains in the ACP core, a series of molecular dynamics simulations were per-
formed on the apo, holo and acyl forms of the ACPs from the MmpA module of the mupirocin
cluster (ACP-mupA3a and ACP-mupA2a). Experimentally determined ACP structures and
molecular dynamics studies on FAS ACPs have shown the formation of a hydrophobic tun-
nel within the ACP core, which sequesters the growing saturated fatty acid chain, protecting
it from the outer hydrophilic environment, but this had not been seen for PKS ACPs. Chan
et al. (2008) have shown that an optimal acyl chain length from eight carbons up to ten carbons
can be stably accommodated by the E. coli FAS ACP. In this chapter, the acyl chains were of
12C and 14C backbone atoms long. Three independent simulations of 50 ns each were set up
for all the structures namely apo ACP-mupA3a (WT and W44L), holo ACP-mupA3a (WT and
W44L), acyl ACP-mupA3a (WT and W44L), acyl 14C ACP-mupA3a and acyl ACP-mupA2
were setup. The starting structures for the holo as well as the acyl structures had solvent ex-
posed ligands attached to the catalytic serine. Chan et al. (2008) ran 50 ns simulations for the
structures with solvent exposed acyl chains, the time scale was enough for acyl chains of four,
six, eight, ten and sixteen carbons in length to find their way into the cavity. Acyl chains with
twelve, fourteen and eighteen carbons failed to find the cavity even in extended simulations.
Here, three independent 50 ns simulations per holo and acyl structure seem to be a good
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starting point for sampling enough phase space for the ligands to find their way into the proposed
cavity. However, as there was no experimental evidence of cavity formation and sequestering
of acyl chains in the PKS systems, there was no clear idea of how long a simulation should
be to see the sequestering of the ligand, if indeed sequestering occurred. Therefore, one of the
multiple 50 ns simulations that showed a transition of the acyl chain into the proposed cavity
space was extended upto 200 ns for apo and holo ACPs, with one simulation of the wild type
ACP-mupA3a charged with its cognate substrate simulated for 1µs. The simulation of the apo
ACP-mupA3a WT was also extended to 1 µs as a control.
The root mean square deviation (RMSD) of the backbone atoms of the simulated structures
from their reference starting structure remained under 2.5 Å, suggesting that the structures in
apo, holo or acyl forms did not undergo any extreme unfolding events. This observation was
crucial to test the stability of the holo and acyl forms since the solved ACP-mupA3a structure
did not have the coordinates for the phosphopantetheine or for any of the acyl chains. The
topology information for the phosphopantetheine and the acyl chains were built manually and
the bond, angle, dihedral and van der Waals forcefield parameters were derived from the General
Amber Force Field (GAFF), with partial charges derived by the RESP method, since these
parameters were not in the GROMACS suite. The GAFF parameters and RESP charges were
designed to be compatible with the AMBER99SB-ILDN forcefield.
Chan et al. (2008) utilized the GROMOS96 43a2 forcefield for their ACP simulation and
most of the atom types in the acyl chain and parameters for the for the atom types which were not
present in the parent GROMOS96 43a2 forcefield database were generated through GAUSSIAN
quantum mechanics software. Observations from their simulations were similar to what was
observed here. RMSF values showed a general trend of more fluctuation in the mutant structures
as compared to their wild type counter parts, these observations are consistent with the MD
simulations mentioned in Chapter 3, Section 3.2.2.1. Most of the fluctuation was observed
from residues 34 to 40 (around the catalytic S38) and 52 to 68 (loop II and helix III).
A cavity was detected in more time frames during the holo and ACP simulations as com-
pared to the apo ACP-mupA3a structures. The cavity volumes detected for the holo as well as
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the acyl forms were also larger in size as compared to the apo structures. These observations
suggested that the attachment of phosphopantetheine and acyl chains not only induced the for-
mation of the cavity but that the attachment also influenced the size of the cavity formed. Upon
utilizing the same parameters for the cavity detection the reference FAS ACP (PDB ID 1L0I)
structure recorded a volume of 253 Å3 which was comparable to the largest cavity detected for
acyl ACP-mupA3a WT. However, the shape of the cavity for the FAS ACP was found to be like
a deep tunnel as compared to the wide, shallow and surface exposed cavity in the PKS ACPs. A
similar trend for wide, shallow and surface exposed cavities, as those seen in the ACP-mupA3a
WT was seen in the other simulations of PKS ACPs performed here.
Chan et al. (2008) found that the average cavity volume continuously increases in size ac-
cording to the size of the ligand for upto ten carbons and but for chains between 10 and 18
carbon long remained unchanged. Here the acyl chains are twelve and fourteen backbone car-
bons long and the cavity volumes seen in these simulations do not seem to vary with chain
length. Interestingly the average size of the cavity induced by the phosphopantetheine alone
was also of the same size as that induced by the fourteen backbone carbon long acyl form. Vi-
sual inspection of the MD simulation trajectory revealed that the phosphopantetheine occupies
the same cavity space as the substrate occupies in the acyl ACP-mupA3a simulations, in the
latter case the phosphopantetheine is in solvent. This observation may be because the size of
the phosphopantetheine backbone is similar to the size of the ACP-mupA3a cognate substrate
backbone (i.e. 14C). and because the shape of the cavity is surface exposed the highly polar
phosphopantetheine can hydrogen bond with the solvent while still residing in the cavity.
The shallow surface exposed cavities also meant that no part of the acyl chains was buried
inside the ACP but rather the acyl chains were in constant interaction with the solvent. This
hypothesis was based on the thinking that the polyketide molecules usually have some polar
groups which can hydrogen bond with the solvent and do not necessarily require a hydrophobic
casing to segregate them from the solvent. This does not equally apply to the FAS ACPs because
the acyl chains in fatty acid synthesis are usually saturated and non polar in nature (except the
β-carbon processed intermediates) and would experience a constant repulsion from the solvent.
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It would rather be energetically favourable for a highly hydrophobic chain to envelope itself
within a hydrophobic core. In principle a hydrophobic chain without such sequestration inside
the ACP, could also attach itself to other hydrophobic entities in the cell making it not available
to the FAS proteins.
The hypothesis that the acyl chains were in constant interaction with the solvent was also
supported by the observation that the SASA calculated for the phosphopantetheine and the acyl
chains (once the ligands have associated themselves with the protein) over time was constant,
avoiding any further dips which would have suggested a transition from a less to more buried
state. Chan et al. (2008) showed a very low solvent accessible surface area (SASA) for the
acyl chains upto eight carbons long, which increases rapidly for an acyl chain of ten to eighteen
carbons long, as the FAS ACP could not shield completely a carbon chain more than ten carbons
long. The lowest SASA value recorded for an acyl chain in the PKS ACPs was for acyl 14C
ACP-mupA3a, which was ≈43 Å2, ≈9.5 Å2 more than the SASA value calculated for the 14C
acyl chain by Chan et al. (2008). Not surprisingly the highest SASA value calculated was
for the phosphopantetheine, which was ≈16 Å2 more than the SASA for the 14C saturated
acyl chain. The SASA calculations were also supported by the number of hydrogen bonds
made between the ligands (phosphopantetheine and the acyl chains) and the protein/solvent.
Phosphopantetheine as well as the acyl chains were constantly making hydrogen bonds with
the solvent as well as the protein, although the number of H-bond to solvent did not correlate
with the size of the cavity induced.
During the smulations, as the PKS ACPs become more like the FAS ACP structure the
volume of the cavity increased, as evidenced by the RMSD between the PKS and FAS ACPs
decreasing as the cavity volume increased (negative correlation) in all the structures except one.
However, as the cavity formed in the PKS structures is wide, shallow and surface exposed,
as compared to deep tunnel in the FAS ACP, it is clear that only part of the structure was
changing to be like an FAS ACP. A stronger correlation between the FAS and W44L mutant
ACP structures suggested that having a less bulky residue in the PKS ACP core might allow the
PKS ACPs structures to move closer to the reference FAS ACP.
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Comparing the PKS apo ACP-mupA3a WT structure with the reference FAS ACP, revealed
I61 in the ACP-mupA3a (which is an A59 in the FAS ACP) blocking the entry of the tunnel.
Multiple sequence alignment of FAS and PKS ACPs revealed that position I61/A59 is highly
conserved with an alanine in the FAS ACP and a bulkier residue in the PKS ACPs. This position
also seems to have co-evolved with the X of the GXDS motif (active site serine) in the PKS and
FAS ACPs, with a bulky residue at the position X in the PKS ACPs and an alanine in the FAS
ACPs. It would be interesting to mutate position I61 and/or X in the GXDS motif to alanine in
the ACP-mupA3a and possibly monitor a deeper transition of the acyl chain through NMR.
The observations here support the hypothesis that the PKS ACPs do form a cavity upon
the attachment of the phosphopantetheine and acyl chains. However, whether different chain
lengths influence the size of the cavity was not tested. The cavity formed does not form a deep
tunnel that envelopes the acyl chain and thus shields it from the solvent, but is solvent exposed
which enables the polar groups on the acyl chain to hydrogen bond with the solvent. It was
also seen that I61 in the PKS ACPs is bulkier than A59 in the FAS ACPs and prohibits the
formation of a deep tunnel. In the absence of any experimental data in this regard another set of
MD simulations in a different PKS system for example ACP from module 2 of DEBS system
(PDB ID 2JU1) and ACP from curacin system (PDB ID 2LIU) could be performed to verify
a similar mechanism of acyl chain sequestering as observed here. It would also be interesting
to test whether an FAS ACP would envelope a polyketide molecule into its hydrophobic core
in lieu of a fatty acid acyl chain. These studies might explain the dynamic mechanism through
which small proteins like an ACP recognize/interact with various domains in a complex PKS
machinery. The information gathered from such studies not only helps to gain a deeper under-
standing of protein structure and function in general but would also help to re-engineer PKS
pathways for the production of novel compounds.
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Chapter 6
Ligand specificity and dynamics in the mup
cluster domains
6.1 Introduction
This chapter focusses on understanding two observations made in two different unrelated studies
in the mup cluster. The first study builds on work conducted in Prof. Thomas’ group by Dr.
Joanne Hothersall in order to identify the tailoring enzyme responsible for the synthesis of
the 6-hydroxyl of mupirocin. According to the position of the 6-hydroxyl (Figure 1.26) in
the mupirocin molecule it was hypothesized that the enzyme responsible must be acting after
MmpD. Dr. Hothersall proposed MupA may be the likely candidate and therefore in order to
confirm her prediction she created two different mutants ∆mupA and mupA G127A, D134A.
The point mutations were chosen by comparison of MupA with other oxygenases, e.g. PedJ, to
identify the active site residues. MupA belongs to the reduced flavin mononucleotide (FMNH2)-
dependent oxygenase family of proteins that are responsible for the addition of a hydroxyl
group to the substrates in many different metabolic pathways (El-Sayed et al. 2003). Bioassay
and HPLC showed that the deletion strain had no biological activity and wasn’t producing
pseudomonic acid A; and that the mupA G127A, D134A mutant strain was essentially like wild
type Pseudomonas fluorescens NCIMB 10586. The strains were sent to our collaborators in
Bristol for analysis by HPLC, LC-MS and proton NMR, which confirmed these results. They
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found that the deletion strain produced mupiric acid but not mupirocin H (Wu et al. 2008).
Mupiric acid is thought to be formed by the release of an intermediate from module 4 of MmpD.
Since no intermediates longer than mupiric acid were found this fits with the idea that MupA is
acting after MmpD. However, it doesn’t confirm that it is the 6-hydroxylase.
This observation raised a new question that, if MupA is responsible for 6-hydroxylation and
the deletion strain therefore produces a product with no 6-hydroxyl (α-hydroxyl) and does not
progress beyond MmpD, what prohibits the non hydroxylated molecule from proceeding further
in the synthesis pathway. It was hypothesized that the KS-mupA2 in the second module of the
MmpA subunit might be specific for the α-hydroxylated intermediate and that in the absence of
a α-hydroxyl it does not catalyse Claisen condensation. To determine what in the KS-mupA2
might recognise the α-hydroxyl, a docking study was performed in which the modelled KS-
mupA2 dimer was docked with the expected cognate mupirocin intermediate. The docking was
performed to reproduce the decarboxylation stage of the Claisen condensation with the substrate
attached to the catalytic cysteine in the KS active site and the extender molecule (malonate) at-
tached to phosphopantetheine of the ACP, positioned ready for decarboxylation and subsequent
elongation of the substrate. The cognate ACP-mupA2 was docked attached to the phosphopan-
tetheine with distance restraints to ensure that the phosphopantetheine was stretched along the
active site tunnel. Key residues for hydroxyl recognition as suggested by docking and sequence
analysis were investigated by mutagenesis experiments carried out by Miss Yousra Alsamarraie
from Prof. Thomas’ group.
The second study discussed here arose from observations during the molecular dynamics
simulations of an ACP-mupA3a:MupH complex described in Chapter 4, Section 4.2.5. The
50 ns long simulations of the complex revealed a movement in two loop regions covering the
MupH active site. These loop movements suggested that they might be assisting in the accom-
modation of the ligand upon ACP-mupA3a/b docking to MupH. In order to understand this
phenomenon, the variation in distance between the two loops was measured during the ACP-
mupA3a:MupH simulations as well as simulations of the, ACP-mupA3a:MupH dimer, MupH
wild type monomer and MupH monomer C115 acetylated. The idea behind simulating the
202
ACP-mupA3a:MupH dimer was to see if the dimeric state of MupH (if it exists as a dimer)
would affect the loop movements. The MupH monomer acetylated at C115 was simulated to
see if the acetylation of the catalytic cysteine in the MupH alone would also trigger the same
loop movements. Simulation of the non-acetylated wild type MupH monomer was used as a
control.
6.2 Results
6.2.1 A loop at the KS dimer interface appears to be responsible for the
substrate specificity
In order to understand what might be responsible for KS-mupA2 not to accepting the acyl chain
that lacks the α-hydroxyl (6-hydroxyl in the final mupirocin molecule), the expected natural
substrate of KS-mupA2 was docked into a homology model of the KS-mupA2 dimer structure
(as described in Section 2.3.4.2). The KS-mupA2 dimer along with the docking domains was
modelled using the X-ray structure of the KS-AT dimer from DEBS module 3 (PDB ID 2QO3,
(Tang et al. 2007)), as described in Section 2.3.1.3. Docking was performed to reproduce the
decarboxylation stage of the Claisen condensation reaction mechanism described in Section
1.2.4.3. KS dimer crystal structures show that the active site is made from atoms from both the
KS subunits, which was thus also seen in our MupH model and MupH residues within a 5 Å
radius of the docked α-hydroxyl included a motif D128, N129, Y130, K131 on the loop of the
subunit not covalently carrying the substrate.
Figure 6.1 shows the overall docked complex with the lowest energy. Figure 6.2 shows the
closeup view of the loop with the residues within 5 Å radius of the α-hydroxyl highlighted.
Figure 6.2 also shows the backbone NH atoms of residues C158 and A403 which were used
to restrain the acyl chain close to the catalytic cysteine (C158) in order to mimic the oxyanion
hole during acyl chain transfer. Residues F219, H293 and H333 were used to restrain malonate
within the active site in order to mimic the decarboxylation step, since these are implicated in
decarboxylation as discussed in Section 1.2.4.3. The catalytic serine S38 of ACP-mupA2 was
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restrained to be within 2 Å of the phosphate of the phosphopantetheine.
A multiple sequence alignment (Figure 6.3) of the KS sequences from the mupirocin and
thiomarinol clusters revealed that the DNYK motif was conserved in KSs of the second module
of MmpA and its equivalent TmpA but not in the other KSs. On the whole much less conserva-
tion was found among the other positions in the loop connecting an α-helix at the N-terminus
and a β-strand at the C-terminus (Figure 6.3). Based on this observations it was hypothesized
that if this loop were swapped with the loops from KS-mupA1 or KS-mupA3, which do not
require a substrate with an α-hydroxyl, then the KS mutant might allow the pathway to proceed
further. Figure 6.4 shows the loop region of interest on the KS-mupA2 and the sections of KS-
mupA1 and KS-mupA3 to replace it. Miss Yousra Alsamarraie carried out suicide mutagenesis
to swap the loops and HPLC to detect antibiotic production.
At the time of writing this thesis Miss Y. Alsamrarraie was able to replace the loop from
KS-mupA2 with the loop of KS-mupA1 in P. fluorescens NCIMB 10586 wild type and P. flu-
orescens ∆mupA strains. The blue line in Figures 6.5 and 6.6 show the HPLC trace for the P.
fluorescens ∆mupA strain which was used as the control, there is no peak at 21 mins, which
would correspond to pseudomonic acid A production. The red line in Figure 6.5 shows the
HPLC trace for the KS-mupA2 loop replaced with the loop from KS-mupA1 expressed in the
P. fluorescens ∆mupA strain. The trace shows a small peak at around 22:30 mins, which sug-
gests that the substrate was processed by KS-mupA2 however, the metabolite produced still
needs to be characterised. The red line in Figure 6.6 shows the HPLC trace for the KS-mupA2
loop replaced with the loop from KS-mupA1 expressed in P. fluorescens NCIMB 10586 wild
type strain. This trace also shows a small peak at around 22 mins, suggesting that the KS-
mupA1 loop is tolerant to both the substrates with and without α-hydroxyl. These samples have

















































































































































































































Figure 6.2: Close up view of the KS-mupA2 dimer and ACP-mupA2 docking interface. This configuration
of substrates represents the decarboxylation/condensation stage of the KS reaction mechanism. Chains
A and B of the KS-mupA2 dimer are coloured as green and blue respectively with their interface loop
coloured pink, ACP-mupA2 is coloured purple. The DNYK motif is shown as sticks. The malonate
extender unit attached to the phosphopantetheine was docked inside the KS-mupA2 active site with three
distance restraints requiring it to be 3 Å from each of F219, H293 and H333. The distance between
phosphopantetheine and S38 of ACP-mupA2 was restrained to be 2 Å. The natural substrate of KS-
mupA2 was docked inside the active site with three distance restraints of 1.8 Å to the sulphur of C158,
and 2.93 Å each to the backbone NH of C185 and A403. The substrate is bound to chain A of the KS
whereas the D128NYK motif is predicted to recognise the substrate is on Chain B.
KS-mupA1    DWKGSAT--------GVFIAAERNEY--HLNLLQAQIDPGEGLDQAASMLANRVSHFYDL
KS-mupA2    SLEQEKV--------GVFVGVSKAGH-DNY-------------KDSFFSIANRVSYRFGF
KS-mupA2SS  ----EEE--------EEEE--------------------------HHHHHHHHHHH----
KS-mupA3    GLAASARHEDAEGMVGVFVGVTYEEY-QLYGAQQTAEGRPLVLSMSPSSIANRVSFVNGF
KS-mupD1    ALAGSRT--------GVFVAAFNYDYKQLLESAGLPIDAHHSTGNAAAVIANRISHFYDL
KS-mupD2    QRRAEV---------SVYVGCEQGDYDQLFDDMPPPQSFW---GNAPSIVPARIAYYLDL
KS-mupD3    ALRRT----------GVYVGVMYQEY-QLFGAEQTLLGRPMALSGSSASIANRVSWSLGL
KS-mupD4    ATEGQPV--------GVYVGASASDYRSLFAEAAPAQAFW---GNASSIIPARIAYHLDL
KS-tmpA1    SLRGSNT--------GVFVGFERNEY--LLNLIESGHDTGESLHQSDSMIANNISYFFDF
KS-tmpA2    ELESDTV--------GVFVGISKAGF-DNY-------------KDSYFSAANRISYRFNF
KS-tmpA3    ALAQSTMIDKTPGVVGVYVGVTYQEY-QLYGAQETMLGNPMVLSMSPSSIANRVSYFCDF
KS-tmpD1    TLSGQNV--------GVYIGAFNFDYKELLEKHERPIEAYQSTGTANAIIANRISHFYDF
KS-tmpD2    SIDGNAV--------SIYVGCEQGDYERLFADSPLPQSFW---GNAPSIIPARLSYHLNL
KS-tmpD3    SKLGDHV--------GVFVGVMYSEY-QLYGAQQGVLGTPISLGGSAASIANRVSFSLNF
KS-tmpD4    PEFGENA--------GVYVGCNSGDYKNILSDEAPAQAFW---GNAGSITPARLSYYLNL
Figure 6.3: Portion of the multiple sequence alignment of the KS domains from mupirocin (MmpA/D)





Figure 6.4: Region of the loop on the KS-mupA2 which was proposed to be swapped by the loops from
KS-mupA1 and KS-mupA3.
Figure 6.5: HPLC trace for the KS-mupA2 loop replaced with the loop from KS-mupA1 in P. fluorescens
∆mupA strain, shown in red. The blue line represents the HPLC trace for P. fluorescens ∆mupA strain
used as control.
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Figure 6.6: HPLC trace for the KS-mupA2 loop replaced with the loop from KS-mupA1 in P. fluorescens
NCIMB 10586 wild type strain, shown in red. The blue line represents the HPLC trace for P. fluorescens
∆mupA strain used as control.
6.2.2 Movement of MupH surface loops may have a role in ligand binding
Three independent molecular dynamics simulations of the ACP-mupA3a:MupH complex with
the bound substrate, each of 50 ns length, revealed large movements in two loop regions causing
a separation between the loops which would otherwise cover the MupH active site tunnel, loop
I and II in Figure 6.7. To further explore this observation, each of the three simulations were
extended to 100 ns, as described in Section 2.3.2.7. Out of the two loops, loop II showed
greater movement (Figure 6.8) and upon visualizing the movie for the simulation of the ACP-
mupA2a:MupH complex the loop movement appears to aid the accommodation of the ligand in
the active site by widening the active site tunnel (Figure 6.7). This observation also lead to the
hypothesis that such a loop movement in MupH may be required to let a large ligand, like monic
acid attached to a phosphopantetheine, to enter inside its active site. Plotting the average of the
distances between P207 in loop II and each of L150, M151 and I152 in loop I, for simulation
replicate 1 (Figure 6.9), as well as the average distances between D208 and S209 in loop II
and L150, M151 and I152 in loop I revealed that the loops widen up to 3 nm during the first
30 ns and then narrow down to around 1 nm the remaining 70 ns. Replicate 2 did not show
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any huge fluctuation in the distance and replicate 3 showed only moderate fluctuation on two
different occasions along the trajectory (Figure 6.10 and 6.11). The procedure to measure the
distances between the loops is described in the methods Section 2.3.2.13. Table 6.1 summarizes
the different simulations setup for the analysis of loop movements in MupH.
Figure 6.7: Simulation of ACP-mupA3a:MupH monomer with substrate shows movements of loops over
the MupH active site. (A) without and (B) with cognate substrate of MupH attached to the side chain
of ACP-mupA3a S38 rendered as spheres. Snapshots at every 5 ns of the 50 ns molecular dynamics
simulation revealed the movement in the loop I (residue 147-171) and II (residue 198-214) which may
assist in the binding of the ligand. Loop II showed greater movement than loop I. Different coloured
loops represent different snapshots.
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Figure 6.8: MupH atomic RMSF for the ACP-mupA3a:MupH monomer simulation. RMSF values for
the residues in loop II (residue 198-214) can be seen larger than the residues on the loop I (residue
147-171). Blue, red and yellow lines represents the three replicates respectively.
Figure 6.9: Distances between residues in loop I and loop II for the ACP-mupA3a:MupH monomer
complex simulation replicate 1. Distances were measured between the three Cα on the loop I (L150,
M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines represents
the average distance of P207, D208 and S209 respectively from the three residues on the loop I. The
distance between the loops rise upto 3nm within 30 ns and then stabilized around 1nm.
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Figure 6.10: Distances between residues in loop I and loop II for the ACP-mupA3a:MupH monomer
complex simulation replicate 2. Distances were measured between the three Cα on the loop I (L150,
M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines represents
the average distance of P207, D208 and S209 respectively from the three residues on the loop I.
Figure 6.11: Distances between residues in loop I and loop II for the ACP-mupA3a:MupH monomer
complex simulation replicate 3. Distances were measured between the three Cα on the loop I (L150,
M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines represents
the average distance of P207, D208 and S209 respectively from the three residues on the loop I.
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Table 6.1: MupH simulation setup summary







3 X 100 ns 2.3.2.7
ACP-mupA3a:MupH dimer MupH C115 acetylated
ACP-mupA3a cognate sub-
strate
3 X 50 ns 2.3.2.7
MupH monomer WT - 3 X 50 ns 2.3.2.8
MupH acetylated C115 C115 acetylated 3 X 50 ns 2.3.2.8
A similar simulation with three independent replicates of 50 ns each, was also carried out
with MupH in the dimeric form together with ACP-mupA3a docked to one of the monomers
of MupH (as described in Section 2.3.2.7). It is quite likely that MupH exists as a dimer since
other HMG-CoA orthologues exist as dimers and PIER analysis of a MupH model suggested
an interface consistent with that seen in the crystal structure (Chapter 3, Section 3.2.6.2). The
RMSF calculated for all atoms averaged per residue of MupH in the simulation of the ACP-
mupA3a:MupH dimer complex showed lower values for the loop II than loop I (Figure 6.12).
The distance measured between the two loops in the simulation of the ACP-mupA3a:MupH
dimer complex also showed slightly lowered values for the largest distance reached between
the two loops as compared to the ACP-mupA3a:MupH monomer simulation. The distance
between the two loops remained constant throughout 50 ns in all the three replicates averaging
around 1 nm and 1.5 nm with a rise up to 2 nm in two out of three replicates (Figures from
6.13 to 6.15). Figure 6.15 shows replicate 3 for the ACP-mupA3a:MupH dimer simulation in
which the distance between the loops reached and remained at 2 nm and stayed plateaued for
around 15 ns. These observations support the hypothesis that the dimer formation hinders the
loop II movement, both in terms of its fluctuation on its position as well as its relative distance
from loop I. This could be because loop II, being close to the dimer interface, interacts with the
residues from the other monomer and hence stabilizes its position. Simulating the MupH dimer
for a longer time scale might allow better sampling of the large ACP-mupA3a:MupH dimer
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complex which may not be enough within the 50 ns of simulations here. Due to lack of time it
was not possible to run longer simulation on this complex.
Figure 6.12: ACP-mupA3a:MupH dimer complex, RMSF of all atoms averaged per residue of MupH.
RMSF values for the residues in loop II (residue 198-214) can be seen smaller than the residues on the
loop I (residue 147-171). Blue, red and yellow lines represents the three replicates respectively.
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Figure 6.13: ACP-mupA3a:MupH dimer complex simulation replicate 1, distance measured between
the loop I and II over the time of 50ns. Distances were measured between the three Cα on the loop I
(L150, M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines
represents the average distance of P207, D208 and S209 respectively from the three residues on the loop
I.
Figure 6.14: ACP-mupA3a:MupH dimer complex simulation replicate 2, distance measured between
the loop I and II over the time of 50ns. Distances were measured between the three Cα on the loop I
(L150, M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines
represents the average distance of P207, D208 and S209 respectively from the three residues on the loop
I.
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Figure 6.15: ACP-mupA3a:MupH dimer complex simulation replicate 3, distance measured between
the loop I and II over the time of 50ns. Distances were measured between the three Cα on the loop I
(L150, M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines
represents the average distance of P207, D208 and S209 respectively from the three residues on the loop
I.
One hypothesis that the loop movement may be triggered by the acetylation of the catalytic
cysteine in MupH, that would signal MupH to open up the loops to let the ligand in. To test
this hypothesis three independent 50 ns simulations were setup for the MupH monomer with
C115 acetylated (as described in Section 2.3.2.8). RMSFs calculated for all atoms averaged
per residue of MupH do not seem to be very different between loop I and II (Figure 6.16).
Figures 6.17 to 6.18 show the distances measured between the loops for the MupH monomer
with C115 acetylated simulations. Distances measured in the three replicates remained below
2 nm averaging around 1 nm. These loop movements do not seem to be different from the
movements seen in the ACP docked simulations.
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Figure 6.16: MupH monomer with C115 acetylated simulation, RMSF of all atoms averaged per residue
of MupH. RMSF values for the residues in loop II (residue 198-214) and loop I (residue 147-171) does
not seem to be very different from each other. Blue, red and yellow lines represents the three replicates
respectively.
Figure 6.17: MupH monomer with C115 acetylated simulation replicate 1, distance measured between
the loop I and II over the time of 50ns. CYA was the acytylated cysteine. Distances were measured
between the three Cα on the loop I (L150, M151 and I152) and three Cα on the loop II (P207, D208 and
S209). Red, green and blue lines represents the average distance of P207, D208 and S209 respectively
from the three residues on the loop I.
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Figure 6.18: MupH monomer with C115 acetylated simulation replicate 2, distance measured between
the loop I and II over the time of 50ns. CYA was the acytylated cysteine. Distances were measured
between the three Cα on the loop I (L150, M151 and I152) and three Cα on the loop II (P207, D208 and
S209). Red, green and blue lines represents the average distance of P207, D208 and S209 respectively
from the three residues on the loop I.
Figure 6.19: MupH monomer with C115 acetylated simulation replicate 3, distance measured between
the loop I and II over the time of 50ns. CYA was the acytylated cysteine. Distances were measured
between the three Cα on the loop I (L150, M151 and I152) and three Cα on the loop II (P207, D208 and
S209). Red, green and blue lines represents the average distance of P207, D208 and S209 respectively
from the three residues on the loop I.
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The next obvious question was to see if this loop movement can be observed in the non-
acetylated wild type MupH monomer, without being docked to ACP or with a ligand in its active
site. If the loop movement is triggered by the docking of ACP or the presence of the ligand
then there shouldn’t be any huge fluctuation in the distances between the loops throughout
the simulation. In order to test this hypothesis three independent simulations were run for a
non-acetylated wild type MupH monomer for 50 ns each. RMSFs calculated for all atoms
averaged per residue of MupH showed larger fluctuation in loop II than loop I, similar to the
ACP-mupA3a:MupH monomer simulation (Figure 6.20). Figure 6.22 shows the replicate 2 of
the non-acetylated wild type MupH monomer simulation and it can be seen that the distance
between the loops could fluctuate beyond 3 nm which was even more than with the bound
ligand. Figures 6.21 to 6.23 show the distances measured for all the three replicates. These
observations suggest that maybe this loop movement is intrinsic to MupH monomer proteins and
it does not require binding of ACP or ligand to trigger it. However, it would also be interesting
to see if this inter loop distance is consistent in the wild type ACP free MupH dimer as well.
Due to lack of time it was not possible to run the non-acetylated wild type MupH dimer or
MupH dimer with C115 acetylated simulations.
Figure 6.20: Non-acetylated wild type MupH monomer simulation, RMSF of all atoms averaged per
residue of MupH. RMSF values for the residues in loop II (residue 198-214) can be seen larger than
the residues on the loop I (residue 147-171). Blue, red and yellow lines represents the three replicates
respectively.
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Figure 6.21: Non-acetylated wild type MupH monomer simulation replicate 1, distance measured be-
tween the loop I and II over the time of 50ns. Distances were measured between the three Cα on the loop
I (L150, M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines
represents the average distance of P207, D208 and S209 respectively from the three residues on the loop
I.
Figure 6.22: Non-acetylated wild type MupH monomer simulation replicate 2, distance measured be-
tween the loop I and II over the time of 50ns. Distances were measured between the three Cα on the loop
I (L150, M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines
represents the average distance of P207, D208 and S209 respectively from the three residues on the loop
I.
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Figure 6.23: Non-acetylated wild type MupH monomer simulation replicate 3, distance measured be-
tween the loop I and II over the time of 50ns. Distances were measured between the three Cα on the loop
I (L150, M151 and I152) and three Cα on the loop II (P207, D208 and S209). Red, green and blue lines
represents the average distance of P207, D208 and S209 respectively from the three residues on the loop
I.
6.3 Discussion
6.3.1 A loop at the KS dimer interface appears to be responsible for the
substrate specificity
To find out what in the mup cluster is responsible for the addition of the 6-hydroxyl (α-hydroxyl),
Dr. Joanne Hothersall from Prof. Thomas group carried out mutagenesis to delete mupA, a tai-
loring gene. According to the position of occurrence of the 6-hydroxyl in the mupirocin (Figure
1.26) it was hypothesized that MupA must be acting after MmpD. She found that the deletion
strain produced mupiric acid but not mupirocin H (Wu et al. 2008). It was inferred that this
was formed by the release of an intermediate from module 4 of MmpD. Since no intermediates
longer than mupiric acid were found this fits with the idea that MupA is acting after MmpD
and if it is acting as a hydrolase, as hypothesised, then it suggests the non-hydroxylated monic
acid intermediate cannot be recognised by the first extender domain of MmpA. Supposing that
MupA was responsible for the addition of the 6-hydroxyl and that a lack of it would produce an
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intermediate without an α-hydroxyl, then what might be stopping KS-mupA2 from recognizing
the non α-hydroxylated substrate?
Previous studies on the cis-AT DEBS systems have shown that the KSs were able to be
acylated by unnatural substrates but were not able to carry out the elongation step, suggesting
that the pathway stalled at the KS with the clogged intermediate (Watanabe et al. 2003). In a
recent study, Busch et al. (2013) have shown a gate keeping mechanism in iterative KSs from the
cis-AT aureothin system. However, studies conducted by Menzella et al. (2005) showed PKSs
accepting unnatural substrates in a cis-AT system. Thus the substrate recognition mechanisms
in the cis-AT KSs are still not very well understood.
In the trans-AT PKSs, Nguyen et al. (2008) showed a strong correlation between the KS se-
quences and their preferred substrates. Based on this association of different substrates with dif-
ferent KS clades Jenner et al. (2013) determined the basis of substrate specificity of a trans-AT
KS associated with accepting β-branched substrates. Using a novel mass spectrometry method
they identified a position in the trans-AT BaeL KS5 (bacillaene cluster) which is responsible
for accepting only β-branched substrates.
To investigate the hypothesis that KS-mupA2 is specific for an α-hydroxylated precursor of
monic acid the expected α-hydroxylate substrate was docked into a model of the KS-mupA2
dimer structure. A malonate molecule attached to the phosphopantetheine was also docked,
while keeping the substrate C158 interaction, to mimic the decarboxylation stage of the Claisen
condensation, with the phosphopantetheine attached to a modelled ACP-mupA2. The final
docked conformation mimics the system ready to carry out the carbon-carbon bond formation
and the acyl chain transfer to the phosphopantetheinylated ACP. Docking results revealed a
motif, DNYK, within 5 Å of the α-hydroxyl, in a loop contributed by the opposite subunit
at the dimer interface. This loop connects an α-helix at its N-terminus to a β-strand at its
C-terminus. The loop is similar to its counterpart in the thiomarinol TmpA module, whose
synthetic pathway also produces a product hydroxylated at the same position, with TmpA and
MmpA both having the conserved DNYK motif, but this loop is not conserved among the other
KSs from the mupirocin and thiomarinol clusters. It was hypothesized that if this loop were to
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be swapped with the loops from KS-mupA1 or KS-mupA3 then the KS which does not process
a substrate with an α-hydroxyl might allow the pathway to proceed further.
There seems to be no similar DNYK motif present in the structures available in the PDB,
determined by using the PDBe Motif webserver. Limiting the search to a motif in a helical con-
text found only the Vaccinia Virus H7 protein (PDB ID 4W5X) containing this motif, however
no ligand information was present. Looking into the structure of Vaccinia Virus H7 protein, the
DNYK motif lies in a loop with the D of the motif (D56) at the C-terminus of a helix. Vaccinia
Virus H7 protein has a unique fold with no sequence homology outside poxvirus family. The
Vaccinia Virus H7 protein shares some similarity in secondary structure and surface properties
with the PX domains, which highlights surface residues K108, R109 and K112 forming a basic
patch that are found to be important for binding phosphoinositides (Kolli et al. 2015). However,
the DNYK motif is structurally far away (≈25 Å) from this basic patch and seems to have no
role in the binding of phosphoinositides. Moreover, the loop points to solvent with no obvious
interaction partners in the crystal lattice and in no way looks like a binding site. Limiting the
search finding a DNYK motif in a loop context did not find any matching structure. Search-
ing the motif without limiting the search for any secondary structure information found 31
structures with only a rabbit IGG fc fragment (PDB ID 2VUO) associated with ligand binding
information. In the rabbit IGG fc fragment structure the backbone atoms of D389 are in van der
Waals contact with an azide ion and the backbone nitrogen of N390 is making a hydrogen bond
with the azide ion. The NZ of K392 is in van der Waals contact with the carbon of a formic
acid molecule. Although this structure shows the DNYK motif to be in contact with the bound
ligands, neither of the ligands carries an α-hydroxyl and the motif is on a β-strand rather than
on a loop or helix. Searching for DLYK, DLFK and DLLK variants did not yield any results
different results from the DNYK motif search.
To test the importance of this loop in recognizing the substrate, Miss. Y. Alsamrarraie from
Prof. Thomas group inserted the key loop from KS-mupA1 into KS-mupA2 in a P. fluorescens
∆mupA strain and in the wild type P. fluorescens NCIMB 10586. HPLC traces revealed a peak
for both the mutant strains which was not detected in the parent P. fluorescens ∆mupA strain.
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This implies that the pathway has produced a full length substrate, and thus must have been
successfully processed by the KS-mupA2 mutants. Thus, the chimera of KS-mupA2 with KS-
mupA1 loop processed the substrates from WT and ∆mupA strains, presumed to be with and
without α-hydroxyl. This could mean that the wild type KS-mupA2 serves as a checkpoint,
which only allows an α-hydroxylated substrate to pass through and stalls the pathway in case
of an α-dehydroxylated substrate. The structure of the metabolites produced are still to be con-
firmed from our collaborators at Bristol but is likely to be more hydrophobic than pseudomonic
acid since it has a longer retention on the column, which is consistent with 6-dehydroxylated
pseudomonic acid A. Once it is confirmed that the pathway has produced a molecule which
lacks 6-hydroxyl further point mutations can be done to pin point the residue(s) responsible for
the α-hydroxyl substrate specificity. Target point mutations may also help not only to modulate
the specificity of KS-mupA2 towards accepting an non α-hydroxylated substrate but might also
increase the amount of the metabolite produced as compared to swapping the whole loop. These
insights would eventually lead towards successfully re-engineering trans-AT KSs for accepting
non natural substrates for the production of novel compounds, and may also apply to cis-AT
systems but further experiments are required.
6.3.2 Movement of MupH surface loops may have a role in ligand binding
A large movement in two of the surface loops over the active site of MupH was seen in the sim-
ulations of an ACP-mupA3a:MupH complex (Chapter 4, Section 4.2.5) with the ACP-mupA3a
cognate substrate attached to the ACP and an acetyl molecule covalently bound to the catalytic
C115 in MupH. This observation lead to the hypothesis that this large movement of MupH
surface loops at the opening of the MupH active site might be assisting in accommodating the
ligand inside the MupH active site. To test the hypothesis that the movement may be triggered
either by the acetyl transfer to the catalytic C115 in MupH (see HMG-CoA reaction mechanism
in Section 3.1) or due the ACP-mupA3a docking to the MupH, three independent simulations
were performed for each of the systems: ACP-mupA3a:MupH monomer, ACP-mupA3a:MupH
dimer, MupH monomer with C115 acetylated and wild type MupH monomer structure.
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The simulations of the MupH monomer structure showed a general trend of larger move-
ment in loop II, both in terms of its over all fluctuation (RMSF) and the distance between loop II
and loop I, however, these fluctuations decreased in the simulations with a dimeric MupH. This
could be because loop II, being close to the dimer interface, would interact with the residues
from the other monomer, which might restrict its movement. It was also seen that the loops
in the MupH monomer with ligand docked in the active site tend to have a large distance be-
tween them at the beginning of the simulation which decreases eventually and then remains at
a roughly constant value of 10 Å. One interpretation is that the MupH monomer structures may
allow easy access to the active site until the substrate is bound. Whether these observations
are biologically relevant or not is difficult to say with the available data. Multiple or longer
simulation runs with monomeric and dimeric states might provide more evidence.
Determining experimentally that MupH exists as a monomer or dimer may provide some
insight into the simulations or may lead to further experiments. In my previous analysis in
Chapter 3, Section 3.2.6.2 real value evolutionary trace and PIER analysis showed a strong sig-
nal on the MupH surface corresponding to the dimer interface in the HMG-CoA homologue
structure, hence suggesting that MupH is also a dimer. To test this experimentally a simple
technique such as electrospray ionization mass spectrometry (ESI-MS) may be utilized. Since,
ESI-MS is a ‘soft ionization’technique which produces very few fragments, it would be straight
forward to determine the mass of the whole MupH or MupH dimer (preserving the noncov-
lent interactions (Huang et al. 1993)). ESI-MS can also be utilized to quantify protein-protein





The aim of the thesis was to explore details of the mupirocin biosynthesis pathway, focussing
in particular on aspects of the function of the MmpA complex and its in trans interactions.
Generalizing some of the principles found should aid in the redesign of existing PKS, for the
synthesis of novel compounds, with particular interest in medicinal compounds such as new
antibiotics or potential anticancer agents.
In order to investigate the mechanism of MmpA this thesis focused mainly on exploiting
already existing molecular modelling methods and proposes some protocols which can be used
for similar purposes. Along with utilizing various pre existing molecular modelling methods
the projects in this thesis heavily relied on Perl scripts written during the course of the project
for various purposes for example HMM analysis and integrating GAFF parameters into GRO-
MACS software. The computational protocols used along with the experimental validation
of the predictions underlines the importance of molecular modelling in modern biological re-
search, allowing the prediction of key residues in MmpA and its interacting partner MupH that
would have been expensive and very time consuming to discover solely by experiments.
At the inception of this thesis the major outstanding question was the β-branching mech-
anism in the mupirocin as well as other polyketide biosynthesis pathway. β-branching which
is the addition of a methyl branch at the β position was hypothesised to be caused by the con-
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certed action of five proteins collectively called the HCS cassette. Out of the five proteins an
HMG-CoA homologue (MupH in the mupirocin system) protein is the first to interact with an
ACP carrying the substrate to be β-branched. It was not understood what MupH recognizes on
the C-terminal ACPs of MmpA. There are 16 ACPs associated with the PKSs and 5 discrete
ACPs associated with the tailoring proteins in the mupirocin cluster. Out of the 21 ACPs how
does MupH recognizes its partner ACP? According to the position of the β-branch in the monic
acid moiety it was easy to deduce that the β-branching happens at the end of the third module of
MmpA. However, it does not tell us how does MupH exclude all the 21 possible partner APCs
and only choose the two tandem ACPs in the MmpA.
Sequence analysis carried out by Dr. Tony Haines discovered the presence of a conserved
tryptophan six residues downstream of the catalytic cysteine in the ACPs associated with the
β-branching but never conserved in the non-branching ACPs. Structure determination of the
ACP-mupA3ab didomain by Dr. Matt Crump indicated that the tryptophan is buried at the
core of the ACPs surrounded by the other highly conserve hydrophobic residues. Cross com-
plementation experiments in Prof. Thomas’ group showed that the branching ACPs from the
thiomarinol system complements branching ACPs in the mupirocin system but that the non-
branching ACPs do not. These experiments established that the branching ACPs differ from
the non-branching ACPs and probably the structural variations between the two helps MupH in
recognizing the correct ACP. However, a mechanistic view of what is happening at the inter-
face of the two proteins when they interact was missing. Computational studies which included
docking, molecular dynamics, hidden Markov model analysis, and sequence and structure based
interface prediction carried out in this regard proposed the importance of the tryptophan at the
core of the protein in maintaining the correct packaging of the core. This correct packaging
would lead to the correct orientation of the helix III which forms the interface of the ACP with
MupH. One residue mutation on the helix III, Y62F/A showed the importance of helix III at the
interface.
Although the predicted ACP:MupH complex laid down the general rules for the β-branching
ACP and HCS interaction there are more residues involved at the interface which define pair
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wise specificity between the ACP:HCS pairs in the different systems. Cross complementa-
tion experiments showed that BatC (the MupH homologue from kalimantacin system) failed to
complement MupH in the mupirocin cluster. A sequence analysis revealed one residue near the
ACP:MupH interface, that differs between the TmlH and MupH, which complements ∆mupH
in trans and BatC that does not. The L to M mutation was found to lead to gain of function with
BatC L219M complements ∆mupH.
Another way to resume the failed complementation of ∆mupH by BatC might be to swap
the mupirocin ACPs for the cognate ACPs of BatC from the kalimantacin system. Suicide mu-
tagenesis experiments were conducted to express the β-branching ACPs from the kalimantacin
cluster in the mupirocin cluster. No pseudomonic acid production was detected in the HPLC
traces for the strains expressing kalimantacin ACPs and the wild type MupH. This observa-
tion was in line with the initial hypothesis. However, upon expressing kalimantacin ACPs with
the wild type BatC there was also no pseudomonic acid production detected. However, a new
peak was detected which may correspond to a new metabolite being produced similar to the
pseudomonic acids and experiments are on going to characterise it.
An alternative method for investigating pairwise specificity might be to make changes in
the ACP-mupA3ab β-branching ACPs native to the mupirocin cluster, to allow them to func-
tion efficiently with the batC when expressed in trans, as previous experiments have shown
the suitability of BatC in the mupirocin cluster. Molecular dynamics simulation of the ACP-
mupA3a:MupH complex helped to refine the docking interface proposing residues at the inter-
face which might play role in improving ACP-mupA3a’s ability to interact well with the BatC.
However, comparing the sequences of ACPs from the clusters which are likely to complement
MupH and the ones which do not, there were no obvious patterns that identified putative key
residues.
The docking experiments of ACP-mupA3a and MupH have shown that in order to reach
the ligand in the correct orientation for the β-branching almost all of the phosphopantetheine
along with the 16C monic acid precursor needs to get completely inside the MupH active site.
It has always been intriguing on how a large substrate like this is accommodated in the MupH
227
active site. The docking analysis of rigid static structures does not tell us if there is an in-
volvement of a dynamic element during the process. Molecular dynamics simulations on the
ACP-mupA3a:MupH complex revealed a large movement in two loops at the surface of MupH
at the opening of the MupH active site. Upon visualising the simulation trajectories it seems that
these loop movement assist in the accommodation of the ligand in the active site. The distance
between the mobile loops was found to be larger in the MupH monomer structures as compared
to the MupH dimer structure. HMG-CoA orthologues exists as a dimer therefore its quite likely
that MupH also exists as a dimer however, an experimental validation will be required to sup-
port this hypothesis. These large loop movements were not previously reported either through
experiments or computational methods.
Dynamic change in the structure upon ligand binding was also identified in the ACPs. FAS
ACPs are shown to sequester the acyl chains within their hydrophobic core through experiments
as well as molecular dynamics simulations. However, no such observations had been made in
the PKS ACPs. In order to explore this phenomenon in the PKS ACPs different apo, holo, and
acyl forms of ACPs from the mupirocin cluster were simulated in explicit solvent for upto 1
µs. The molecular dynamics simulations revealed that the PKS ACPs do form a cavity upon
the attachment of the phosphopantetheine and acyl chains. The length of the acyl chain might
also influence the size of the cavity. The cavity formed does not form a deep tunnel as in the
FAS ACPs but, is rather a shallow, solvent exposed, surface groove, enabling the polar groups
on the acyl chain to hydrogen bond with the solvent whilst shielding the hydrophobic parts
of the polyketide. It was also seen that a bulky residue at the proposed tunnel opening in the
PKS ACPs prohibits the formation of a deep tunnel as opposed to the smaller residue at the
equivalent position in the FAS ACPs. These dynamic behaviours were seen for the first time in
the PKS ACPs in this work.
In re-engineering polyketides there are two major problems, the recognition specificity be-
tween the protein domains and the recognition specificity of the substrate. In the present work
I worked on analysing the KS substrate specificity for an α-hydroxylated polyketide substrate
by molecular docking of the cognate substrate of KS-mupA2 with the KS-mupA2 homo dimer.
228
Dr. Joanne Hothersall knocked out MupA, which is thought to hydroxylate pseudomonic acid
at the 6-OH position. For ∆mupA the longest intermediate found was mupric acid which is
produced by MmpD. This observation led to the hypothesis that an un α-hydroxylated substrate
cannot be recognized by the KS-mupA2, the first condensing domain in the MmpA, resulting
in the pathway shutdown. Docking the expected α-hydroxylated cognate substrate to the KS-
mupA2 homo dimer revealed a loop in the opposite monomer at the dimer interface interacting
with the α-OH. A sequence alignment of this loop from KS-mupA2 with all the other KSs from
the mupirocin and thiomarinol cluster showed a similar loop in the equivalent KS from the
thiomarinol system but no conservation was found with the other KSs. With this observation
it was hypothesised that replacing this loop in KS-mupA2 with the equivalent loops from the
KSs preceding and following it, KS-mupA1 and KS-mupA3, for which the cognate substrates
does not have an α-OH, might allow the pathway to proceed further. By the time of writing this
thesis Miss Yousra Alsamarraie from Prof. Thomas group was able to replace the KS-mupA2
loop with KS-mupA1 loop. The HPLC trace showed no peak for pseudomonic acid A or B but
a new peak with larger retention time suggested that the pathway has produced a full length
substrate, that is slightly more hydrophobic than pseudomonic acid A, consistent with dehy-
droxylated form of the product. More detailed structural analysis of the product is awaited, but
the experiments do seem to show that these loops are important for specificity.
7.2 Conclusions
The body of the work here shows the effectiveness of a range of modelling and bioinformatics
techniques for the analysis of the protein-protein, domain-domain and protein-substrate inter-
action involved in polyketide synthesis. Combined with experiments performed by me and
others elucidated key details of control of substrate flow at the start of the MmpA subunit from
mupirocin system and of the β-methylation step at the end of the MmpA subunit. The methods
used here and the results obtained should be applicable to other systems. In the future this may
lead to experimental and computational tools to design and synthesis novel compounds de novo.
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A.1 Steps involved in the HMM analysis
Step 1. Built the HMM models for the branching ACPs (38 seq; wacp.hmm) and non-branching
ACPs (178 seq; stdacp.hmm) using the sequences provided by Dr. Anthony Haines.
Step 2. Searched, scored and plotted the HMMs against the sequences used for model building
of both the models, to identify the respective clusters.
Step 3. Searched, scored and plot the HMMs against the test sequences (provided by Dr. An-
thony Haines) for both the models, to confirm the selectivity of the models and cluster-
ing.
Step 4. Fetched the sequences using stdACP hmm from Refseq microbial (6408654 seq) and
Uniprot Trembl (20127441 seq) database.
Step 5. Used Perl scripts (Script A.2.1 and Script A.2.2) to read the hmmsearch (a tool in HM-
MER3 suite) output, extracted the sequence for the each domain matched and arranged
the results in decreasing order of sequence length. Only the sequences above the length
of 60 residues were considered. The length of the model used was 67.
Step 6. Duplicate sequences were removed from both the sets using Script A.2.3.
Step 7. A multiple sequence alignment was carried out for both the sets and checked for the
presence of the active site serine (Script A.2.4). The sequences which lacked the active
site serine at the aligned position were removed.
Step 8. Both the sets were merged and again searched for any duplicates resulting in the final
set of 10076 sequences.
Step 9. The filtered set resulted in 16490 sequences which were then further extended by 7
residues on both the ends to ensure they would cover the full length of the models
(Script A.2.5).
Step 10. The final set of 16490 extended sequences was then scored using both the HMM
models and plotted.
A.2 Scripts used in the HMM analysis
A.2.1 Script to extract the individual domain sequence matched by stdACP






# This script is used to extract the domain sequences matched by the stdACP
hmm model against refseq database







while( <> ) {
my $fa = undef;
my $seq = undef;
$winnDomain = $1 if /\=\= domain\s(\d+)/; # Search for the line which
starts with ==domain num and read the number of the domain
if( m/ˆ\s+(gi\|[\w\|\_\-\.]+|sp\|[\w\|\_\-\.]+)\s+\d+.([A-Za-z_\-]+)/ )
{
$fa = $1; # Store the name or tag
$seq = $2; # Store the sequence
}
# Push everything catched above in an array





push @len, length( $seq );
}
}
# Sort all the sequences according to lenght in decreasing order
my @sorted = sort { $len[$b] <=> $len[$a] } 0 .. $#len;
#print Dumper @fastatag; # This is to crosscheck
# Output the final list
for my $i ( @sorted ) {
if(length($sequence[$i])>=60)
{
print ’>’. $fastatag[$i] . "Domain_" . $winnDomains[$i] . "\n";





print "Number of sequences in sorted array", scalar @sorted;
A.2.2 Script to extract the individual domain sequence matched by stdACP





# This script is used to extract the domain sequences matched by the stdACP
hmm model against trembl database







while( <> ) {
my $fa = undef;
my $seq = undef;
$winnDomain = $1 if /\=\= domain\s(\d+)/; # Search for the line which
starts with ==domain num and read the number of the domain
if( m/ˆ\s+(tr\|[\w\|\_\-\.]+|sp\|[\w\|\_\-\.]+)\s+\d+.([A-Za-z_\-]+)/ )
{
$fa = $1;#Store the name or tag
$seq = $2;#Sotre the sequence
}
# Push everything catched above in an array





push @len, length( $seq );
}
}
# Sort all the sequences according to lenght in decreasing order
my @sorted = sort { $len[$b] <=> $len[$a] } 0 .. $#len;
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#print Dumper @fastatag; # This is to crosscheck
# Output the final list
for my $i ( @sorted ) {
if(length($sequence[$i])>=60)
{
print ’>’. $fastatag[$i] . "|Domain_" . $winnDomains[$i] . "\n";




print "Number of sequences in sorted array: ",scalar @sorted;




# This script is used to filter the duplicate sequences using BioPerl module
my %unique;
my $file = $ARGV[0];
my $seqio = Bio::SeqIO->new(-file => $file, -format => "fasta");
my $outseq = Bio::SeqIO->new(-file => ">$file.unique.fasta", -format =>
"fasta");
while(my $seqs = $seqio->next_seq) {
my $id = $seqs->display_id;












# This script is used to check for catalytic S at the aligned position in a
MSA file
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my $in = Bio::SeqIO->new(-file =>




while ( my $seq = $in->next_seq() )
{









A.2.5 Script to extend the sequences on either ends by 7 residues
Note: This script was written with the help of Dr. Anthony Haines.
#!/usr/bin/perl -w
use strict;
# Open the database containing 10076 sequences














$tag =˜ m/ˆ(.+\|)Domain\_(\d+)/; # Exclude the Domain_num from the fasta
tag line and extract the highest domain number
# To read refseq database


























# Read the original database files
open(DATA2, "refseq_all.fasta") || die "Can’t open file";











for($domain = $useful{$name}; $domain>0;$domain--) # Iterate the loop till
the maximum number of domain name found in the previous block
{
#check if the name read exist in the hash storing tag and sequence in the
previous block
#if yes then check whether the corresponding sequence matches and extract
the 7 residues on either sides
if(defined($tag_seq{"${name}Domain_$domain"}))# For refseq database;
#if(defined($tag_seq{"${name}|Domain_$domain"}))# For trembl database
{
# The reg exp to extract 7 residues on either side of the sequence matched
255




print ">${name}Domain_$domain\n"; # For refseq database
















A.3 Script to generate the mutant sequences
#!/usr/bin/perl -w
use strict;
#This script was used to generate single point mutation in a sequence with all
the other 19 amino acids.
#The highest scoring sequence from the previous generation.
my td3a=split(//,"SVICEALSDALKVPKKMIDPTEAFSDYGLDSITGVNV
AQTISSVLNVDLKTTALFDYVCIDQLARYV");





for($i=0; $i<=$#td3a; $i++) #Iterate every position in the original sequence
{
@temp=@td3a;
for($j=0;$j<=$#amino;$j++) #Iterate every amino acid in the array
{
if($td3a[$i] ne $amino[$j]) #Check if the amino acid is in the position or











A.4 Scripts to convert GAFF parameters into Gromacs for-
mat
These scripts were written during the course of the PhD and were used to convert GAFF pa-
rameters into Gromacs format in order to integrate the values into the AMBER 99sb-ILDB
forcefield parameter databases.
A.4.1 Script to convert atom type parameters from GAFF to Gromacs
format
#!/usr/bin/perl
# This script was used to convert the format of atom name and mass from GAFF
to Gromacs format (atomtypes.atp).
# The input required was a file containing the list of atoms with mass from
GAFF in Amber suite.
use strict;
use warnings;
if ($#ARGV < 0) {
print STDERR "Usage: $0 <file.txt>\n";
exit -1;
}












A.4.2 Script to convert bond length parameters from GAFF to Gromacs
format
#!/usr/bin/perl
# This script was used to convert the format of bond parameters from GAFF to
Gromacs format (ffbonded.itp).
# The input required was a file containing the list of bond parameters from
GAFF in Amber suite.
use strict;
use warnings;
if ($#ARGV < 0) {
print STDERR "Usage: $0 <file.txt>\n";
exit -1;
}















A.4.3 Script to convert bond angle parameters from GAFF to Gromacs
format
#!/usr/bin/perl
# This script was used to convert the format of bond angle parameters from
GAFF to Gromacs format (ffbonded.itp).
# The input required was a file containing the list of bond angle parameters
from GAFF in Amber suite.
use strict;
use warnings;
if ($#ARGV < 0) {
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print STDERR "Usage: $0 <file.txt>\n";
exit -1;
}















A.4.4 Script to convert dihedral angle parameters from GAFF to Gro-
macs format
#!/usr/bin/perl
# This script was used to convert the format of dihedral angle parameters from
GAFF to Gromacs format (ffbonded.itp).
# The input required was a file containing the list of dihedral angle
parameters from GAFF in Amber suite.
use strict;
use warnings;
if ($#ARGV < 0) {
print STDERR "Usage: $0 <file.txt>\n";
exit -1;
}















print " ",$dihedralatom1," ",$dihedralatom2," ",$dihedralatom3,"
",$dihedralatom4," 9 ",$phase," ",$kth," ",$PN," ; ",$description,"\n";
}
close(FILE);
A.4.5 Script to convert improper angle parameters from GAFF to Gro-
macs format
#!/usr/bin/perl
# This script was used to convert the format of improper angle parameters from
GAFF to Gromacs format (ffbonded.itp).
# The input required was a file containing the list of improper angle
parameters from GAFF in Amber suite.
use strict;
use warnings;
if ($#ARGV < 0) {
print STDERR "Usage: $0 <file.txt>\n";
exit -1;
}














print $dihedralatom1," ",$dihedralatom2," ",$dihedralatom3,"





A.4.6 Script to convert nonbonded parameters from GAFF to Gromacs
format
#!/usr/bin/perl
# This script was used to convert the format of non bonded parameters from
GAFF to Gromacs format (ffnonbonded.itp).
# The input required was a file containing the list of non bonded parameters
from GAFF in Amber suite.
use strict;
use warnings;
if ($#ARGV < 0) {
print STDERR "Usage: $0 <file.txt>\n";
exit -1;
}




my $atomtype = substr($_,2,2);
my $sigma = sprintf("%.5e",(substr($_,13,6) * ((2**(5/6))/10)));
my $epsilon = sprintf("%.5e",(substr($_,22,6) * 4.184));
my $description=substr($_,41);
if($atomtype=˜ m/ˆc/ and not $atomtype=˜ m/cl/)
{























































open(PDB, "<$multiplepdb") or die "Can not open file";
open(OUT, ">protein2.pdb") or die "Can not create file";






























B.1 List of new residues with charges added to the AMBER99SB-
ILDN forcefield in Gromacs format
B.1.1 Charges for phosphopantetheine
Residue name: SPT
Atoms Atomtype Charge Number
------------------------------------
N N -0.41570 1
H H 0.27190 2
CA CT -0.08800 3
HA H1 0.15590 4
CB CT 0.03140 5
HB1 H1 0.08540 6
HB2 H1 0.08540 7
OG OS -0.43570 8
PD p5r 1.04280 9
OE or -0.73120 10
OH or -0.73120 11
OZ osr -0.40080 12
CQ c3r -0.02100 13
HQ1 h1r 0.10220 14
HQ2 h1r 0.10220 15
CI c3r 0.12870 16
CIA c3r -0.15840 17
HIA1 hcr 0.03550 18
HIA2 hcr 0.03550 19
HIA3 hcr 0.03550 20
CIB c3r -0.15840 21
HIB1 hcr 0.03550 22
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HIB2 hcr 0.03550 23
HIB3 hcr 0.03550 24
CIG c3r -0.00210 25
HIG h1r 0.16460 26
OID ohr -0.58750 27
HID hor 0.40570 28
CIE cr 0.38430 29
OIZ or -0.49960 30
NH nr -0.28870 31
HH hnr 0.25640 32
CIQ c3r 0.03840 33
HIQ1 h1r 0.05000 34
HIQ2 h1r 0.05000 35
CK c3r -0.17820 36
HK1 hcr 0.07800 37
HK2 hcr 0.07800 38
CKA cr 0.51920 39
OKB or -0.57540 40
NKG nr -0.40580 41
HKG hnr 0.27300 42
CKD c3r 0.02980 43
HKD1 h1r 0.06100 44
HKD2 h1r 0.06100 45
CKE c3r -0.00750 46
HKE1 h1r 0.09690 47
HKE2 h1r 0.09690 48
SKZ shr -0.42300 49
HKZ hsr 0.21670 50
C C 0.59730 51
O O -0.56790 52
B.1.2 Charges for unbranched monic acid attached to phosphopanteth-
eine
Residue name: SPM
Atoms Atomtype Charge Number
------------------------------------
N N -0.4157 1
H H 0.2719 2
CA CT -0.0880 3
HA H1 0.1559 4
CB CT 0.0314 5
HB1 H1 0.0854 6
HB2 H1 0.0854 7
OG OS -0.4357 8
PD p5r 1.0428 9
OE or -0.7312 10
OH or -0.7312 11
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OZ osr -0.4008 12
CQ c3r -0.0210 13
HQ1 h1r 0.1022 14
HQ2 h1r 0.1022 15
CI c3r 0.1287 16
CIA c3r -0.1584 17
HIA1 hcr 0.0355 18
HIA2 hcr 0.0355 19
HIA3 hcr 0.0355 20
CIB c3r -0.1584 21
HIB1 hcr 0.0355 22
HIB2 hcr 0.0355 23
HIB3 hcr 0.0355 24
CIG c3r -0.0021 25
HIG h1r 0.1646 26
OID ohr -0.5875 27
HID hor 0.4057 28
CIE cr 0.3843 29
OIZ or -0.4996 30
NH nr -0.2887 31
HH hnr 0.2564 32
CIQ c3r 0.0384 33
HIQ1 h1r 0.0500 34
HIQ2 h1r 0.0500 35
CK c3r -0.1782 36
HK1 hcr 0.0780 37
HK2 hcr 0.0780 38
CKA cr 0.6244 39
OKB or -0.5521 40
NKG nr -0.5468 41
HKG hnr 0.2730 42
CKD c3r -0.1108 43
HKD1 h1r 0.1309 44
HKD2 h1r 0.1309 45
CKE c3r 0.0796 46
HKE1 h1r 0.0565 47
HKE2 h1r 0.0565 48
SKZ ssr -0.278 49
CKH cr 0.4936 50
OKQ or -0.4762 51
CX c3r -0.0376 52
HX1 hcr 0.0292 53
HX2 hcr 0.0292 54
CXA cr 0.5017 55
OXB or -0.4804 56
CXG c3r -0.0339 57
HXG1 hcr 0.0325 58
HXG2 hcr 0.0325 59
CXD c3r 0.1369 60
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HXD h1r 0.1344 61
OXE ohr -0.6552 62
HXE hor 0.4331 63
CXZ c3r -0.0199 64
HXZ h1r 0.1196 65
OXH ohr -0.6166 66
HXH hor 0.3962 67
CXQ c3r 0.1625 68
HXQ h1r 0.1158 69
OM ohr -0.6569 70
HM hor 0.4266 71
CMA c2r 0.1042 72
CMB c3r -0.1920 73
HMB1 hcr 0.0639 74
HMB2 hcr 0.0639 75
HMB3 hcr 0.0639 76
CMG cer -0.2584 77
HMG har 0.1528 78
CMD cer -0.1381 79
HMD har 0.1190 80
CME c2r -0.1661 81
HME har 0.1142 82
CMZ c3r 0.0367 83
HMZ hcr 0.0647 84
CMH c3r -0.1807 85
HMH1 hcr 0.0480 86
HMH2 hcr 0.0480 87
HMH3 hcr 0.0480 88
CMQ c3r 0.2814 89
HMQ h1r 0.0165 90
ON ohr -0.6655 91
HN hor 0.4035 92
CNA c3r -0.2053 93
HNA1 hcr 0.0630 94
HNA2 hcr 0.0630 95
HNA3 hcr 0.0630 96
C C 0.5973 97
O O -0.5679 98
B.1.3 Charges for fully saturated carbon chain attached to phosphopan-
tetheine
Residue name: SPD
Atoms Atomtype Charge Number
------------------------------------
N N -0.4157 1
H H 0.2719 2
CA CT -0.0880 3
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HA H1 0.1559 4
CB CT 0.0314 5
HB1 H1 0.0854 6
HB2 H1 0.0854 7
OG OS -0.4357 8
PD p5r 1.0428 9
OE or -0.7312 10
OH or -0.7312 11
OZ osr -0.4008 12
CQ c3r -0.0210 13
HQ1 h1r 0.1022 14
HQ2 h1r 0.1022 15
CI c3r 0.1287 16
CIA c3r -0.1584 17
HIA1 hcr 0.0355 18
HIA2 hcr 0.0355 19
HIA3 hcr 0.0355 20
CIB c3r -0.1584 21
HIB1 hcr 0.0355 22
HIB2 hcr 0.0355 23
HIB3 hcr 0.0355 24
CIG c3r -0.0021 25
HIG h1r 0.1646 26
OID ohr -0.5875 27
HID hor 0.4057 28
CIE cr 0.3843 29
OIZ or -0.4996 30
NH nr -0.2887 31
HH hnr 0.2564 32
CIQ c3r 0.0384 33
HIQ1 h1r 0.0500 34
HIQ2 h1r 0.0500 35
CK c3r -0.1782 36
HK1 hcr 0.0746 37
HK2 hcr 0.0746 38
CKA cr 0.5692 39
OKB or -0.5754 40
NKG nr -0.4058 41
HKG hnr 0.2730 42
CKD c3r 0.0298 43
HKD1 h1r 0.0610 44
HKD2 h1r 0.0610 45
CKE c3r -0.0075 46
HKE1 h1r 0.0969 47
HKE2 h1r 0.0969 48
SKZ ssr -0.4230 49
CKH c3r -0.1364 50
HKH1 hcr 0.0980 51
HKH2 hcr 0.0980 52
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CX c3r 0.0624 53
HX1 hcr 0.0311 54
HX2 hcr 0.0311 55
CXA c3r -0.0179 56
HXA1 hcr -0.0035 57
HXA2 hcr -0.0035 58
CXG c3r 0.0472 59
HXG1 hcr -0.0190 60
HXG2 hcr -0.0190 61
CXD c3r 0.0036 62
HXD1 hcr -0.0024 63
HXD2 hcr -0.0024 64
CXZ c3r 0.0074 65
HXZ1 hcr -0.0008 66
HXZ2 hcr -0.0008 67
CXQ c3r 0.0074 68
HXQ1 hcr -0.0008 69
HXQ2 hcr -0.0008 70
CMA c3r 0.0036 71
HMA1 hcr -0.0024 72
HMA2 hcr -0.0024 73
CMG c3r -0.0198 74
HMG1 hcr 0.0053 75
HMG2 hcr 0.0053 76
CMD c3r 0.0074 77
HMD1 hcr -0.0008 78
HMD2 hcr -0.0008 79
CME c3r -0.0091 80
HME1 hcr -0.0008 81
HME2 hcr -0.0008 82
CMZ c3r 0.0190 83
HMZ1 hcr -0.0013 84
HMZ2 hcr -0.0013 85
CMQ c3r 0.0329 86
HMQ1 hcr -0.0053 87
HMQ2 hcr -0.0053 88
CNA c3r -0.0579 89
HNA1 hcr 0.0097 90
HNA2 hcr 0.0097 91
HNA3 hcr 0.0097 92
C C 0.5973 93
O O -0.5679 94
B.1.4 Charges for C14 mupirocin intermediate attached to phosphopan-
tetheine
Residue name: SPB
Atoms Atomtype Charge Number
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------------------------------------
N N -0.4157 1
H H 0.2719 2
CA CT -0.0880 3
HA H1 0.1559 4
CB CT 0.0314 5
HB1 H1 0.0854 6
HB2 H1 0.0854 7
OG OS -0.4357 8
PD p5r 1.0428 9
OE or -0.7312 10
OH or -0.7312 11
OZ osr -0.4008 12
CQ c3r -0.0210 13
HQ1 h1r 0.1022 14
HQ2 h1r 0.1022 15
CI c3r 0.1287 16
CIA c3r -0.1584 17
HIA1 hcr 0.0355 18
HIA2 hcr 0.0355 19
HIA3 hcr 0.0355 20
CIB c3r -0.1584 21
HIB1 hcr 0.0355 22
HIB2 hcr 0.0355 23
HIB3 hcr 0.0355 24
CIG c3r -0.0021 25
HIG h1r 0.1646 26
OID ohr -0.5875 27
HID hor 0.4057 28
CIE cr 0.3843 29
OIZ or -0.4996 30
NH nr -0.2887 31
HH hnr 0.2564 32
CIQ c3r 0.0384 33
HIQ1 h1r 0.0500 34
HIQ2 h1r 0.0500 35
CK c3r -0.1134 36
HK1 hcr 0.0353 37
HK2 hcr 0.0353 38
CKA cr 0.6244 39
OKB or -0.5521 40
NKG nr -0.5991 41
HKG hnr 0.3539 42
CKD c3r 0.0208 43
HKD1 h1r 0.0485 44
HKD2 h1r 0.0485 45
CKE c3r 0.0518 46
HKE1 h1r 0.0613 47
HKE2 h1r 0.0613 48
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SKZ ssr -0.2812 49
CXA cr 0.5541 50
OXB or -0.4720 51
CXG c3r -0.1453 52
HXG1 hcr 0.0647 53
HXG2 hcr 0.0647 54
CXD c3r 0.2284 55
HXD h1r 0.1019 56
OXE ohr -0.5954 57
HXE hor 0.4071 58
CXZ c3r 0.0214 59
HXZ h1r 0.1137 60
OXH ohr -0.6254 61
HXH hor 0.3978 62
CXQ c3r 0.1110 63
HXQ h1r 0.1173 64
OM ohr -0.6240 65
HM hor 0.3929 66
CMA c2r 0.1146 67
CMB c3r -0.1914 68
HMB1 hcr 0.0624 69
HMB2 hcr 0.0624 70
HMB3 hcr 0.0624 71
CMG cer -0.2579 72
HMG har 0.1484 73
CMD cer -0.1291 74
HMD har 0.1234 75
CME c2r -0.1780 76
HME har 0.1196 77
CMZ c3r 0.0148 78
HMZ hcr 0.0736 79
CMH c3r -0.1712 80
HMH1 hcr 0.0441 81
HMH2 hcr 0.0441 82
HMH3 hcr 0.0441 83
CMQ c3r 0.3047 84
HMQ h1r 0.0121 85
ON ohr -0.6719 86
HN hor 0.4045 87
CNA c3r -0.2237 88
HNA1 hcr 0.0668 89
HNA2 hcr 0.0668 90
HNA3 hcr 0.0668 91
C C 0.5973 92
O O -0.5679 93
B.1.5 Charges for acetyl moiety attached to a cysteine
Residue name: CYA
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Atoms Atomtype Charge Number
------------------------------------
N N -0.4157 1
H H 0.2719 2
CA CT 0.0213 3
HA H1 0.1124 4
CB CT -0.1231 5
HB1 H1 0.1112 6
HB2 H1 0.1112 7
SG ssr -0.3079 8
CD cr 0.5660 9
OE or -0.4305 10
CZ c3r -0.3248 11
HZ1 hcr 0.1262 12
HZ2 hcr 0.1262 13
HZ3 hcr 0.1262 14
C C 0.5973 15




C.1 Formation and change in cavity volume in PKS ACPs
over time
Figure C.1: Formation and change in cavity volume over time (200 ns) in the apo ACP-mupA3a WT.
The time frames which had a zero value for the volume were omitted from the plot. Red line represents
the running average over 500 frames and green line represents the mean.
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Figure C.2: Formation and change in cavity volume over time (1 µs) in the apo ACP-mupA3a WT. The
time frames which had a zero value for the volume were omitted from the plot. Red line represents the
running average over 500 frames and green line represents the mean.
Figure C.3: Formation and change in cavity volume over time in the apo ACP-mupA3a W44L. The time
frames which had a zero value for the volume were omitted from the plot. Red line represents the running
average over 500 frames and green line represents the mean.
274
Figure C.4: Formation and change in cavity volume over time in the holo ACP-mupA3a WT. The time
frames which had a zero value for the volume were omitted from the plot. Red line represents the running
average over 500 frames and green line represents the mean.
Figure C.5: Formation and change in cavity volume over time in the holo ACP-mupA3a W44L. The time
frames which had a zero value for the volume were omitted from the plot. Red line represents the running
average over 500 frames and green line represents the mean.
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Figure C.6: Formation and change in cavity volume over time (200ns) in the acyl ACP-mupA3a WT. The
time frames which had a zero value for the volume were omitted from the plot. Red line represents the
running average over 500 frames and green line represents the mean.
Figure C.7: Formation and change in cavity volume over time (1 µs) in the acyl ACP-mupA3a WT. The
time frames which had a zero value for the volume were omitted from the plot. Red line represents the
running average over 500 frames and green line represents the mean.
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Figure C.8: Formation and change in cavity volume over time in the acyl ACP-mupA3a W44L. The time
frames which had a zero value for the volume were omitted from the plot. Red line represents the running
average over 500 frames and green line represents the mean.
Figure C.9: Formation and change in cavity volume over time in the acyl 14C ACP-mupA3a. The time
frames which had a zero value for the volume were omitted from the plot. Red line represents the running
average over 500 frames and green line represents the mean.
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Figure C.10: Formation and change in cavity volume over time in the acyl ACP-mupA2a. The time
frames which had a zero value for the volume were omitted from the plot. Red line represents the running
average over 500 frames and green line represents the mean.
Figure C.11: Space filled diagram of the largest (A) and the modal (B) cavity volume in the apo ACP-
mupA3a WT.
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Figure C.12: Space filled diagram of the largest (A) and the modal (B) cavity volume in the apo ACP-
mupA3a W44L.
Figure C.13: Space filled diagram of the largest (A) and the modal (B) cavity volume in the holo ACP-
mupA3a WT.
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Figure C.14: Space filled diagram of the largest (A) and the modal (B) cavity volume in the holo ACP-
mupA3a W44L.
Figure C.15: Space filled diagram of the largest (A) and the modal (B) cavity volume in the acyl ACP-
mupA3a W44L.
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Figure C.16: Space filled diagram of the largest (A) and the modal (B) cavity volume in the acyl 14C
ACP-mupA3a.
Figure C.17: Space filled diagram of the largest (A) and the modal (B) cavity volume in the acyl ACP-
mupA2a.
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C.1.1 Change in RMSD of PKS ACPs from FAS ACP over time
Figure C.18: RMSD between FAS ACP and apo ACP-mupA3a WT over time (200 ns). Green line
represents the mean.
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Figure C.19: RMSD between FAS ACP and apo ACP-mupA3a WT over time (1 µs). Green line represents
the mean.
Figure C.20: RMSD between FAS ACP and apo ACP-mupA3a W44L over time. Green line represents
the mean.
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Figure C.21: RMSD between FAS ACP and the holo ACP-mupA3a WT over time. Green line represents
the mean.
Figure C.22: RMSD between FAS ACP and the holo ACP-mupA3a W44L over time. Green line repre-
sents the mean.
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Figure C.23: RMSD between FAS ACP and the acyl ACP-mupA3a WT over time (200 ns). Green line
represents the mean.
Figure C.24: RMSD between FAS ACP and the acyl ACP-mupA3a WT over time (1 µs). Green line
represents the mean.
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Figure C.25: RMSD between FAS ACP and the acyl ACP-mupA3a W44L over time. Green line represents
the mean.
Figure C.26: RMSD between FAS ACP and the acyl 14C ACP-mupA3a over time. Green line represents
the mean.
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Figure C.27: RMSD between FAS ACP and the acyl ACP-mupA2a over time. Green line represents the
mean.
C.1.2 Hydrogen bonding between the phosphopantetheine, acyl groups
and protein/solvent
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Figure C.28: Number of hydrogen bonds formed between the phosphopantetheine and the ACP-mupA3a
WT surface residues. Red line represents the running average over 500 frames and green line represents
the mean.
Figure C.29: Number of hydrogen bonds formed between the phosphopantetheine and the ACP-mupA3a
W44L surface residues. Red line represents the running average over 500 frames and green line repre-
sents the mean.
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Figure C.30: Number of hydrogen bonds formed between the phosphopantetheine and the solvent in the
ACP-mupA3a WT. Red line represents the running average over 500 frames and green line represents
the mean.
Figure C.31: Number of hydrogen bonds formed between the phosphopantetheine and the solvent in the
ACP-mupA3a W44L. Red line represents the running average over 500 frames and green line represents
the mean.
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Figure C.32: Number of hydrogen bonds formed between the ACP-mupA3a cognate substrate and the
ACP-mupA3a WT surface residues over time (200 ns). Red line represents the running average over 500
frames and green line represents the mean.
Figure C.33: Number of hydrogen bonds formed between the ACP-mupA3a cognate substrate and the
ACP-mupA3a WT surface residues over time (1 µs). Red line represents the running average over 500
frames and green line represents the mean.
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Figure C.34: Number of hydrogen bonds formed between the phosphopantetheine and the ACP-mupA3a
W44L surface residues over time. Red line represents the running average over 500 frames and green
line represents the mean.
Figure C.35: Number of hydrogen bonds formed between the ACP-mupA3a cognate substrate and the
solvent in the acyl ACP-mupA3a WT simulation (200 ns). Red line represents the running average over
500 frames and green line represents the mean.
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Figure C.36: Number of hydrogen bonds formed between the ACP-mupA3a cognate substrate and the
solvent in the acyl ACP-mupA3a WT simulation (1 µs). Red line represents the running average over 500
frames and green line represents the mean.
Figure C.37: Number of hydrogen bonds formed between the ACP-mupA3a cognate substrate and the
solvent in the acyl ACP-mupA3a W44L simulation. Red line represents the running average over 500
frames and green line represents the mean.
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Figure C.38: Number of hydrogen bonds formed between the ACP-mupA2 cognate substrate and the
ACP-mupA2a surface residues. Red line represents the running average over 500 frames and green line
represents the mean.
Figure C.39: Number of hydrogen bonds formed between the ACP-mupA2 cognate substrate and the
solvent in the acyl ACP-mupA2a simulation. Red line represents the running average over 500 frames
and green line represents the mean.
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C.1.3 Change in solvent accessible surface area of the ligand over time
Figure C.40: Change in the solvent accessible area of phosphopantetheine over time in the holo ACP-
mupA3a WT simulation. Blue line represents hydrophobic SAS, red line represents hydrophilic SAS,
yellow line represents total SAS and green line represents the mean of the total SAS.
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Figure C.41: Change in the solvent accessible surface (SAS) of phosphopantetheine over time in the holo
ACP-mupA3a W44L simulation. Blue line represents hydrophobic SAS, red line represents hydrophilic
SAS, yellow line represents total SAS and green line represents the mean of the total SAS.
Figure C.42: Change in the solvent accessible area of the ACP-mupA3a cognate substrate over time (200
ns) in the acyl ACP-mupA3a WT simulation. Blue line represents hydrophobic SAS, red line represents
hydrophilic SAS, yellow line represents total SAS and green line represents the mean of the total SAS.
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Figure C.43: Change in the solvent accessible surface (SAS) of the ACP-mupA3a cognate substrate over
time (1 µs) in the acyl ACP-mupA3a WT simulation.. Blue line represents hydrophobic SAS, red line
represents hydrophilic SAS, yellow line represents total SAS and green line represents the mean of the
total SAS.
Figure C.44: Change in the solvent accessible surface (SAS) of the ACP-mupA3a cognate substrate
over time in the acyl ACP-mupA3a W44L simulation. Blue line represents hydrophobic SAS, red line
represents hydrophilic SAS, yellow line represents total SAS and green line represents the mean of the
total SAS.
296
Figure C.45: Change in the solvent accessible surface (SAS) of the 14C saturated chain over time in the
acyl 14C ACP-mupA3a simulation. Blue line represents hydrophobic SAS and green line represents the
mean of the total SAS.
Figure C.46: Change in the solvent accessible surface (SAS) of the ACP-mupA2 cognate substrate over
time in the acyl ACP-mupA2a simulation. Blue line represents hydrophobic SAS, red line represents
hydrophilic SAS, yellow line represents total SAS and green line represents the mean of the total SAS.
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C.1.4 Sequence logos








































































































































































































































































































































































































































































D.1 Computational Tools available for the PKS researcher.
Comparing all the resources mentioned in Section 1.5 the various tasks that can be performed
can be divided into four major categories: 1) obtaining a well curated PKS/NRPS cluster
database for further analysis; 2) domain detection for various modular PKSs and NRPs; 3) pre-
dicting substrate specificity for various starter and extender units; and 4) correlating identified
clusters to their corresponding metabolites.
The NRPS-PKS database serves as an amalgamated source for PKS clusters (both modu-
lar and iterative), NRPS clusters and chalcone like products. At the time of first publication
data in this database was derived from the PKSDB (19 modular PKS cluster), NRPSDB (17
NRPS clusters and 5 hybrid PKS+NRPS clusters), ITERDB (21 iterative PKSs) and CHSDB
(11 plant chalcone PKSs and 3 bacterial chalcone PKSs) databases (Yadav et al. 2003b). An-
other database ASMPKS at the time of publication contained 41 characterized PKS pathways
including everything in PKSDB, with more entries being added (Tae et al. 2007). Users may
also add or delete their own entries. NORINE is a database for non-ribosomal peptides contain-
ing 1122 peptide products and over 500 monomers as of 04/2010, however it does not provide
information on biosynthesis (Caboche et al. 2008).
Why is there a need for specialized databases for PKS/NRPS research when databases like
CDD (Marchler-bauer et al. 2011) and interPro (Hunter et al. 2012), or domain finding software
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like SMART (Letunic et al. 2012) exist? It was observed by Yadav et al. (2003a) during the
construction of PKSDB/SEARCHPKS that inspite of CDD and interPro being a vast source of
protein domains they suffer from being general and not tailored for a specific purpose. Compar-
ing the CDD results from their domain identification program they found that at that time CDD
failed to detect any of the DH domains in the modular PKS clusters and was also not able to
distinguish between the KR and ER domains. However, over the time CDD has improved and
in my analysis with the MmpD subunit from the mupirocin pathway it is able to predict all the
domains except the catalytically inactive DH domain in module 1.
Tailored NRPS/PKS domain prediction has been achieved by either a BLAST (Altschul
et al. 1990) search of the query sequence against a backend database or through querying a
database of profile hidden markov models (HMMs) trained on domains from PKS/NRPS clus-
ters. The domain detection algorithms in NRPS-PKS, ASMPKS and SBSPKS use BLAST
whereas ClustScan, NRPSsp, CLUSEAN and antiSMASH uses profile HMMs. HMMs have
also been used by Ansari and coworkers (Ansari et al. 2008) to identify methyl transferase
(MT) domains present in type I PKS and NRPS megasynthases and to sub-group them into
N-MT, C-MT and O-MT groups based on the prediction of their site of methylation. In another
study, Foerstner et al. (2008) used HMMs to screen eight metagenomics shot gun data sets in
order to estimate the frequency of type I PKSs, using HMMs for eight domains. They also
incorporated analysis of maximum-likelihood phylogenetic trees to increase the reliability and
resolution of the dataset and to discriminate true PKS I domains from evolutionarily related but
functionally different ones.
ClustScan (Starcevic et al. 2008) also utilizes profile HMMs, both extracted from Pfam
and specifically constructed profiles. ClustScan works as a client server application with the
main program running on a linux server and a Java client running on the user’s computer,
making it compatible with Windows, Mac OS and Linux operating systems. It uses Glim-
mer or GeneMark for the gene prediction followed by HMMs for the domain identification in
PKS/NRPS/PKS-NRPS hybrid clusters. At the time of publication ClustScan database con-
tained data for 57 PKS clusters, 51 NRPS clusters and 62 PKS-NRPS hybrid clusters (Starcevic
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et al. 2008). Apart from domain identification and substrate specificity detection ClustScan can
also exports the chemical structures of predicted products in a SMILES/SMARTS format for
further analysis by standard chemistry programs. ClustScan also acts as a graphical interface
to CompGen, a tool that undertakes in silico homologous recombination of PKS gene clusters,
predicting whether a particular recombination is likely to be functional, and the polyketide prod-
uct to be expected (Starcevic et al. 2012). ClustScan can be accessed using a 30-day evaluation
license; the database behind ClustScan, ClustScanDB is freely available via a web interface
(http://csdb.bioserv.pbf.hr/csdb/ClustScanWeb.html).
To facilitate the systematic mapping of secondary metabolites in fungal genomes Khaldi et
al. (2010) developed the SMURF (Secondary Metabolite Unknown Region Finder). SMURF is
a web based tool which relies on hidden Markov model searches against Pfam and TIGRFAMs
(Haft et al. 2001) domains to detect backbone genes in sequenced fungal genomes. SMURF
is not only capable of predicting backbone genes but also tailoring enzymes and Khaldi et al.
(2010) used SMURF to catalogue putative clusters in 27 publically available fungal genomes.
They also compared the predicted results with genetically characterized clusters from 6 fungal
species and demonstrated that SMURF is capable of predicting accurately all of these clusters.
Recently NRPSpredictor2 (Röttig et al. 2011) used an innovative method employing a ma-
chine learning algorithm called a transductive support vector machine (SVM) for predicting
the specificity of adenylation domains in NRPs from amino acid sequence data. The method
is based on previous work (Rausch et al. 2005) from the same group however the new version
outperforms the previous version by predicting the specificity of adenylation domains at four
hierarchical levels, ranging from gross physicochemical properties of an A-domain’s substrate
to single amino acid substrates as well as predicting A-domain specificity in fungal systems,
which was not achieved in the previous version. The NRPSpredictor2 utilizes the active site
lining residues within 8 Å of the bound phenylalanine ligand in the crystal structure (PDB ID
1AMU) of the peptide synthetase gramicidin S synthetase 1 (GrsA). These 34 extracted posi-
tions were then located in the A-domain sequences of the training data set, and this data was
input into the SVM to train predictors of substrate specificity. The NRPSpredictor2 also has a
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larger database of training data including the sequences from fungal counterparts, as compared
to its previous version, thus enabling a wider and more accurate prediction rate. This work is
an extension of ideas built up by a number of researchers over a number of years, as discussed
further below.
Many research groups have used structural data to determine conserved residues lining the
active site, which they then use for the prediction of substrate specificity. In the case of PKS
this is typically specificity for extender or starter units, in the case of NRPs specificity for
amino acids. Prior to NRPSpredictor2, Stachelhaus and coworkers (Stachelhaus et al. 1999)
had utilized the 10 active site lining residues from the same crystal structure of the peptide
synthetase gramicidin S synthetase 1 (GrsA, PDB ID 1AMU) and succeeded in predicting the
specificity of the A-domain for 20 substrates. Shortly after their work Challis et al. (Challis et al.
2000), adopting a similar strategy, extended the number of predictable NRPS substrates to 33.
Challis et al. (2000) used 8 amino acids within the binding pocket combined the phylogenetic
clustering. They also performed modelling for the structures of a variety of binding pockets.
Similarly, during the compilation of the first polyketide synthase database (PKSDB) and
associated domain prediction program SEARCHPKS, Yadav et al. (2003a) identified 13 active
site positions in AT domains required to discriminate between malonate and methylmalonate as
starter and extender units in type I modular polyketide synthases. The 13 active site residues
were identified on the basis of the crystal structure of acyltransferase from Escherichia coli
FAS (PDB ID 1MLA). By modelling malonate and methylmalonate in the active site of the AT
they identified the residue which is responsible for controlling substrate specificity. The online
server at SEARCHPKS assigns a substrate for the AT domain if all the 13 positions in the query
amino acid sequence match identically to the corresponding positions in any of the AT domains
found in the PKSDB database.
Further utilizing structural modelling of the active site Yadav et al. (2009) identified that
certain residues in iterative KS domains can potentially control the size of final product by
governing the total number of iterations. In the same work Yadav et al. also utilized profile
HMMs to distinguish KS domains between modular PKSs and iterative PKSs, they also ob-
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served that HMMs are not only capable of broadly classifying KSs as modular or iterative but
also of grouping them into subtypes. They proposed that such a method can help the sequencing
projects as just by analyzing the KS domains of a novel PKS cluster one can identify its type
and subtype and decide whether sequencing the entire cluster would be of interest. From these
recent works HMMs prove to be a promising tool for various types of analysis ranging from
domain identification to substrate specificity.
Recently available coordinates of crystal structures of various type I PKS catalytic domains
(Keatinge-Clay and Stroud 2006; Khosla et al. 2007; Tang et al. 2007; Keatinge-clay 2008;
Khosla 2009; Tsai and Ames 2009) and an almost complete module of the homo dimeric mam-
malian FAS protein (Maier et al. 2008) allow the modelling of PKS domains in a homo dimeric
modular context, assuming the PKSs have a similar structure to the mammalian FAS (Gokhale et
al. 2007; Tsai and Ames 2009). Based on this, Mohanty’s group developed SBSPKS (Anand et
al. 2010). SBSPKS is a web based tool and probably the first which can model the 3D structures
of a PKS module in a biologically active dimeric conformation. SBSPKS consists of three main
components, MODEL 3D PKS, DOCK DOM ANAL and an updated version of NRPS-PKS
which was previously developed by the same group. MODEL 3D PKS component models the
3D structures of a complete module of a type I modular PKS protein in dimeric form. The ho-
mology modelling protocol used involves aligning the query module sequence to the sequence
of the templates by standalone BLAST and side chain modelling using SCRWL (Canutescu
et al. 2003). The templates used for the various domains of PKSs were PDB ID 2HG4, 3LE6,
1IZ0 and 2FR0 along with nine threading model based on 2FR0 for modelling structural sub-
domains of KR in the cases where DH-KR and DH-ER linkers lacked homology to 2FR0. The
modelled domains are then superimposed on to the corresponding mammalian FAS module to
provide the relative orientation of the PKS domains in a dimeric state. MODEL 3D PKS can
model 3D structures for any of the four typical combinations of modular PKS i.e. KS-AT-ACP,
KS-AT-KR-ACP, KS-AT-DH-KR-ACP, KS-AT-DH-ER-KR-ACP, excluding the ACP domain
as there is no experimental information available to provide the relative orientation of ACP do-
mains to the rest of the domains in the module. Although MODEL 3D PKS can model the
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typical combinations of domains found in modular PKSs it is not designed to model the module
from trans AT systems, although it may be possible to trick the system into modelling this. The
MODEL 3D PKS web interface also has an embedded JMOL applet for quick visualization of
the modelled structure.
The DOCK DOM ANAL module of the SBSPKS analyses the docking domains between
the related subunits in a modular PKS. The docking domains are the inter-subunit linker re-
gion characterized by a four helical bundle, one helix is from the C-terminus of the preceding
protein and three helices are from the N-terminus of the succeeding protein. In previous stud-
ies (Broadhurst et al. 2003; Weissman 2006; Weissman and Müller 2008) a “docking code”
was proposed, in which the electrostatic interaction between two residues in the docking do-
mains were responsible for the inter-subunit contacts. DOCK DOM ANAL estimates the cru-
cial inter-subunit contacts and predict the preferred order of substrate channelling utilizing the
method developed by Yadav et al. (2009). As a point of terminology these inter subunit docking
domains should not be confused with intra module segments seen in trans AT PKS I systems,
which show sequence similarity to the N and C termini of cis-AT domain, and may thus be
remnants of such domains although their role is still poorly understood (Gurney and Thomas
2011).
The most important updated feature in NRPS-PKS component of SBSPKS is a wider range
of substrate specificity detection for the AT domain. The initial version of the AT domain
specificity protocol was only able to discriminate between the malonate and methyl malonate
selectivity while the new version can now detect specificity for a total of 13 substrates. Another
enhanced feature is its integration into the SBSPKS interface, thus providing links for automated
input of its results to various other programs in the suite.
Apart from the easy-to-use web servers and client server based applications like ClustScan,
recent initiatives by Weber and co-workers resulted in CLUSEAN which is “a computer-based
framework for the automated analysis of bacterial secondary metabolite biosynthetic gene clus-
ters” (Weber et al. 2009). CLUSEAN (CLUster SEquence ANalyzer) is an open source resource
for semi-automatic analysis of secondary metabolite gene clusters. It is a modular framework
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of Bioperl (Rausch et al. 2007) programs that are compatible with LINUX, UNIX, or MS Win-
dows systems. It currently includes BLAST and HMMER as the tools for sequence annotation
and domain identification respectively. CLUSEAN scripts search the NCBI non redundant pro-
tein database with BLASTp, and use HMMER to search the following Hidden Markov Models:
Pfam domains, PKS/NRPS domains and motifs, and the C-domain types and NRPS adenylation
domain models developed by Rausch and co-worker (Rausch et al. 2005; Rausch et al. 2007).
Another software pipeline probably the first and most recent of its type called antiSMASH
(antibiotics and Secondary Metabolite Analysis Shell) (Medema et al. 2011) has been developed
for identifying secondary metabolite biosynthesis gene clusters with the advanced features pro-
viding the analysis and annotation of the identified clusters. It serves as a meta server which
amalgamates the data and methods available from various sources (Rausch et al. 2007; Ansari
et al. 2008; Yadav et al. 2009; Weber et al. 2009; Letunic et al. 2009; Jong et al. 2010; Finn
et al. 2010). It is capable of analyzing not only PKS/NRPS clusters as most of the software
mentioned above do, but also for the identification of the biosynthetic loci for various other sec-
ondary metabolites as listed in Table 1.1. AntiSMASH can be accessed via a web server or it
can be run as a standalone Java graphical user interface. It utilizes Glimmer3/GlimmerHMM for
the gene prediction in the input sequence data and HMMER3 for the prediction of biosynthetic
gene clusters using both existing profile HMMs as well as new profile HMMs from seed align-
ments. The substrate specificity of AT and adenylation domains were performed as proposed
by (Yadav et al. 2003a) and (Röttig et al. 2011) respectively along with the method proposed
by (Minowa et al. 2007) for both. The stereochemistry predictions for PKSs based on the Ke-
toreductase (KR) domain were carried out using the method used in the program ClustScan
(Starcevic et al. 2008). To predict the biosynthetic order of PKS/NRPS modules antiSMASH
uses the same method as SBSPKS to match the docking domain residues in the ORFs of type
I modular PKSs, and otherwise assumes colinearity in the biosynthetic gene cluster. It also
generates the SMILES string for the final predicted core chemical structure along with its pic-
ture. antiSMASH can also annotate the accessory genes by utilizing the HMMs constructed on
smCOG (secondary metabolite clusters of orthologous groups). It also provides features like
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ClusterBlast which can be used for comparative gene cluster analysis between the queried clus-
ter and the clusters in the database. Utilizing CLUSEAN framework modules antiSMASH can
also perform various other genome-wide analysis.
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